Exhibit
|
|
Description
|
99.1
|
|
The Registrant’s Annual Audited Consolidated Financial Statements as at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
99.2
|
|
The Registrant’s Management's Discussion and Analysis of Financial Condition and Results of Operations for the financial year ended December 31, 2018
|
99.3
|
|
The Registrant's Management Information Circular dated March 26, 2019 for its Annual Meeting of Shareholders to be held on May 8, 2019
|
99.4
|
|
Form of Proxy
|
99.5
|
|
Amended and Restated Shareholder Rights Plan Agreement between the Registrant and Computershare Trust Company of Canada, as Rights Agent
|
|
Aeterna Zentaris Inc.
|
|
(Registrant)
|
Date: March 28, 2019
|
|
|
/s/ Michael V. Ward
|
|
Michael V. Ward
|
|
CEO
|
Aeterna Zentaris Inc.
|
||
Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and years ended December 31, 2018, 2017 and 2016
|
Consolidated Statements of
Changes in Shareholders' (Deficiency) Equity
|
|
Aeterna Zentaris Inc.
|
||
Consolidated Statements of Financial Position
|
||
(in thousands of US dollars)
|
|
|
December 31, 2018
|
|
December 31, 2017
|
||
|
|
$
|
|
$
|
||
ASSETS
|
|
|
|
|
||
Current assets
|
|
|
|
|
||
Cash and cash equivalents (note 7)
|
|
14,512
|
|
|
7,780
|
|
Trade and other receivables (note 8)
|
|
294
|
|
|
221
|
|
Inventory (note 9)
|
|
240
|
|
|
554
|
|
Prepaid expenses and other current assets (note 10)
|
|
1,210
|
|
|
826
|
|
Total current assets
|
|
16,256
|
|
|
9,381
|
|
Restricted cash equivalents (note 11)
|
|
418
|
|
|
381
|
|
Property, plant and equipment (note 12)
|
|
65
|
|
|
101
|
|
Deferred tax assets (note 20)
|
|
—
|
|
|
3,479
|
|
Identifiable intangible assets (note 13)
|
|
62
|
|
|
90
|
|
Other non-current assets
|
|
—
|
|
|
150
|
|
Goodwill (note 14)
|
|
8,210
|
|
|
8,613
|
|
Total Assets
|
|
25,011
|
|
|
22,195
|
|
LIABILITIES
|
|
|
|
|
||
Current liabilities
|
|
|
|
|
||
Payables and accrued liabilities (note 15)
|
|
2,966
|
|
|
2,814
|
|
Provision for restructuring and other costs (note 16)
|
|
887
|
|
|
2,469
|
|
Income taxes (note 22)
|
|
1,669
|
|
|
—
|
|
Current portion of deferred revenues (note 6)
|
|
74
|
|
|
486
|
|
Total current liabilities
|
|
5,596
|
|
|
5,769
|
|
Deferred revenues (note 6)
|
|
258
|
|
|
55
|
|
Warrant liability (note 17)
|
|
3,634
|
|
|
3,897
|
|
Employee future benefits (note 18)
|
|
13,205
|
|
|
14,229
|
|
Non-current portion of provision for restructuring and other costs (note 16)
|
|
411
|
|
|
1,028
|
|
Total liabilities
|
|
23,104
|
|
|
24,978
|
|
SHAREHOLDERS' EQUITY (DEFICIENCY)
|
|
|
|
|
||
Share capital (note 19)
|
|
222,335
|
|
|
222,335
|
|
Other capital (note 19)
|
|
89,342
|
|
|
88,772
|
|
Deficit
|
|
(309,781
|
)
|
|
(314,161
|
)
|
Accumulated other comprehensive income
|
|
11
|
|
|
271
|
|
Total shareholders' equity (deficiency)
|
|
1,907
|
|
|
(2,783
|
)
|
Total liabilities and shareholders' equity
|
|
25,011
|
|
|
22,195
|
|
/s/ Carolyn Egbert
|
|
/s/ Gérard Limoges
|
Carolyn Egbert
Chair of the Board
|
|
Gérard Limoges
Director
|
Aeterna Zentaris Inc.
|
||
Consolidated Statements of Changes in Shareholders' (Deficiency) Equity
|
||
For the years ended December 31, 2018, 2017 and 2016
|
||
(in thousands of US dollars, except share data)
|
|
Common shares (number of)
1
|
|
Share capital
|
|
Other capital
|
|
Deficit
|
|
Accumulated other comprehensive income
|
|
Total
|
||||||
|
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
||||||
Balance - January 1, 2018
|
16,440,760
|
|
|
222,335
|
|
|
88,772
|
|
|
(314,161
|
)
|
|
271
|
|
|
(2,783
|
)
|
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
4,187
|
|
|
—
|
|
|
4,187
|
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Foreign currency translation adjustments
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(260
|
)
|
|
(260
|
)
|
Actuarial gain on defined benefit plans (note 18)
|
—
|
|
|
—
|
|
|
—
|
|
|
193
|
|
|
—
|
|
|
193
|
|
Comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
4,380
|
|
|
(260
|
)
|
|
4,120
|
|
Share-based compensation costs
|
—
|
|
|
—
|
|
|
570
|
|
|
—
|
|
|
—
|
|
|
570
|
|
Balance - December 31, 2018
|
16,440,760
|
|
|
222,335
|
|
|
89,342
|
|
|
(309,781
|
)
|
|
11
|
|
|
1,907
|
|
1
|
Issued and paid in full.
|
|
|
Common shares (number of)
1
|
|
Share capital
|
|
Pre-funded warrants
|
|
Other capital
|
|
Deficit
|
|
Accumulated other comprehensive income (loss)
|
|
Total
|
|||||||
|
|
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|||||||
Balance - January 1, 2017
|
|
12,917,995
|
|
|
213,980
|
|
|
—
|
|
|
88,590
|
|
|
(298,059
|
)
|
|
1,701
|
|
|
6,212
|
|
Net loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(16,796
|
)
|
|
—
|
|
|
(16,796
|
)
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Foreign currency translation adjustments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,430
|
)
|
|
(1,430
|
)
|
Actuarial gain on defined benefit plans (note 18)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
694
|
|
|
—
|
|
|
694
|
|
Comprehensive loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(16,102
|
)
|
|
(1,430
|
)
|
|
(17,532
|
)
|
Share issuances pursuant to the exercise of pre-funded warrants (note 19)
|
|
301,343
|
|
|
977
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
977
|
|
Share issuances in connection with "at-the-market" drawdowns (note 19)
|
|
3,221,422
|
|
|
7,378
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
7,378
|
|
Share-based compensation costs
|
|
|
|
—
|
|
|
—
|
|
|
182
|
|
|
—
|
|
|
—
|
|
|
182
|
|
|
Balance - December 31, 2017
|
|
16,440,760
|
|
|
222,335
|
|
|
—
|
|
|
88,772
|
|
|
(314,161
|
)
|
|
271
|
|
|
(2,783
|
)
|
Aeterna Zentaris Inc.
|
||
Consolidated Statements of Changes in Shareholders' (Deficiency) Equity
|
||
For the years ended December 31, 2018, 2017 and 2016
|
||
(in thousands of US dollars, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Common shares (number of)
1
|
|
Share capital
|
|
Pre-funded warrants
|
|
Other capital
|
|
Deficit
|
|
Accumulated other comprehensive income (loss)
|
|
Total
|
|||||||
|
|
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|||||||
Balance - January 1, 2016
|
|
9,928,697
|
|
|
204,596
|
|
|
—
|
|
|
87,508
|
|
|
(271,621
|
)
|
|
1,132
|
|
|
21,615
|
|
Net loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(24,959
|
)
|
|
—
|
|
|
(24,959
|
)
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Foreign currency translation adjustments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
569
|
|
|
569
|
|
Actuarial loss on defined benefit plan (note 18)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,479
|
)
|
|
—
|
|
|
(1,479
|
)
|
Comprehensive loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(26,438
|
)
|
|
569
|
|
|
(25,869
|
)
|
Share issuances in connection with a public offering (note 19)
|
|
1,150,000
|
|
|
3,377
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3,377
|
|
Pre-funded warrant issuances in connection with a public offering (note 19)
|
|
—
|
|
|
—
|
|
|
2,789
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,789
|
|
Share issuances pursuant to the exercise of pre-funded warrants (note 19)
|
|
950,000
|
|
|
2,789
|
|
|
(2,789
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Share issuances in connection with "at-the-market" drawdowns (note 19)
|
|
889,298
|
|
|
3,218
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3,218
|
|
Share-based compensation costs
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,082
|
|
|
—
|
|
|
—
|
|
|
1,082
|
|
Balance - December 31, 2016
|
|
12,917,995
|
|
|
213,980
|
|
|
—
|
|
|
88,590
|
|
|
(298,059
|
)
|
|
1,701
|
|
|
6,212
|
|
1
|
Issued and paid in full.
|
Aeterna Zentaris Inc.
|
||
Consolidated Statements of Comprehensive Income (Loss)
|
||
For the years ended December 31, 2018, 2017 and 2016
|
||
(in thousands of US dollars, except share and per share data)
|
|
|
Years Ended December 31,
|
|||||||
|
|
2018
|
|
2017
|
|
2016
|
|||
|
|
$
|
|
$
|
|
$
|
|||
Revenues
|
|
|
|
|
|
|
|||
License fees (note 6)
|
|
24,325
|
|
|
458
|
|
|
497
|
|
Product sales (note 6)
|
|
2,167
|
|
|
—
|
|
|
—
|
|
Royalty income (note 6)
|
|
184
|
|
|
—
|
|
|
—
|
|
Sales commission and other
|
|
205
|
|
|
465
|
|
|
414
|
|
Total revenues
|
|
26,881
|
|
|
923
|
|
|
911
|
|
Cost of sales
|
|
2,104
|
|
|
—
|
|
|
—
|
|
Gross income
|
|
24,777
|
|
|
923
|
|
|
911
|
|
Operating expenses (note 20)
|
|
|
|
|
|
|
|||
Research and development costs
|
|
2,932
|
|
|
10,704
|
|
|
16,495
|
|
General and administrative expenses
|
|
8,894
|
|
|
8,198
|
|
|
7,147
|
|
Selling expenses
|
|
3,109
|
|
|
5,095
|
|
|
6,745
|
|
Total operating expenses
|
|
14,935
|
|
|
23,997
|
|
|
30,387
|
|
Income (loss) from operations
|
|
9,842
|
|
|
(23,074
|
)
|
|
(29,476
|
)
|
Settlements (note 27)
|
|
(1,400
|
)
|
|
—
|
|
|
—
|
|
Gain (loss) due to changes in foreign currency exchange rates
|
|
656
|
|
|
502
|
|
|
(70
|
)
|
Change in fair value of warrant liability (note 17)
|
|
263
|
|
|
2,222
|
|
|
4,437
|
|
Other finance income
|
|
278
|
|
|
75
|
|
|
150
|
|
Net finance income (costs)
|
|
1,197
|
|
|
2,799
|
|
|
4,517
|
|
Income (loss) before income taxes
|
|
9,639
|
|
|
(20,275
|
)
|
|
(24,959
|
)
|
Income tax (expense) recovery (note 22)
|
|
(5,452
|
)
|
|
3,479
|
|
|
—
|
|
Net income (loss)
|
|
4,187
|
|
|
(16,796
|
)
|
|
(24,959
|
)
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|||
Items that may be reclassified subsequently to profit or loss:
|
|
|
|
|
|
|
|||
Foreign currency translation adjustments
|
|
(260
|
)
|
|
(1,430
|
)
|
|
569
|
|
Items that will not be reclassified to profit or loss:
|
|
|
|
|
|
|
|||
Actuarial gain (loss) on defined benefit plans
|
|
193
|
|
|
694
|
|
|
(1,479
|
)
|
Comprehensive income (loss)
|
|
4,120
|
|
|
(17,532
|
)
|
|
(25,869
|
)
|
Net income (loss) per share (basic) (note 26)
|
|
0.25
|
|
|
(1.12
|
)
|
|
(2.41
|
)
|
Net income (loss) per share (diluted) (note 26)
|
|
0.24
|
|
|
(1.12
|
)
|
|
(2.41
|
)
|
Weighted average number of shares outstanding (note 26)
|
|
|
|
|
|
|
|||
Basic
|
|
16,440,760
|
|
|
14,958,704
|
|
|
10,348,879
|
|
Diluted
|
|
17,034,812
|
|
|
14,958,704
|
|
|
10,348,879
|
|
Aeterna Zentaris Inc.
|
||
Consolidated Statements of Cash Flows
|
||
For the years ended December 31, 2018, 2017 and 2016
|
||
(in thousands of US dollars)
|
|
|
Years Ended December 31,
|
|||||||
|
|
2018
|
|
2017
|
|
2016
|
|||
|
|
$
|
|
$
|
|
$
|
|||
Cash flows from operating activities
|
|
|
|
|
|
|
|||
Net income (loss) for the year
|
|
4,187
|
|
|
(16,796
|
)
|
|
(24,959
|
)
|
Items not affecting cash and cash equivalents:
|
|
|
|
|
|
|
|
||
Change in fair value of warrant liability (note 17)
|
|
(263
|
)
|
|
(2,222
|
)
|
|
(4,437
|
)
|
Provision for restructuring and other costs (note 16)
|
|
(136
|
)
|
|
3,083
|
|
|
(8
|
)
|
Recapture of inventory previously written off
|
|
—
|
|
|
(643
|
)
|
|
—
|
|
Depreciation, amortization and impairment (notes 12 and 13)
|
|
58
|
|
|
94
|
|
|
280
|
|
Deferred income taxes (note 22)
|
|
3,479
|
|
|
(3,479
|
)
|
|
—
|
|
Share-based compensation costs
|
|
570
|
|
|
182
|
|
|
1,082
|
|
Employee future benefits (note 18)
|
|
316
|
|
|
246
|
|
|
382
|
|
Amortization of deferred revenues (note 6)
|
|
(609
|
)
|
|
(458
|
)
|
|
(345
|
)
|
Foreign exchange (gain) loss on items denominated in foreign currencies
|
|
(652
|
)
|
|
(553
|
)
|
|
87
|
|
Gain on disposal of property, plant and equipment
|
|
(9
|
)
|
|
(136
|
)
|
|
(1
|
)
|
Other non-cash items
|
|
35
|
|
|
(19
|
)
|
|
(83
|
)
|
Transaction cost allocated to warrants issued (note 19)
|
|
—
|
|
|
—
|
|
|
56
|
|
Changes in operating assets and liabilities (note 21)
|
|
(151
|
)
|
|
(2,212
|
)
|
|
(1,064
|
)
|
Net cash provided by/(used in) operating activities
|
|
6,825
|
|
|
(22,913
|
)
|
|
(29,010
|
)
|
Cash flows from financing activities
|
|
|
|
|
|
|
|||
Proceeds from issuances of common shares, warrants (including pre-funded warrants), net of cash transaction costs of $nil, $250 and $1,107 in 2018, 2017, and 2016, respectively (note 19)
|
|
—
|
|
|
7,788
|
|
|
9,924
|
|
Proceeds from warrants exercised (note 19)
|
|
—
|
|
|
242
|
|
|
—
|
|
Net cash provided by financing activities
|
|
—
|
|
|
8,030
|
|
|
9,924
|
|
Cash flows from investing activities
|
|
|
|
|
|
|
|||
Purchase of property, plant and equipment (note 12)
|
|
(9
|
)
|
|
(4
|
)
|
|
(66
|
)
|
Proceeds for disposals of property, plant and equipment (note 12)
|
|
24
|
|
|
161
|
|
|
2
|
|
Change in restricted cash equivalents
|
|
(50
|
)
|
|
150
|
|
|
(250
|
)
|
Net cash provided by (used in) investing activities
|
|
(35
|
)
|
|
307
|
|
|
(314
|
)
|
Effect of exchange rate changes on cash and cash equivalents
|
|
(58
|
)
|
|
357
|
|
|
(51
|
)
|
Net change in cash and cash equivalents
|
|
6,732
|
|
|
(14,219
|
)
|
|
(19,451
|
)
|
Cash and cash equivalents – beginning of year (note 6)
|
|
7,780
|
|
|
21,999
|
|
|
41,450
|
|
Cash and cash equivalents – end of year (note 6)
|
|
14,512
|
|
|
7,780
|
|
|
21,999
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Methods
|
|
Annual rates and period
|
Equipment
|
|
Declining balance and straight-line
|
|
20%
|
Furniture and fixtures
|
|
Declining balance and straight-line
|
|
10% and 20%
|
Computer equipment
|
|
Straight-line
|
|
25% and 33
1
/3%
|
Leasehold improvements
|
|
Straight-line
|
|
Remaining lease term
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
December 31,
|
||||
|
|
2018
|
|
2017
|
||
|
|
$
|
|
$
|
||
Cash on hand and balances with banks
|
|
3,501
|
|
|
7,099
|
|
Interest-bearing deposits with maturities of three months or less
|
|
11,011
|
|
|
681
|
|
|
|
14,512
|
|
|
7,780
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
December 31,
|
||||
|
|
2018
|
|
2017
|
||
|
|
$
|
|
$
|
||
Trade accounts receivable (net of allowance for doubtful accounts of $55 (2017 - $5))
|
|
142
|
|
|
20
|
|
Value added tax
|
|
49
|
|
|
186
|
|
Other receivables
|
|
103
|
|
|
15
|
|
|
|
294
|
|
|
221
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Cost
|
|||||||||||||
|
|
Equipment
|
|
Furniture and fixtures
|
|
Computer equipment
|
|
Leasehold improvements
|
|
Total
|
|||||
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|||||
At January 1, 2017
|
|
3,919
|
|
|
19
|
|
|
737
|
|
|
37
|
|
|
4,712
|
|
Additions
|
|
2
|
|
|
—
|
|
|
2
|
|
|
—
|
|
|
4
|
|
Disposals / Retirements
|
|
(2,160
|
)
|
|
—
|
|
|
(43
|
)
|
|
—
|
|
|
(2,203
|
)
|
Impact of foreign exchange rate changes
|
|
507
|
|
|
—
|
|
|
94
|
|
|
5
|
|
|
606
|
|
At December 31, 2017
|
|
2,268
|
|
|
19
|
|
|
790
|
|
|
42
|
|
|
3,119
|
|
Additions
|
|
1
|
|
|
—
|
|
|
8
|
|
|
—
|
|
|
9
|
|
Disposals / Retirements
|
|
(758
|
)
|
|
—
|
|
|
(137
|
)
|
|
—
|
|
|
(895
|
)
|
Reclassifications
|
|
11
|
|
|
(11
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
Impact of foreign exchange rate changes
|
|
(64
|
)
|
|
(1
|
)
|
|
(24
|
)
|
|
(2
|
)
|
|
(91
|
)
|
At December 31, 2018
|
|
1,458
|
|
|
7
|
|
|
637
|
|
|
40
|
|
|
2,142
|
|
|
|
Accumulated depreciation
|
|||||||||||||
|
|
Equipment
|
|
Furniture and fixtures
|
|
Computer equipment
|
|
Leasehold improvements
|
|
Total
|
|||||
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|||||
At January 1, 2017
|
|
3,799
|
|
|
2
|
|
|
692
|
|
|
15
|
|
|
4,508
|
|
Disposals / Retirements
|
|
(2,135
|
)
|
|
—
|
|
|
(43
|
)
|
|
—
|
|
|
(2,178
|
)
|
Depreciation expense
|
|
50
|
|
|
2
|
|
|
30
|
|
|
18
|
|
|
100
|
|
Impact of foreign exchange rate changes
|
|
496
|
|
|
—
|
|
|
90
|
|
|
2
|
|
|
588
|
|
At December 31, 2017
|
|
2,210
|
|
|
4
|
|
|
769
|
|
|
35
|
|
|
3,018
|
|
Disposals / Retirements
|
|
(752
|
)
|
|
—
|
|
|
(137
|
)
|
|
—
|
|
|
(889
|
)
|
Depreciation expense
|
|
19
|
|
|
1
|
|
|
14
|
|
|
1
|
|
|
35
|
|
Impact of foreign exchange rate changes
|
|
(63
|
)
|
|
—
|
|
|
(22
|
)
|
|
(2
|
)
|
|
(87
|
)
|
At December 31, 2018
|
|
1,414
|
|
|
5
|
|
|
624
|
|
|
34
|
|
|
2,077
|
|
|
|
Carrying amount
|
|||||||||||||
|
|
Equipment
|
|
Furniture and fixtures
|
|
Computer equipment
|
|
Leasehold improvements
|
|
Total
|
|||||
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|||||
At December 31, 2017
|
|
58
|
|
|
15
|
|
|
21
|
|
|
7
|
|
|
101
|
|
At December 31, 2018
|
|
44
|
|
|
2
|
|
|
13
|
|
|
6
|
|
|
65
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Year ended December 31, 2018
|
|
Year ended December 31, 2017
|
||||||||||||||
|
|
Cost
|
|
Accumulated amortization
|
|
Carrying value
|
|
Cost
|
|
Accumulated amortization
|
|
Carrying value
|
||||||
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
||||||
Balances – Beginning of the year
|
|
34,246
|
|
|
(34,156
|
)
|
|
90
|
|
|
30,032
|
|
|
(29,962
|
)
|
|
70
|
|
Additions
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Impairment (loss) reversal*
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
44
|
|
|
44
|
|
Recurring amortization expense*
|
|
—
|
|
|
(23
|
)
|
|
(23
|
)
|
|
—
|
|
|
(38
|
)
|
|
(38
|
)
|
Impact of foreign exchange rate changes
|
|
(1,603
|
)
|
|
1,598
|
|
|
(5
|
)
|
|
4,214
|
|
|
(4,200
|
)
|
|
14
|
|
Balances – End of the year
|
|
32,643
|
|
|
(32,581
|
)
|
|
62
|
|
|
34,246
|
|
|
(34,156
|
)
|
|
90
|
|
|
|
Cost
|
|
Accumulated impairment loss
|
|
Carrying amount
|
|||
|
|
$
|
|
$
|
|
$
|
|||
At January 1, 2017
|
|
7,553
|
|
|
—
|
|
|
7,553
|
|
Impact of foreign exchange rate changes
|
|
1,060
|
|
|
—
|
|
|
1,060
|
|
At December 31, 2017
|
|
8,613
|
|
|
—
|
|
|
8,613
|
|
Impact of foreign exchange rate changes
|
|
(403
|
)
|
|
—
|
|
|
(403
|
)
|
At December 31, 2018
|
|
8,210
|
|
|
—
|
|
|
8,210
|
|
|
|
December 31,
|
||||
|
|
2018
|
|
2017
|
||
|
|
$
|
|
$
|
||
Trade accounts payable
|
|
1,282
|
|
|
1,222
|
|
Accrued research and development costs
|
|
26
|
|
|
127
|
|
Salaries, employment taxes and benefits
|
|
183
|
|
|
390
|
|
Financing of insurance premiums (a)
|
|
738
|
|
|
—
|
|
Other accrued liabilities
|
|
737
|
|
|
1,075
|
|
|
|
2,966
|
|
|
2,814
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
(a)
|
Represents financing of the Company's 2019 insurance premiums, carrying interest at 6.5% and repayable in eight equal monthly installments commencing January 31, 2019.
|
|
|
Other provision
|
|
Cetrotide
(R)
onerous contracts
|
|
2017 German Restructuring: onerous lease
|
|
2017 German Restructuring: severance
|
|
Total
|
|||||
|
|
|
|
$
|
|
$
|
|
$
|
|
$
|
|||||
January 1, 2017
|
|
158
|
|
|
574
|
|
|
—
|
|
|
—
|
|
|
732
|
|
Provision recognized
|
|
—
|
|
|
—
|
|
|
1,113
|
|
|
2,002
|
|
|
3,115
|
|
Utilization of provision
|
|
(152
|
)
|
|
(145
|
)
|
|
(19
|
)
|
|
(138
|
)
|
|
(454
|
)
|
Change in the provision
|
|
—
|
|
|
(20
|
)
|
|
10
|
|
|
(41
|
)
|
|
(51
|
)
|
Unwinding of discount and impact of foreign exchange rate changes
|
|
3
|
|
|
64
|
|
|
104
|
|
|
(16
|
)
|
|
155
|
|
December 31, 2017
|
|
9
|
|
|
473
|
|
|
1,208
|
|
|
1,807
|
|
|
3,497
|
|
Provision recognized
|
|
—
|
|
|
317
|
|
|
—
|
|
|
—
|
|
|
317
|
|
Utilization of provision
|
|
(9
|
)
|
|
(222
|
)
|
|
(467
|
)
|
|
(1,202
|
)
|
|
(1,900
|
)
|
Change in the provision
|
|
—
|
|
|
—
|
|
|
(21
|
)
|
|
(432
|
)
|
|
(453
|
)
|
Unwinding of discount and impact of foreign exchange rate changes
|
|
—
|
|
|
(21
|
)
|
|
(57
|
)
|
|
(85
|
)
|
|
(163
|
)
|
December 31, 2018
|
|
—
|
|
|
547
|
|
|
663
|
|
|
88
|
|
|
1,298
|
|
Less: current portion
|
|
—
|
|
|
(136
|
)
|
|
(663
|
)
|
|
(88
|
)
|
|
(887
|
)
|
Non-current portion
|
|
—
|
|
|
411
|
|
|
—
|
|
|
—
|
|
|
411
|
|
|
|
Years ended December 31,
|
|||||||
|
|
2018
|
|
2017
|
|
2016
|
|||
|
|
$
|
|
$
|
|
$
|
|||
Balance – Beginning of the year
|
|
3,897
|
|
|
6,854
|
|
|
10,891
|
|
Share purchase warrants issued during the year (note 19)
|
|
—
|
|
|
—
|
|
|
400
|
|
Share purchase warrants exercised during the year
|
|
—
|
|
|
(735
|
)
|
|
—
|
|
Change in fair value of share purchase warrants
|
|
(263
|
)
|
|
(2,222
|
)
|
|
(4,437
|
)
|
Balance - End of the year
|
|
3,634
|
|
|
3,897
|
|
|
6,854
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Years ended December 31,
|
|
||||||||||||||||
|
|
2018
|
|
2017
|
|
2016
|
|
||||||||||||
|
|
Number
|
|
Weighted average exercise price ($)
|
|
Number
|
|
Weighted average exercise price ($)
|
|
Number
|
|
Weighted average exercise price ($)
|
|
||||||
Balance – Beginning of the year
|
|
3,417,840
|
|
|
7.59
|
|
|
3,779,245
|
|
|
9.66
|
|
|
2,842,309
|
|
|
11.30
|
|
|
Issued (note 19)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
945,000
|
|
|
4.70
|
|
|
Exercised
|
|
—
|
|
|
—
|
|
|
(331,730
|
)
|
*
|
1.07
|
|
|
—
|
|
|
—
|
|
|
Expired (note 19)
|
|
(25,996
|
)
|
|
185.00
|
|
|
(29,675
|
)
|
|
345.00
|
|
|
(8,064
|
)
|
|
4.23
|
|
|
Balance – End of the year
|
|
3,391,844
|
|
|
6.23
|
|
|
3,417,840
|
|
|
7.59
|
|
|
3,779,245
|
|
|
9.66
|
|
|
*
|
A portion of the Series A warrants was exercised using the cashless feature. Therefore, the total number of equivalent shares issued was 301,343.
|
|
|
|
|||
Exercise price ($)
|
|
Number
|
|
Weighted average remaining contractual life (years)
|
|
1.07
|
|
115,844
|
|
|
1.19
|
4.70
|
|
945,000
|
|
|
1.34
|
7.10
|
|
2,331,000
|
|
|
1.96
|
|
|
3,391,844
|
|
|
1.76
|
|
|
Number of equivalent shares
|
|
Market-value per share price ($)
|
|
Weighted average exercise price ($)
|
|
Risk-free annual interest rate (a)
|
|
Expected volatility
(b)
|
|
Expected life (years) (c)
|
|
Expected dividend yield
(d)
|
||||||
March 2015 Series A Warrants (e)
|
|
115,844
|
|
|
2.94
|
|
|
1.07
|
|
|
2.58
|
%
|
|
81.81
|
%
|
|
1.19
|
|
0.00
|
%
|
December 2015 Warrants
|
|
2,331,000
|
|
|
2.94
|
|
|
7.10
|
|
|
2.47
|
%
|
|
122.00
|
%
|
|
1.96
|
|
0.00
|
%
|
November 2016 Warrants (f)
|
|
945,000
|
|
|
2.94
|
|
|
4.70
|
|
|
2.56
|
%
|
|
78.95
|
%
|
|
1.34
|
|
0.00
|
%
|
(a)
|
Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants.
|
(b)
|
Based on the historical volatility of the Company's stock price over the most recent period consistent with the expected life of the warrants, as well as on future expectations.
|
(c)
|
Based upon time to expiry from the reporting period date.
|
(d)
|
The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
(e)
|
For the
March 2015
Series A Warrants, the inputs and assumptions applied to the Black-Scholes option pricing model have been further adjusted to take into consideration the value attributed to certain anti-dilution provisions. Specifically, the weighted average exercise price is subject to adjustment (see
note 19 - Share and other capital
).
|
(f)
|
For the
November 2016
Warrants, the Company reduced the fair value of these warrants to take into consideration the fair value of the
$10
call option, which was also calculated using the Black-Scholes pricing model. (see
note 19 - Share and other capital
).
|
|
|
Pension benefit plans
Years ended December 31, |
|
Other benefit plans
Years ended December 31, |
||||||||||||||
|
|
2018
|
|
2017
|
|
2016
|
|
2018
|
|
2017
|
|
2016
|
||||||
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
||||||
Balances – Beginning of the year
|
|
14,145
|
|
|
13,197
|
|
|
12,375
|
|
|
84
|
|
|
217
|
|
|
281
|
|
Current service cost
|
|
66
|
|
|
107
|
|
|
87
|
|
|
6
|
|
|
14
|
|
|
13
|
|
Interest cost
|
|
224
|
|
|
237
|
|
|
282
|
|
|
1
|
|
|
3
|
|
|
—
|
|
Actuarial (gain) loss arising from changes in financial assumptions
|
|
(193
|
)
|
|
(694
|
)
|
|
1,479
|
|
|
19
|
|
|
(115
|
)
|
|
—
|
|
Benefits paid
|
|
(492
|
)
|
|
(485
|
)
|
|
(399
|
)
|
|
(2
|
)
|
|
(66
|
)
|
|
(60
|
)
|
Impact of foreign exchange rate changes
|
|
(650
|
)
|
|
1,783
|
|
|
(627
|
)
|
|
(3
|
)
|
|
31
|
|
|
(17
|
)
|
Balances – End of the year
|
|
13,100
|
|
|
14,145
|
|
|
13,197
|
|
|
105
|
|
|
84
|
|
|
217
|
|
Amounts recognized:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
In net loss
|
|
(290
|
)
|
|
(344
|
)
|
|
(369
|
)
|
|
(26
|
)
|
|
98
|
|
|
(13
|
)
|
In other comprehensive income (loss)
|
|
843
|
|
|
(1,089
|
)
|
|
(852
|
)
|
|
3
|
|
|
(31
|
)
|
|
17
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Pension benefit plans
|
|
Other benefit plans
|
||||||||
|
|
Years ended December 31,
|
|
Years ended December 31,
|
||||||||
Actuarial assumptions
|
|
2018
|
|
2017
|
|
2016
|
|
2018
|
|
2017
|
|
2016
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
|
%
|
Discount rate
|
|
1.90
|
|
1.70
|
|
1.60
|
|
1.90
|
|
1.70
|
|
1.60
|
Pension benefits increase
|
|
1.80
|
|
1.80
|
|
1.80
|
|
1.80
|
|
1.80
|
|
1.80
|
Rate of compensation increase
|
|
2.00
|
|
2.00
|
|
2.00
|
|
2.00
|
|
2.00
|
|
2.00
|
|
|
2018
|
|
2017
|
|
2016
|
Retiring at the end of the reporting period:
|
|
|
|
|
|
|
Male
|
|
20
|
|
20
|
|
20
|
Female
|
|
24
|
|
24
|
|
24
|
Retiring 20 years after the end of the reporting period:
|
|
|
|
|
|
|
Male
|
|
28
|
|
22
|
|
22
|
Female
|
|
31
|
|
26
|
|
26
|
|
|
$
|
|
2019
|
|
453
|
|
2020
|
|
458
|
|
2021
|
|
463
|
|
2022
|
|
468
|
|
2023
|
|
476
|
|
Thereafter
|
|
13,658
|
|
|
|
15,976
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
Assumption
|
Increase
|
Decrease
|
||
|
|
|
||
Change interest rate by 0.25%
|
(467
|
)
|
498
|
|
Change salary rate by 0.25%
|
19
|
|
(17
|
)
|
Change pension by 0.25%
|
372
|
|
(355
|
)
|
Change mortality by 1 year
|
464
|
|
(463
|
)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Years ended December 31,
|
||||||||||||||||
|
|
2018
|
|
2017
|
|
2016
|
||||||||||||
US dollar-denominated options
|
|
Number
|
|
Weighted average exercise price (US$)
|
|
Number
|
|
Weighted average exercise price (US$)
|
|
Number
|
|
Weighted average exercise price (US$)
|
||||||
Balance – Beginning of the year
|
|
712,415
|
|
|
4.66
|
|
|
966,539
|
|
|
7.23
|
|
|
272,874
|
|
|
25.88
|
|
Granted
|
|
426,000
|
|
|
1.74
|
|
|
390,000
|
|
|
2.05
|
|
|
713,573
|
|
|
3.47
|
|
Forfeited
|
|
(249,599
|
)
|
|
3.23
|
|
|
(643,271
|
)
|
|
6.02
|
|
|
(10,034
|
)
|
|
99.22
|
|
Cancelled
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(9,874
|
)
|
|
157.11
|
|
Expired
|
|
—
|
|
|
—
|
|
|
(853
|
)
|
|
704.88
|
|
|
—
|
|
|
—
|
|
Balance – End of period
|
|
888,816
|
|
|
3.66
|
|
|
712,415
|
|
|
4.66
|
|
|
966,539
|
|
|
7.23
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Years ended December 31,
|
||||||||||||||||
|
|
2018
|
|
2017
|
|
2016
|
||||||||||||
Canadian dollar-denominated stock options
|
|
Number
|
|
Weighted average exercise price (CAN$)
|
|
Number
|
|
Weighted average exercise price (CAN$)
|
|
Number
|
|
Weighted average exercise price (CAN$)
|
||||||
Balance – Beginning of the year
|
|
1,503
|
|
|
605.84
|
|
|
1,858
|
|
|
820.27
|
|
|
3,787
|
|
|
845.46
|
|
Forfeited
|
|
(104
|
)
|
|
668.65
|
|
|
—
|
|
|
—
|
|
|
(1,028
|
)
|
|
967.63
|
|
Cancelled
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(901
|
)
|
|
758
|
|
Expired
|
|
(530
|
)
|
|
367.70
|
|
|
(355
|
)
|
|
1,728.15
|
|
|
—
|
|
|
—
|
|
Balance – End of the year
|
|
869
|
|
|
743.56
|
|
|
1,503
|
|
|
605.84
|
|
|
1,858
|
|
|
820.27
|
|
|
|
Total US$ share-based awards as at December 31, 2018
|
||||||
Exercise price
(US$) |
|
Number
|
|
Weighted average remaining
contractual life (years) |
|
Weighted average exercise price
(US$) |
||
1.46 to 1.79
|
|
211,000
|
|
|
8.62
|
|
1.71
|
|
1.80 to 2.11
|
|
490,000
|
|
|
6.41
|
|
2.06
|
|
2.12 to 3.50
|
|
157,148
|
|
|
4.75
|
|
3.46
|
|
3.51 to 4.58
|
|
26,000
|
|
|
3.97
|
|
4.58
|
|
4.59 to 1,044.00
|
|
4,668
|
|
|
2.77
|
|
260.87
|
|
|
|
888,816
|
|
|
6.55
|
|
3.66
|
|
|
|
Total exercisable US$ share-based awards as at December 31, 2018
|
|||||||
Exercise price
(US$) |
|
Number
|
|
Weighted average remaining
contractual life (years) |
|
Weighted average exercise price
(US$) |
|||
1.46 to 1.79
|
|
161,000
|
|
|
9.35
|
|
|
1.79
|
|
1.80 to 2.11
|
|
130,000
|
|
|
5.62
|
|
|
2.05
|
|
2.12 to 3.50
|
|
104,774
|
|
|
4.75
|
|
|
3.46
|
|
3.51 to 4.58
|
|
26,000
|
|
|
3.97
|
|
|
4.58
|
|
4.59 to 1,044.00
|
|
4,668
|
|
|
2.77
|
|
|
260.87
|
|
|
|
426,442
|
|
|
6.68
|
|
|
5.29
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
CAN$ options outstanding and exercisable as at December 31, 2018
|
|||||||
Exercise price
(CAN$) |
|
Number
|
|
Weighted average remaining
contractual life (years) |
|
Weighted average exercise price
(CAN$) |
|||
570.00 to 741.00
|
|
428
|
|
|
0.94
|
|
|
570.00
|
|
741.01 to 912.00
|
|
441
|
|
|
1.87
|
|
|
912.00
|
|
|
|
869
|
|
|
1.41
|
|
|
743.56
|
|
|
|
Years ended December 31,
|
|
||||||
|
|
2018
|
|
|
2017
|
|
|||
Expected dividend yield
|
(a)
|
0.00
|
|
%
|
|
0.00
|
|
%
|
|
Expected volatility
|
(b)
|
129.23
|
|
%
|
|
137.60
|
|
%
|
|
Risk-free annual interest rate
|
(c)
|
2.51
|
|
%
|
|
1.53
|
|
%
|
|
Expected life (years)
|
(d)
|
|
3.6
|
|
|
|
3.26
|
|
|
Weighted average share price
|
|
$1.74
|
|
|
$2.05
|
|
|||
Weighted average exercise price
|
|
$1.74
|
|
|
$2.05
|
|
|||
Weighted average grant date fair value
|
|
$1.39
|
|
|
$1.62
|
|
(a)
|
The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
|
(b)
|
Based on the historical volatility of the Company's stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations.
|
(c)
|
Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options.
|
(d)
|
Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Years ended December 31,
|
|||||||
|
|
2018
|
|
2017
|
|
2016
|
|||
|
|
$
|
|
$
|
|
$
|
|||
Key management personnel compensation
(1)
|
|
|
|
|
|
|
|||
Salaries and short-term employee benefits
|
|
2,388
|
|
|
2,081
|
|
|
2,430
|
|
Consultants fees
|
|
62
|
|
|
—
|
|
|
—
|
|
Termination benefits
|
|
356
|
|
|
—
|
|
|
—
|
|
Post-employment benefits
|
|
147
|
|
|
59
|
|
|
78
|
|
Share-based compensation costs
|
|
462
|
|
|
87
|
|
|
1,051
|
|
|
|
3,415
|
|
|
2,227
|
|
|
3,559
|
|
Other employees compensation:
|
|
|
|
|
|
|
|||
Salaries and short-term employee benefits
|
|
1,325
|
|
|
3,584
|
|
|
3,574
|
|
Termination benefits (note 16)
|
|
—
|
|
|
1,806
|
|
|
—
|
|
Post-employment benefits
|
|
275
|
|
|
441
|
|
|
500
|
|
Share-based compensation costs
|
|
108
|
|
|
95
|
|
|
31
|
|
|
|
1,708
|
|
|
5,926
|
|
|
4,105
|
|
Professional fees
|
|
6,421
|
|
|
7,153
|
|
|
7,157
|
|
Insurance
|
|
1,303
|
|
|
949
|
|
|
870
|
|
Third-party R&D
|
|
498
|
|
|
3,758
|
|
|
11,796
|
|
Contracted sales force
|
|
256
|
|
|
22
|
|
|
14
|
|
Travel
|
|
256
|
|
|
831
|
|
|
1,185
|
|
Marketing services
|
|
176
|
|
|
698
|
|
|
5
|
|
Laboratory supplies
|
|
139
|
|
|
2
|
|
|
30
|
|
Other goods and services
|
|
342
|
|
|
162
|
|
|
160
|
|
Leasing costs, net of sublease receipts of $121 in 2018, $359 in 2017 and $345 in 2016
(2)
|
|
344
|
|
|
2,247
|
|
|
1,131
|
|
Transaction costs related to share purchase warrants
|
|
—
|
|
|
—
|
|
|
56
|
|
Depreciation and amortization
|
|
60
|
|
|
138
|
|
|
195
|
|
Impairment (reversal) losses
|
|
—
|
|
|
(44
|
)
|
|
85
|
|
Operating foreign exchange (gains) losses
|
|
17
|
|
|
(72
|
)
|
|
39
|
|
|
|
9,812
|
|
|
15,844
|
|
|
22,723
|
|
|
|
14,935
|
|
|
23,997
|
|
|
30,387
|
|
(1)
|
Key management includes the Company's executive management team and directors.
|
(2)
|
Leasing costs also include changes in the onerous lease provision (note 16 - provisions for restructuring and other costs), other than attributable to the unwinding of the discount.
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Years ended December 31,
|
|||||||
|
|
2018
|
|
2017
|
|
2016
|
|||
|
|
$
|
|
$
|
|
$
|
|||
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|||
Trade and other receivables
|
|
(95
|
)
|
|
158
|
|
|
228
|
|
Inventory
|
|
314
|
|
|
—
|
|
|
—
|
|
Prepaid expenses and other current assets
|
|
448
|
|
|
(343
|
)
|
|
(45
|
)
|
Other non-current assets
|
|
150
|
|
|
39
|
|
|
(233
|
)
|
Payables and accrued liabilities
|
|
(586
|
)
|
|
(1,080
|
)
|
|
(199
|
)
|
Taxes payable
|
|
1,669
|
|
|
—
|
|
|
—
|
|
Deferred revenues
|
|
400
|
|
|
—
|
|
|
555
|
|
Provision for restructuring and other costs (note 16)
|
|
(1,957
|
)
|
|
(435
|
)
|
|
(911
|
)
|
Employee future benefits (note 18)
|
|
(494
|
)
|
|
(551
|
)
|
|
(459
|
)
|
|
|
(151
|
)
|
|
(2,212
|
)
|
|
(1,064
|
)
|
|
|
Years ended December 31,
|
|||||||
|
|
2018
|
|
2017
|
|
2016
|
|||
|
|
$
|
|
$
|
|
$
|
|||
Current tax (expense) recovery
|
|
—
|
|
|
—
|
|
|
—
|
|
Deferred tax:
|
|
|
|
|
|
|
|||
Origination and reversal of temporary differences
|
|
(4,003
|
)
|
|
6,395
|
|
|
9,199
|
|
Adjustments in respect of prior years
|
|
742
|
|
|
(149
|
)
|
|
36
|
|
Change in unrecognized tax assets
|
|
(2,191
|
)
|
|
(2,767
|
)
|
|
(9,235
|
)
|
Income tax (expense) recovery
|
|
(5,452
|
)
|
|
3,479
|
|
|
—
|
|
|
|
Years ended December 31,
|
|||||||
|
|
2018
|
|
2017
|
|
2016
|
|||
Combined Canadian federal and provincial statutory income tax rate
|
|
26.7
|
%
|
|
26.8
|
%
|
|
26.9
|
%
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Years ended December 31,
|
|||||||
|
|
2018
|
|
2017
|
|
2016
|
|||
|
|
$
|
|
$
|
|
$
|
|||
Income tax (expense) recovery based on combined statutory income tax rate
|
|
(2,574
|
)
|
|
5,434
|
|
|
6,714
|
|
Change in unrecognized tax assets
|
|
(1,963
|
)
|
|
(2,701
|
)
|
|
(9,235
|
)
|
Change in unrecognized tax assets related to OCI
|
|
(188
|
)
|
|
(228
|
)
|
|
436
|
|
Share issuance costs
|
|
(40
|
)
|
|
164
|
|
|
224
|
|
Permanent difference attributable to the use of local currency for tax reporting
|
|
792
|
|
|
(71
|
)
|
|
(30
|
)
|
Change in enacted rates used
|
|
(58
|
)
|
|
(358
|
)
|
|
(16
|
)
|
Permanent difference attributable to net change in fair value of warrant liability
|
|
70
|
|
|
595
|
|
|
1,194
|
|
Share-based compensation costs
|
|
(152
|
)
|
|
(49
|
)
|
|
(291
|
)
|
Difference in statutory income tax rate of foreign subsidiaries
|
|
(917
|
)
|
|
768
|
|
|
972
|
|
Adjustments in respect of prior years
|
|
(372
|
)
|
|
(149
|
)
|
|
36
|
|
Other
|
|
(50
|
)
|
|
74
|
|
|
(4
|
)
|
|
|
(5,452
|
)
|
|
3,479
|
|
|
—
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
December 31,
|
||||
|
|
2018
|
|
2017
|
||
|
|
$
|
|
$
|
||
Deferred tax assets
|
|
|
|
|
||
Current:
|
|
|
|
|
||
Operating losses carried forward
|
|
—
|
|
|
3,479
|
|
Non-current:
|
|
|
|
|
||
Operating losses carried forward
|
|
764
|
|
|
696
|
|
Intangible assets
|
|
3,646
|
|
|
4,812
|
|
|
|
4,410
|
|
|
8,987
|
|
Deferred tax liabilities
|
|
|
|
|
||
Current:
|
|
|
|
|
||
Deferred revenues
|
|
38
|
|
|
—
|
|
Restricted cash
|
|
153
|
|
|
—
|
|
Payables and accrued liabilities
|
|
95
|
|
|
—
|
|
|
|
286
|
|
|
—
|
|
Non-current:
|
|
|
|
|
||
Property, plant and equipment
|
|
3
|
|
|
5
|
|
Deferred revenues
|
|
4,074
|
|
|
5,316
|
|
Other
|
|
47
|
|
|
187
|
|
|
|
4,124
|
|
|
5,508
|
|
|
|
4,410
|
|
|
5,508
|
|
Deferred tax assets (liabilities), net
|
|
—
|
|
|
3,479
|
|
|
|
December 31,
|
||||
|
|
2018
|
|
2017
|
||
|
|
$
|
|
$
|
||
Deferred tax assets
|
|
|
|
|
||
Current:
|
|
|
|
|
||
Deferred revenues and other provisions
|
|
649
|
|
|
584
|
|
|
|
649
|
|
|
584
|
|
Non-current:
|
|
|
|
|
||
Deferred revenues
|
|
—
|
|
|
—
|
|
Operating losses carried forward
|
|
81,731
|
|
|
82,421
|
|
SR&ED Pool
|
|
9,148
|
|
|
9,167
|
|
Unused tax credits
|
|
5,894
|
|
|
8,019
|
|
Employee future benefits
|
|
2,048
|
|
|
2,296
|
|
Property, plant and equipment
|
|
448
|
|
|
407
|
|
Share issuance expenses
|
|
467
|
|
|
841
|
|
Other
|
|
241
|
|
|
335
|
|
|
|
99,977
|
|
|
103,486
|
|
Unrecognized deferred tax assets
|
|
100,626
|
|
|
104,070
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Canada
|
||||
|
|
Federal
|
|
Provincial
|
||
|
|
$
|
|
$
|
||
2028
|
|
7,880
|
|
|
6,494
|
|
2029
|
|
4,791
|
|
|
4,773
|
|
2030
|
|
4,104
|
|
|
4,089
|
|
2031
|
|
1,753
|
|
|
1,737
|
|
2032
|
|
4,250
|
|
|
4,250
|
|
2033
|
|
3,721
|
|
|
3,721
|
|
2034
|
|
4,153
|
|
|
4,153
|
|
2035
|
|
10,418
|
|
|
10,452
|
|
2036
|
|
10,592
|
|
|
10,592
|
|
2037
|
|
7,343
|
|
|
7,343
|
|
2038
|
|
6,557
|
|
|
6,557
|
|
|
|
65,562
|
|
|
64,161
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
December 31, 2018
|
|
Financial assets at amortized cost
|
|
Financial liabilities at FVTPL
|
|
Financial liabilities at amortized cost
|
|
Total
|
||||
|
|
$
|
|
$
|
|
$
|
|
$
|
||||
Cash and cash equivalents (note 7)
|
|
14,512
|
|
|
—
|
|
|
—
|
|
|
14,512
|
|
Trade and other receivables (note 8)
|
|
245
|
|
|
—
|
|
|
—
|
|
|
245
|
|
Restricted cash equivalents (note 11)
|
|
418
|
|
|
—
|
|
|
—
|
|
|
418
|
|
Payables and accrued liabilities (note 15)
|
|
—
|
|
|
—
|
|
|
(2,940
|
)
|
|
(2,940
|
)
|
Provision for restructuring and other costs (note 16)
|
|
—
|
|
|
—
|
|
|
(1,298
|
)
|
|
(1,298
|
)
|
Warrant liability (note 17)
|
|
—
|
|
|
(3,634
|
)
|
|
—
|
|
|
(3,634
|
)
|
|
|
15,175
|
|
|
(3,634
|
)
|
|
(4,238
|
)
|
|
7,303
|
|
December 31, 2017
|
|
Financial assets at amortized cost
|
|
Financial liabilities at FVTPL
|
|
Financial liabilities at amortized cost
|
|
Total
|
||||
|
|
$
|
|
$
|
|
$
|
|
$
|
||||
Cash and cash equivalents (note 7)
|
|
7,780
|
|
|
—
|
|
|
—
|
|
|
7,780
|
|
Trade and other receivables (note 8)
|
|
35
|
|
|
—
|
|
|
—
|
|
|
35
|
|
Restricted cash equivalents (note 11)
|
|
381
|
|
|
—
|
|
|
—
|
|
|
381
|
|
Payables and accrued liabilities (note 15)
|
|
—
|
|
|
—
|
|
|
(2,687
|
)
|
|
(2,687
|
)
|
Provision for restructuring and other costs (note 16)
|
|
—
|
|
|
—
|
|
|
(3,497
|
)
|
|
(3,497
|
)
|
Warrant liability (note 17)
|
|
—
|
|
|
(3,897
|
)
|
|
—
|
|
|
(3,897
|
)
|
|
|
8,196
|
|
|
(3,897
|
)
|
|
(6,184
|
)
|
|
(1,885
|
)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Carrying
amount |
|
-30%
|
|
+30%
|
|||
|
|
$
|
|
$
|
|
$
|
|||
Warrant liability
|
|
3,634
|
|
|
1,792
|
|
|
(1,504
|
)
|
Total impact on net income – (decrease) / increase
|
|
|
|
1,792
|
|
|
(1,504
|
)
|
|
|
Years ended December 31,
|
|||||||
|
|
2018
|
|
2017
|
|
2016
|
|||
|
|
$
|
|
$
|
|
$
|
|||
Ireland
|
|
24,910
|
|
|
—
|
|
|
—
|
|
United States
|
|
1,416
|
|
|
452
|
|
|
410
|
|
China
|
|
275
|
|
|
262
|
|
|
249
|
|
Singapore
|
|
—
|
|
|
—
|
|
|
101
|
|
British Virgin Islands
|
|
280
|
|
|
206
|
|
|
100
|
|
Other
|
|
—
|
|
|
3
|
|
|
51
|
|
|
|
26,881
|
|
|
923
|
|
|
911
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
December 31,
|
||||
|
|
2018
|
|
2017
|
||
|
|
$
|
|
$
|
||
Germany
|
|
8,599
|
|
|
12,552
|
|
United States
|
|
153
|
|
|
102
|
|
Canada
|
|
3
|
|
|
160
|
|
|
|
8,755
|
|
|
12,814
|
|
*
|
Non-current assets include property, plant and equipment, identifiable intangible assets and goodwill.
|
|
|
Years ended December 31,
|
|||||||
|
|
2018
|
|
2017
|
|
2016
|
|||
|
|
$
|
|
$
|
|
$
|
|||
Net income (loss)
|
|
4,187
|
|
|
(16,796
|
)
|
|
(24,959
|
)
|
Basic weighted average number of shares outstanding
|
|
16,440,760
|
|
|
14,958,704
|
|
|
10,348,879
|
|
Diluted weighted average number of shares outstanding
|
|
17,034,812
|
|
|
14,958,704
|
|
|
10,348.879
|
|
Items excluded from the calculation of diluted net income (loss) per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect
|
|
|
|
|
|
|
|||
Stock options
|
|
889,685
|
|
|
713,918
|
|
|
968,397
|
|
Share purchase warrants
|
|
3,391,844
|
|
|
3,417,840
|
|
|
3,779,245
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Minimum lease payments
|
|
Minimum sublease receipts
|
|
Service and manufacturing
|
|
Total
|
||||
|
|
$
|
|
$
|
|
$
|
|
$
|
||||
Less than 1 year
|
|
408
|
|
|
(117
|
)
|
|
2,180
|
|
|
2,471
|
|
1 - 3 years
|
|
533
|
|
|
(24
|
)
|
|
—
|
|
|
509
|
|
4 - 5 years
|
|
60
|
|
|
—
|
|
|
—
|
|
|
60
|
|
More than 5 years
|
|
5
|
|
|
—
|
|
|
—
|
|
|
5
|
|
Total
|
|
1,006
|
|
|
(141
|
)
|
|
2,180
|
|
|
3,045
|
|
Aeterna Zentaris Inc.
|
||
Notes to Consolidated Financial Statements
|
||
As at December 31, 2018 and December 31, 2017 and for the years ended December 31, 2018, 2017 and 2016
|
||
(tabular amounts in thousands of US dollars, except share/option/warrant/DSU and per share/option/warrant/DSU data and as otherwise noted)
|
|
|
Three months ended December 31,
|
|
Years ended December 31,
|
|||||||||||
(in thousands, except share and per share data)
|
|
2018
|
|
2017
|
|
2018
|
|
2017
|
|
2016
|
|||||
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|||||
Revenues
|
|
|
|
|
|
|
|
|
|
|
|||||
License fees
|
|
(332
|
)
|
|
119
|
|
|
24,325
|
|
|
458
|
|
|
497
|
|
Product sales
|
|
1,446
|
|
|
—
|
|
|
2,167
|
|
|
—
|
|
|
—
|
|
Royalty income
|
|
184
|
|
|
—
|
|
|
184
|
|
|
—
|
|
|
—
|
|
Sales commission and other
|
|
94
|
|
|
59
|
|
|
205
|
|
|
465
|
|
|
414
|
|
Total revenues
|
|
1,392
|
|
|
178
|
|
|
26,881
|
|
|
923
|
|
|
911
|
|
Cost of sales
|
|
1,413
|
|
|
—
|
|
|
2,104
|
|
|
—
|
|
|
—
|
|
Gross income (loss)
|
|
(21
|
)
|
|
178
|
|
|
24,777
|
|
|
923
|
|
|
911
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|||||
Research and development costs
|
|
767
|
|
|
526
|
|
|
2,932
|
|
|
10,704
|
|
|
16,495
|
|
General and administrative expenses
|
|
1,665
|
|
|
2,778
|
|
|
8,894
|
|
|
8,198
|
|
|
7,147
|
|
Selling expenses
|
|
588
|
|
|
452
|
|
|
3,109
|
|
|
5,095
|
|
|
6,745
|
|
Total operating expenses
|
|
3,020
|
|
|
3,756
|
|
|
14,935
|
|
|
23,997
|
|
|
30,387
|
|
Income (loss) from operations
|
|
(3,041
|
)
|
|
(3,578
|
)
|
|
9,842
|
|
|
(23,074
|
)
|
|
(29,476
|
)
|
Settlements
|
|
(1,400
|
)
|
|
—
|
|
|
(1,400
|
)
|
|
—
|
|
|
—
|
|
Gain (loss) due to changes in foreign currency exchange rates
|
|
64
|
|
|
72
|
|
|
656
|
|
|
502
|
|
|
(70
|
)
|
Change in fair value of warrant liability
|
|
(1,489
|
)
|
|
(478
|
)
|
|
263
|
|
|
2,222
|
|
|
4,437
|
|
Warrant exercise inducement fee
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Other finance income
|
|
104
|
|
|
21
|
|
|
278
|
|
|
75
|
|
|
150
|
|
Net finance income (costs)
|
|
(1,321
|
)
|
|
(385
|
)
|
|
1,197
|
|
|
2,799
|
|
|
4,517
|
|
Income (loss) before income taxes
|
|
(5,762
|
)
|
|
(3,963
|
)
|
|
9,639
|
|
|
(20,275
|
)
|
|
(24,959
|
)
|
Income tax recovery (expense)
|
|
636
|
|
|
3,479
|
|
|
(5,452
|
)
|
|
3,479
|
|
|
—
|
|
Net income (loss)
|
|
(5,126
|
)
|
|
(484
|
)
|
|
4,187
|
|
|
(16,796
|
)
|
|
(24,959
|
)
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
|
|
|
|||||
Foreign currency translation adjustments
|
|
(13
|
)
|
|
(238
|
)
|
|
(260
|
)
|
|
(1,430
|
)
|
|
569
|
|
Actuarial gain (loss) on defined benefit plans
|
|
(418
|
)
|
|
59
|
|
|
193
|
|
|
694
|
|
|
(1,479
|
)
|
Comprehensive income (loss)
|
|
(5,557
|
)
|
|
(663
|
)
|
|
4,120
|
|
|
(17,532
|
)
|
|
(25,869
|
)
|
Net loss per share (basic)
|
|
(0.31
|
)
|
|
(0.03
|
)
|
|
0.25
|
|
|
(1.12
|
)
|
|
(2.41
|
)
|
Net loss per share (diluted)
|
|
(0.31
|
)
|
|
(0.03
|
)
|
|
0.24
|
|
|
(1.12
|
)
|
|
(2.41
|
)
|
|
|
December 31,
|
||||
(in thousands)
|
|
2018
|
|
2017
|
||
|
|
$
|
|
$
|
||
Cash and cash equivalents
|
|
14,512
|
|
|
7,780
|
|
Trade and other receivables and other current assets
|
|
1,504
|
|
|
1,047
|
|
Inventory
|
|
240
|
|
|
381
|
|
Restricted cash equivalents
|
|
418
|
|
|
554
|
|
Property, plant and equipment
|
|
65
|
|
|
9,381
|
|
Deferred tax assets
|
|
—
|
|
|
101
|
|
Other non-current assets
|
|
8,272
|
|
|
8,613
|
|
Total assets
|
|
25,011
|
|
|
22,195
|
|
Payables and accrued liabilities and income taxes payable
|
|
4,635
|
|
|
2,814
|
|
Current portion of provision for restructuring and other costs
|
|
887
|
|
|
2,469
|
|
Current portion of deferred revenues
|
|
74
|
|
|
486
|
|
Warrant liability
|
|
3,634
|
|
|
3,897
|
|
Non-financial non-current liabilities
(1)
|
|
13,874
|
|
|
14,229
|
|
Total liabilities
|
|
23,104
|
|
|
24,978
|
|
Shareholders' equity (deficiency)
|
|
1,907
|
|
|
(2,783
|
)
|
Total liabilities and shareholders' equity
|
|
25,011
|
|
|
22,195
|
|
1.
|
Comprised mainly of employee future benefits, provisions for restructuring and other costs and non-current portion of deferred revenues.
|
(in thousands, except for per share data)
|
|
Three months ended
|
||||||||||
|
|
December 31, 2018
|
|
September 30, 2018
|
|
June 30, 2018
|
|
March 31, 2018
|
||||
|
|
$
|
|
$
|
|
$
|
|
$
|
||||
Revenues
|
|
1,392
|
|
|
663
|
|
|
168
|
|
|
24,658
|
|
Net income (loss)
|
|
(5,126
|
)
|
|
(2,509
|
)
|
|
(2,602
|
)
|
|
14,424
|
|
Net income (loss) per share [basic]
|
|
(0.31
|
)
|
|
(0.15
|
)
|
|
(0.16
|
)
|
|
0.88
|
|
Net income (loss) per share [diluted]
|
|
(0.31
|
)
|
|
(0.15
|
)
|
|
(0.16
|
)
|
|
0.87
|
|
(in thousands, except for per share data)
|
|
Three months ended
|
||||||||||
|
|
December 31, 2017
|
|
September 30, 2017
|
|
June 30, 2017
|
|
March 31, 2017
|
||||
|
|
$
|
|
$
|
|
$
|
|
$
|
||||
Revenues
|
|
178
|
|
|
241
|
|
|
243
|
|
|
261
|
|
Net loss
|
|
(484
|
)
|
|
(9,631
|
)
|
|
(2,550
|
)
|
|
(4,131
|
)
|
Net (loss) income per share [basic]
|
|
(0.03
|
)
|
|
(0.61
|
)
|
|
(0.18
|
)
|
|
(0.31
|
)
|
Net loss per share [basic and diluted]
|
|
(0.03
|
)
|
|
(0.61
|
)
|
|
(0.18
|
)
|
|
(0.31
|
)
|
*
|
Net loss per share is based on the weighted average number of shares outstanding during each reporting period, which may differ on a quarter-to-quarter basis. As such, the sum of the quarterly net loss per share amounts may not equal full-year net loss per share.
|
(in thousands)
|
|
Years ended December 31,
|
|||||||
|
|
2018
|
|
2017
|
|
2016
|
|||
|
|
$
|
|
$
|
|
$
|
|||
Cash and cash equivalents - beginning of period
|
|
7,780
|
|
|
21,999
|
|
|
41,450
|
|
Cash (used in) provided by operating activities
|
|
6,825
|
|
|
(22,913
|
)
|
|
(29,010
|
)
|
Cash flows provided by financing activities
|
|
—
|
|
|
8,030
|
|
|
9,924
|
|
Cash flows provided by (used in) investing activities
|
|
(35
|
)
|
|
307
|
|
|
(314
|
)
|
Effect of exchange rate changes on cash and cash equivalents
|
|
(58
|
)
|
|
357
|
|
|
(51
|
)
|
Cash and cash equivalents - end of period
|
|
14,512
|
|
|
7,780
|
|
|
21,999
|
|
|
Warrants
|
Exercise Price
|
Expiry date
|
|
|
#
|
$
|
|
|
March 2015 registered direct offering - Series A
|
115,844
|
|
1.07
|
March 10, 2020
|
December 2015 registered direct offering
|
2,331,000
|
|
7.10
|
May 1, 2020
|
November 2016 registered direct offering
|
945,000
|
|
4.70
|
December 13, 2020
|
|
3,391,844
|
|
|
|
(in thousands)
|
|
Minimum lease payments
|
|
Minimum sublease receipts
|
|
Service and manufacturing
|
|
Total
|
||||
|
|
$
|
|
$
|
|
$
|
|
$
|
||||
Less than 1 year
|
|
408
|
|
|
(117
|
)
|
|
2,180
|
|
|
2,471
|
|
1 - 3 years
|
|
533
|
|
|
(24
|
)
|
|
—
|
|
|
509
|
|
4 - 5 years
|
|
60
|
|
|
—
|
|
|
—
|
|
|
60
|
|
More than 5 years
|
|
5
|
|
|
—
|
|
|
—
|
|
|
5
|
|
Total
|
|
1,006
|
|
|
(141
|
)
|
|
2,180
|
|
|
3,045
|
|
(in thousands)
|
|
Euros
|
|
Less than 1 year
|
|
453
|
|
1 – 3 years
|
|
921
|
|
4 – 5 years
|
|
944
|
|
More than 5 years
|
|
13,658
|
|
Total
|
|
15,976
|
|
1.
|
to receive the audited consolidated financial statements of the Corporation as at and for the year ended December 31, 2018, together with the auditors' report thereon;
|
2.
|
to elect directors;
|
3.
|
to appoint auditors and to authorize the directors to determine their compensation;
|
4.
|
to consider and, if deemed advisable, to pass an ordinary resolution approving the amended and restated shareholder rights plan (the “Rights Plan”);
|
5.
|
to consider and, if deemed advisable, to pass a special resolution to amend the articles of the corporation to change the province in which its registered office is situated from Quebec to Ontario; and
|
6.
|
to transact such other business as may properly come before the meeting.
|
SECTION 1. INTRODUCTION
|
|
SECTION 2 INFORMATION CONCERNING VOTING AT THE MEETING
|
|
2.1 Your Vote is Important
|
|
2.2 Voting
|
|
2.3 How to Vote — Registered Shareholders
|
|
2.4 How to Vote — Non-Registered Shareholders
|
|
2.5 Completing the Form of Proxy and the Exercise of Discretion of Proxies
|
|
2.6 Revocation of Proxies
|
|
SECTION 3 VOTING SHARES, QUORUM AND PRINCIPAL SHAREHOLDERS
|
|
3.1 Voting Shares and Quorum
|
|
3.2 Principal Shareholders
|
|
SECTION 4 PRESENTATION OF THE FINANCIAL STATEMENTS
|
|
SECTION 5 ELECTION OF DIRECTORS
|
|
5.1 Board of Directors
|
|
SECTION 6 DISCLOSURE OF COMPENSATION
|
|
6.1 Remuneration of Directors
|
|
6.2 Compensation of Executive Officers
|
|
6.3 Compensation Discussion & Analysis
|
|
6.4 Incentive Plan Awards — Value Vested or Earned During the Year
|
|
6.5 Securities Authorized for Issuance under Equity Compensation Plans
|
|
6.6 Performance Graph
|
|
6.7 Summary
|
|
SECTION 7 EMPLOYMENT, CHANGE OF CONTROL AND CONSULTING AGREEMENTS
|
|
7.1 Employment, Change of Control and Consulting Agreements
|
|
SECTION 8 APPOINTMENT OF AUDITORS AND AUDIT COMMITTEE DISCLOSURE
|
|
8.1 Appointment of Auditors
|
|
8.2 Audit Committee Disclosure
|
|
8.3 Composition of the Audit Committee
|
|
8.4 Education and Relevant Experience
|
|
8.5 Pre-Approval Policies and Procedures
|
|
8.6 External Auditor Service Fees
|
|
SECTION 9 APPROVAL OF THE RIGHTS PLAN
|
|
9.1 Background
|
|
9.2 Summary of the Rights Plan
|
|
9.3 Recommendation of the Board
|
|
SECTION 10
APPROVAL OF THE CHANGE OF REGISTERED OFFICE
|
|
10.1
Background
|
|
10.2
Recommendation of the Board
|
|
SECTION 11 STATEMENT OF CORPORATE GOVERNANCE PRACTICES
|
|
SECTION 12 INDEBTEDNESS OF DIRECTORS AND OFFICERS
|
|
SECTION 13 INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS
|
|
SECTION 14 SHAREHOLDER PROPOSALS FOR NEXT ANNUAL MEETING OF SHAREHOLDERS
|
|
SECTION 15 ADDITIONAL INFORMATION
|
|
SECTION 16 MAIL SERVICE INTERRUPTION
|
SECTION 17 DIRECTORS APPROVAL
|
|
|
|
ADDENDA
|
|
|
|
Schedule A:
Statement of Corporate Governance Practices
|
|
Schedule B:
Mandate of the Board of Directors
|
|
Schedule C:
Audit Committee Charter
|
|
Schedule D:
Mandate of the Nominating, Governance and Compensation Committee
|
SECTION 1.
|
INTRODUCTION
|
SECTION 2
|
INFORMATION CONCERNING VOTING AT THE MEETING
|
2.1
|
Your Vote is Important
|
2.2
|
Voting
|
1.
|
by telephone;
|
2.
|
by fax;
|
3.
|
on the internet; or
|
4.
|
by mail.
|
2.3
|
How to Vote — Registered Shareholders
|
2.4
|
How to Vote — Non-Registered Shareholders
|
2.5
|
Completing the Form of Proxy and the Exercise of Discretion of Proxies
|
2.6
|
Revocation of Proxies
|
SECTION 3
|
VOTING SHARES, QUORUM AND PRINCIPAL SHAREHOLDERS
|
3.1
|
Voting Shares and Quorum
|
3.2
|
Principal Shareholders
|
SECTION 4
|
PRESENTATION OF THE FINANCIAL STATEMENTS
|
SECTION 5
|
ELECTION OF DIRECTORS
|
5.1
|
Board of Directors
|
Name and Place of
Residence
|
|
Principal Occupation
|
|
Director
since
|
|
Total Securities
|
|
|
|
|
|
|
|
Common Shares
(1)
|
DSUs
|
Egbert, Carolyn
(3)
Texas, USA
|
|
Chair of the Board of Directors of the Corporation
Corporate Director |
|
2012
|
|
1,920
|
23,000
|
Smith Hoke, Robin
(3)
Ohio, USA
|
|
President and Chief Executive Officer of Leiter's Enterprises, Inc. (outsourcing provider of ophthalmology and hospital-based services)
|
|
2018
|
|
—
|
23,000
|
Limoges, Gérard
(2)
Quebec, Canada
|
|
Corporate Director
Former Deputy Chairman of Ernst & Young LLP Canada (accounting firm)
|
|
2004
|
|
1,200
|
23,000
|
Norton, Brent
(2)
Ontario, Canada
|
|
Corporate Director
Founder of PreMD Inc. (predictive medicine company)
|
|
2018
|
|
—
|
23,000
|
Pollack, Jonathan
(2)
Ontario, Canada
|
|
President of the JMP Group (investment and consulting firm) and Chief Financial Officer of AcuityAds (advertising)
|
|
2018
|
|
—
|
23,000
|
(1)
|
We do not have any direct information concerning the number of Common Shares beneficially owned by the nominees or concerning our Common Shares over which such persons exercise control or direction. This information was provided to us by the nominees individually.
|
(2)
|
Member of the Audit Committee.
|
(3)
|
Member of the NGCC.
|
a)
|
is, as at the date of this Circular or has been, within ten years before the date of this Circular, a director, chief executive officer or chief financial officer of any company (including us) that,
|
ii)
|
was subject to a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, that was in effect for a period of more than 30 consecutive days, that was issued after the proposed director ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer; or
|
b)
|
is, as at the date of this Circular, or has been within ten years before the date of this Circular, a director or executive officer of any company (including us) that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or
|
c)
|
has, within the ten years before the date of this Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed director:
|
•
|
Mr. Gérard Limoges served from 1999 to 2013 as a director of Supratek Pharma Inc., a company that was placed under Court protection under the
Companies’ Creditors Arrangement Act (Canada)
(the “CCAA”) in January 2009 and made a proposal that was accepted and homologated by the Court on October 30, 2009. In addition, Mr. Limoges was a director of Hart Stores Inc. when it sought protection under the CCAA on August 30, 2011. On February 27, 2012, the Quebec Superior Court sanctioned and approved the plan of compromise and arrangement filed by Hart Stores Inc. under the CCAA. Hart Stores Inc. was subject to a cease trade order issued by the Canadian securities regulatory authorities for failure to file annual and interim financial statements as well as the related management’s discussion and analysis and Chief Executive Officer and Chief Financial Officer certifications within the prescribed periods.
|
•
|
Dr. Brent Norton was a director and officer of PreMD Inc. in April 2009 when PreMD Inc. voluntarily delisted from the Toronto Stock Exchange. Later in April 2009, a general cease trade order by the Ontario Securities Commission was issued against PreMD Inc. for failure to file financial statements. These financial statements were not filed due to cost reasons and this remains so to date.
|
•
|
On February 24, 2014, Mr. Jonathan Pollack was appointed as a director of Hanfeng Evergreen Inc., which was a reporting issuer in all provinces and territories of Canada, and was listed on the Toronto Stock Exchange. Prior to his appointment as a director, the trading of the shares on the Toronto Stock Exchange of Hanfeng Evergreen Inc. had been previously suspended and a cease trade order for failure of to file financial statements had been previously issued by the British Columbia Securities Commission. Similar cease trade orders were subsequently issued by the Ontario Securities Commission (on March 3, 2014), the Autorité des marchés financiers (on March 7, 2014), the Manitoba Securities Commission (on April 16, 2014) and the Alberta Securities Commission (on April 16, 2014). The shares of Hanfeng Evergreen Inc. were delisted from the Toronto Stock Exchange on June 9, 2014. On August 20, 2014, Ernst & Young Inc. was appointed as a receiver and manager over all of the assets of Hanfeng Evergreen Inc.
|
•
|
Ms. Leslie Auld was Chief Financial Officer and a director of GeneNews Limited on January 18, 2016 when the Toronto Stock Exchange placed GeneNews Limited under remedial delisting review for failing to meet the Toronto Stock Exchange’s requirements with respect to working capital position and market capitalization. GeneNews Limited was granted until June 17, 2016 to demonstrate compliance with these continued listing requirements. In March 2016, the Ontario Securities Commission granted GeneNews Limited a management cease trade order for failure to file annual and interim financial statements as well as the related management’s discussion and analysis, annual information form, and Chief Executive Officer and Chief Financial Officer certifications within the prescribed periods. GeneNews Limited filed its annual filings on May 27, 2016 and completed its March 31, 2016 quarterly filings on June 15, 2016.
|
SECTION 6
|
DISCLOSURE OF COMPENSATION
|
6.1
|
Remuneration of Directors
|
6.1.1
|
Compensation of Outside Directors
|
Type of Compensation
|
|
Annual Retainer for the year 2018
|
Monthly Retainer for January 2018
|
Chair of the Board Retainer
|
|
80,000
|
-
|
Board Member Retainer
|
|
40,000
|
-
|
Audit Committee Chair Retainer
|
|
20,000
|
-
|
Audit Committee Member Retainer
|
|
5,000
|
-
|
NGCC Chair Retainer
|
|
15,000
|
-
|
NGCC Member Retainer
|
|
3,000
|
-
|
SRC Chair Retainer
|
|
-
|
7,500
|
SRC Member Retainer
|
|
-
|
7,500
|
6.1.2
|
Outstanding Option-Based Awards and Share-Based Awards
|
|
|
Option-based Awards
|
|
Share-based Awards
|
||||||||||||||||||||
Name
|
|
Issuance Date
|
|
Number of
Securities
Underlying
Unexercised
Options
|
|
Option
Exercise Price
|
|
Option
Expiration Date
|
|
Value of
Unexercised In-the-money
Options
(1)
|
|
Issuance Date
|
|
Number of
Shares or
Units of Shares
that have Not
Vested
|
|
Market or Payout
Value of Share-based
Awards that have Not Vested
(2)
|
||||||||
|
|
(mm-dd-yyyy)
|
|
(#)
|
|
($)
|
|
(mm-dd-yyyy)
|
|
($)
|
|
(mm-dd-yyyy)
|
|
(#)
|
|
($)
|
||||||||
Cardiff, Michael
|
|
05-10-2016
|
|
|
20,000
|
|
|
3.48
|
|
|
05-09-2023
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
12-06-2016
|
|
|
7,850
|
|
|
3.45
|
|
|
12-06-2023
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
08-15-2017
|
|
|
60,000
|
|
|
2.05
|
|
|
08-15-2024
|
|
|
53,400
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
05-08-2018
|
|
|
23,000
|
|
|
67,620
|
|
|
Egbert, Carolyn
|
|
05-10-2016
|
|
|
10,000
|
|
|
3.48
|
|
|
05-09-2023
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
12-06-2016
|
|
|
7,850
|
|
|
3.45
|
|
|
12-06-2023
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
08-15-2017
|
|
|
60,000
|
|
|
2.05
|
|
|
08-15-2024
|
|
|
53,400
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
05-08-2018
|
|
|
23,000
|
|
|
67,620
|
|
|
Ernst, Juergen
|
|
05-10-2016
|
|
|
10,000
|
|
|
3.48
|
|
|
05-09-2023
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
12-06-2016
|
|
|
7,850
|
|
|
3.45
|
|
|
12-06-2023
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
08-15-2017
|
|
|
60,000
|
|
|
2.05
|
|
|
08-15-2024
|
|
|
53,400
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
05-08-2018
|
|
|
23,000
|
|
|
67,620
|
|
|
Smith Hoke, Robin
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
05-08-2018
|
|
|
23,000
|
|
|
67,620
|
|
Limoges, Gérard
|
|
05-10-2016
|
|
|
10,000
|
|
|
3.48
|
|
|
05-09-2023
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
12-06-2016
|
|
|
7,850
|
|
|
3.45
|
|
|
12-06-2023
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
08-15-2017
|
|
|
60,000
|
|
|
2.05
|
|
|
08-15-2024
|
|
|
53,400
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
05-08-2018
|
|
|
23,000
|
|
|
67,620
|
|
||
Norton, Brent
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
05-08-2018
|
|
|
23,000
|
|
|
67,620
|
|
Pollack, Jonathan
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
05-08-2018
|
|
|
23,000
|
|
|
67,620
|
|
(1)
|
"Value of unexercised in-the-money options" at financial year-end is calculated based on the difference between the closing prices of the Common Shares on the NASDAQ on the last trading day of the fiscal year (December 31, 2018) of $2.94 and the exercise price of the options, multiplied by the number of unexercised options.
|
(2)
|
The Corporation used the closing price of its Common Shares on the NASDAQ as at the last trading day of the fiscal year (December 31, 2018) of $2.94.
|
6.1.3
|
Total Compensation of Outside Directors
|
Name
|
|
Fees earned
(1)
|
|
Share-based
Awards (2) |
|
Option-based
Awards |
|
Non-Equity
Incentive Plan Compensation |
|
Pension
Value |
|
All Other
Compensation |
|
Total
|
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
Cardiff, Michael
|
|
53,555
|
|
41,170
|
|
—
|
|
—
|
|
—
|
|
—
|
|
94,725
|
Egbert, Carolyn
(3)
|
|
177,500
|
|
41,170
|
|
—
|
|
—
|
|
—
|
|
—
|
|
218,670
|
Ernst, Juergen
|
|
51,065
|
|
41,170
|
|
—
|
|
—
|
|
—
|
|
—
|
|
92,235
|
Smith Hoke, Robin
|
|
27,879
|
|
41,170
|
|
—
|
|
—
|
|
—
|
|
—
|
|
69,049
|
Limoges, Gérard
|
|
67,500
|
|
41,170
|
|
—
|
|
—
|
|
—
|
|
—
|
|
108,670
|
Norton, Brent
|
|
29,176
|
|
41,170
|
|
—
|
|
—
|
|
—
|
|
—
|
|
70,346
|
Pollack, Jonathan
|
|
29,176
|
|
41,170
|
|
—
|
|
—
|
|
—
|
|
—
|
|
70,346
|
6.2
|
Compensation of Executive Officers
|
•
|
Mr. Michael V. Ward, who currently serves as President and Chief Executive Officer as an employee;
|
•
|
Mr. James Clavijo, who served as Chief Financial Officer as an employee from March 5, 2018 to September 24, 2018;
|
•
|
Ms. Leslie Auld, who currently serves as Senior Vice President, Chief Financial Officer as an independent contractor from September 24, 2018; and
|
•
|
Dr. Richard Sachse, who served as Senior Vice President and Chief Scientific and Chief Medical Officer until June 14, 2018, Mr. Brian Garrison, who currently serves as Senior Vice President, Global Commercial Operations, and Eckhard Guenther, who currently serves as Vice President, Alliance Management, who were our three most highly compensated executive officers (other than our Chief Executive Officer and our current and former Chief Financial Officer) during 2018.
|
6.2.1
|
Determining Compensation
|
6.3
|
Compensation Discussion & Analysis
|
6.3.1
|
Compensation Philosophy and Objectives
|
•
|
providing the opportunity for an executive to earn compensation that is competitive with the compensation received by executives serving in the same or measurably similar positions within comparable companies;
|
•
|
providing the opportunity for executives to participate in equity-based incentive compensation plans;
|
•
|
aligning executive compensation with our corporate objectives; and
|
•
|
attracting and retaining highly qualified individuals in key positions.
|
6.3.2
|
Compensation Elements
|
6.3.3
|
Positioning
|
6.3.4
|
Risk Assessment of Executive Compensation Program
|
6.3.5
|
2018 Compensation
|
Goal
|
|
Result
|
Commercialization of Macrilen™ (macimorelin) in Europe and ROW
|
Assuming EMA approval, develop strategy and implementation plan for commercialization through the out-licensing of Macrilen™ (macimorelin) for Europe and ROW
|
The Board developed and approved a strategy to out-license macimorelin for the ROW, but the Corporation did not secure acceptable ROW agreements in 2018. The Corporation subsequently (in 2019) engaged Torreya to assist in identifying and executing upon such opportunities.
|
Successfully execute the board-approved strategy and implementation plan.
|
Not completed. The Board approved a strategy and implementation plan to pursue commercialization opportunities for macimorelin for the ROW and to implement non-macimorelin related opportunities. The Corporation explored several potential opportunities, but none resulted in a transaction that was acceptable to the Corporation.
|
|
Deploy all effective resources to ensure timely EMA approval of Macrilen™ (macimorelin).
|
Completed. EMA approval of macimorelin was obtained in January 2019 based on the work of the Corporation during 2018.
|
|
Commercialization of Macrilen™ (macimorelin) in United States and Canada
|
Provide effective support to Strongbridge in its commercialization efforts to ensure Macrilen™ (macimorelin) is timely marketed in 2018.
|
Not completed. The Corporation provided support, but efforts were slowed due to Strongbridge’s sale of its license rights to Novo Nordisk A/S in December 2018.
|
Ensure effective clinical studies are in place to obtain approval of pediatric indication of Macrilen™ (macimorelin).
|
In progress. The Corporation is collaborating with Novo Nordisk (and previously with Strongbridge) and is providing appropriate activities with respect to the ongoing clinical studies that are required to obtain approval for the pediatric indication of Macrilen™.
|
|
Improve operations
|
Manage costs and control expenses to maximize cash conservation.
|
In progress. The Corporation is focused on cost-savings and cash conservation. To this end, the Corporation reduced operating costs in both Germany and the United States in 2018. This continues to be an important objective in 2019.
|
Provide cash forecast by month on a 24-month projection.
|
The Corporation remains focused on aligning essential personnel, both in Germany and the United States, with the Corporation’s strategy and improving cost-effectiveness. In 2018, this included the termination of employment of certain employees.
|
|
Ensure effective and efficient use of resources and personnel.
|
The Corporation remains focused on aligning essential personnel, both in Germany and the United States, with the Corporation’s strategy and improving cost-effectiveness. In 2018, this included the termination of employment of certain employees.
|
|
Ensure that performance milestones for key managers align with and support CEO milestones.
|
Completed.
|
|
|
|
|
6.3.6
|
Long-Term Equity Compensation
|
•
|
any amendment to Section 3.2 of the Stock Option Plan (which sets forth the limit on the number of options that may be granted to insiders) that would have the effect of permitting, without having to obtain shareholder approval on a "disinterested vote" at a duly convened shareholders' meeting, the grant of any option(s) under the Stock Option Plan otherwise prohibited by Section 3.2;
|
•
|
any amendment to the number of securities issuable under the Stock Option Plan (except for certain permitted adjustments, such as in the case of stock splits, consolidations or reclassifications);
|
•
|
any amendment that would permit any option granted under the Stock Option Plan to be transferable or assignable other than by will or in accordance with the applicable laws of estates and succession;
|
•
|
the addition of a cashless exercise feature, payable in cash or securities, which does not provide for a full deduction of the number of underlying securities from the Stock Option Plan reserve;
|
•
|
the addition of a deferred or restricted share unit component or any other provision that results in employees receiving securities while no cash consideration is received by us;
|
•
|
with respect to any Participant, whether or not such Participant is an "insider" and except in respect of certain permitted adjustments, such as in the case of stock splits, consolidations or reclassifications:
|
•
|
any reduction in the exercise price of any option after the option has been granted, or
|
•
|
any cancellation of an option and the re-grant of that option under different terms, or
|
•
|
any extension to the term of an option beyond its Outside Expiry Date to a Participant who is an "insider" (except for extensions made in the context of a "blackout period");
|
•
|
any amendment to the method of determining the exercise price of an option granted pursuant to the Stock Option Plan;
|
•
|
the addition of any form of financial assistance or any amendment to a financial assistance provision which is more favorable to employees; and
|
•
|
any amendment to the foregoing amending provisions requiring Board, shareholder and regulatory approvals.
|
•
|
amendments of a "housekeeping" or clerical nature or to clarify the provisions of the Stock Option Plan;
|
•
|
amendments regarding any vesting period of an option;
|
•
|
amendments regarding the extension of an option beyond an Early Expiry Date in respect of any Participant, or the extension of an option beyond the Outside Expiry Date in respect of any Participant who is a "non-insider";
|
•
|
adjustments to the number of issuable Common Shares underlying, or the exercise price of, outstanding options resulting from a split or a consolidation of the Common Shares, a reclassification, the payment of a stock dividend, the payment of a special cash or non-cash distribution to our shareholders on a
pro rata
basis provided such distribution is approved by our shareholders in accordance with applicable law, a recapitalization, a reorganization or any other event which necessitates an equitable adjustment to the outstanding options in proportion with corresponding adjustments made to all outstanding Common Shares;
|
•
|
discontinuing or terminating the Stock Option Plan; and
|
•
|
any other amendment which does not require shareholder approval under the terms of the Stock Option Plan.
|
•
|
Stock options or stock appreciation rights shall be forfeited, to the extent stock options or stock appreciation rights are not vested and exercisable;
|
•
|
During the applicable restriction period, restricted stock and any accrued but unpaid dividends that are at that time subject to restrictions shall be forfeited; and
|
•
|
During the applicable deferral period or portion thereof to which forfeiture conditions apply, or upon failure to satisfy any other conditions precedent to the delivery of common shares or cash to which RSUs, performance shares or performance units relate, all performance shares, performance units and RSUs and any other accrued but unpaid dividend equivalents with respect to such RSUs that are then subject to deferral or restriction shall be forfeited.
|
•
|
stock options and SARs, whether vested or unvested, will become fully exercisable and holders of these awards will be permitted immediately before the change in control to exercise them;
|
•
|
restricted stock and RSUs with time-based vesting (i.e., not subject to achievement of performance goals) will become fully vested immediately before the change in control, and RSUs will be settled as promptly as is practicable in accordance with applicable law; and
|
•
|
restricted stock, RSUs, performance shares, and performance units that vest based on the achievement of performance goals will become fully vested and earned based on the target performance level as to the performance goals, such that 100% of the target award is earned as of the date of the change of control; and the RSUs and performance units will be settled as promptly as is practicable in accordance with applicable law.
|
|
|
Option-based Awards
|
|
Share-based Awards
|
|||||||||||||
Name
|
|
Issuance Date
|
|
Number of
Securities Underlying Unexercised Options (1) |
|
Option
Exercise Price |
|
Option
Expiration Date |
|
Value of
Unexercised In-the-money Options (2) |
|
Issuance Date
|
|
Number of
Shares or Units of shares that have Not Vested |
|
Market or Payout
Value of Share-based Awards that have Not Vested |
|
|
|
(mm-dd-yyyy)
|
|
(#)
|
|
($)
|
|
(mm-dd-yyyy)
|
|
($)
|
|
|
|
(#)
|
|
($)
|
|
Auld, Leslie
|
|
—
|
|
—
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
Clavijo, James
(3)
|
|
—
|
|
—
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
Garrison, Brian
|
|
11/17/2015
|
|
500
|
|
|
116.00
|
|
11/17/2022
|
|
—
|
|
—
|
|
—
|
|
—
|
|
12/21/2015
|
|
3,000
|
|
|
4.58
|
|
12/21/2022
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
12/06/2016
|
|
2,500
|
|
|
3.45
|
|
12/06/2023
|
|
—
|
|
—
|
|
—
|
|
—
|
|
Guenther, Eckhard
|
|
12/21/2015
|
|
5,000
|
|
|
4.58
|
|
12/21/2022
|
|
—
|
|
—
|
|
—
|
|
—
|
|
11/08/2016
|
|
398
|
|
|
3.50
|
|
11/08/2023
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
12/06/2016
|
|
10,000
|
|
|
3.45
|
|
12/06/2023
|
|
—
|
|
—
|
|
—
|
|
—
|
|
Sachse, Richard
(4)
|
|
—
|
|
—
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
Ward, Michael V.
|
|
08/15/2017
|
|
150,000
|
|
|
2.05
|
|
08/15/2024
|
|
133,500
|
|
—
|
|
—
|
|
—
|
|
04/02/2018
|
|
50,000
|
|
|
1.46
|
|
04/02/2025
|
|
74,000
|
|
—
|
|
—
|
|
—
|
|
|
06/22/2018
|
|
100,000
|
|
|
2.11
|
|
06/22/2025
|
|
83,000
|
|
—
|
|
—
|
|
—
|
(1)
|
The number of securities underlying unexercised options represents all awards outstanding at December 31, 2018.
|
(2)
|
"Value of unexercised in-the-money options" at financial year-end is calculated based on the difference between the closing price of the Common Shares on the NASDAQ on the last trading day of the fiscal year (December 31, 2018) of $2.94 and the exercise price of the options, multiplied by the number of unexercised options.
|
(3)
|
Mr. Clavijo ceased to be the Chief Financial Officer on September 24, 2018. All outstanding stock options held by Mr. Clavijo were cancelled in accordance with the provisions of the Stock Option Plan.
|
(4)
|
Dr. Sachse's employment was terminated effective June 14, 2018. All outstanding stock options held by Dr. Sachse were cancelled in accordance with the provisions of the Stock Option Plan.
|
6.4
|
Incentive Plan Awards — Value Vested or Earned During the Year
|
Name
|
|
Option-based awards — Value
vested during the year (1) |
|
Share-based awards —
Value vested during the year |
|
Non-equity incentive plan compensation — Value earned during the year
|
|
|
($)
|
|
($)
|
|
($)
|
Auld, Leslie
|
|
—
|
|
—
|
|
—
|
Clavijo, James
|
|
—
|
|
—
|
|
—
|
Garrison, Brian
|
|
3,074
|
|
—
|
|
35,000
|
Guenther, Eckhard
|
|
12,299
|
|
—
|
|
—
|
Sachse, Richard
|
|
—
|
|
—
|
|
120,000
|
Ward, Michael V.
|
|
—
|
|
—
|
|
35,000
|
|
|
|
|
|
|
|
(1)
|
Represents the aggregate dollar value that would have been realized if the options had been exercised on the vesting date, based on the difference between the closing price of the Common Shares on the NASDAQ and the exercise price on such vesting date.
|
6.4.1
|
Summary Compensation Table
|
|
Non-equity incentive plan compensation
|
|
|||||||||||||||||||||
Name and principal position
|
Years
|
|
Salary
|
|
Share
based
awards
|
|
Option based awards (1)
|
|
Annual
incentive
plan
|
|
Long-term
incentive
plans
|
Pension
Value
|
|
All other compensation
|
|
Total
compensation
|
|||||||
|
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
|
($)
|
($)
|
|
($)
|
|
($)
|
|||||||
Ward, Michael V.
President and Chief Executive Officer
|
2018
|
|
325,000
|
|
|
—
|
|
|
227,241
|
|
|
35,000
|
|
|
—
|
|
—
|
|
|
—
|
|
|
587,241
|
2017
|
|
121,461
|
|
|
—
|
|
|
242,495
|
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
|
363,956
|
|
2016
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
|
—
|
|
Clavijo, James
(2)
Former Chief Financial Officer
|
2018
|
|
190,574
|
|
|
—
|
|
|
130,240
|
|
|
—
|
|
|
—
|
|
—
|
|
|
137,500
|
|
|
458,314
|
2017
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
|
—
|
|
2016
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
|
—
|
|
Auld, Leslie
Senior Vice President, Chief Financial Officer
|
2018
|
|
62,385
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
|
62,385
|
2017
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
|
—
|
|
2016
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
|
—
|
|
Sachse, Richard
(4)
Former Senior Vice President, Chief Scientific Officer and Chief Medical Officer
|
2018
|
|
403,297
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
|
403,297
|
2017
|
|
222,000
|
|
|
—
|
|
|
—
|
|
|
120,000
|
|
|
—
|
|
37,067
|
|
|
—
|
|
|
379,067
|
|
2016
|
|
222,000
|
|
|
—
|
|
|
257,000
|
|
|
55,500
|
|
|
—
|
|
37,067
|
|
|
—
|
|
|
571,567
|
|
Garrison, Brian
Senior Vice President, Global Commercial Operations
|
2018
|
|
235,015
|
|
|
—
|
|
|
3,550
|
|
|
35,000
|
|
|
—
|
|
—
|
|
|
—
|
|
|
273,565
|
2017
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
|
—
|
|
2016
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
—
|
|
|
—
|
|
|
—
|
|
Guenther, Eckhard
Vice President, Alliance Management |
2018
|
|
191,242
|
|
|
—
|
|
|
—
|
|
|
13,154
|
|
|
—
|
|
3,298
|
|
|
—
|
|
|
207,694
|
2017
|
|
155,318
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
2,970
|
|
|
—
|
|
|
158,288
|
|
2016
|
|
152,510
|
|
|
—
|
|
|
27,797
|
|
|
—
|
|
|
—
|
|
2,851
|
|
|
—
|
|
|
183,158
|
(1)
|
The value of option-based awards represents the closing price of the Common Shares on the NASDAQ on the last trading day preceding the date of grant multiplied by the Black-Scholes factor as at such date and the number of stock options granted on such date. The following table sets forth the value of the option-based awards and the corresponding Black-Scholes factor:
|
(2)
|
Mr. Clavijo received a severance payment of $137,500 following the date that he ceased to be the Chief Financial Officer on September 24, 2018. All outstanding stock options held by Mr. Clavijo were cancelled in accordance with the provisions of the Stock Option Plan.
|
(3)
|
We maintained a reinsured benevolent fund (
Rückgedeckte Unterstützungskasse
), which is a type of private defined contribution pension plan, for Dr. Sachse. We contributed to a private pension provider an amount equal to 2.4% of Dr. Sachse’s salary, up to a monthly salary limit of €6,050, plus an additional contribution of 18% of the amount of Dr. Sachse’s salary that exceeds the monthly limit. Dr. Sachse also contributed a percentage of his salary to the plan. We are liable to Dr. Sachse for the pension benefits that have been promised, if the private pension provider does not, or cannot, pay the promised pension payments. We obtained reinsurance against the insolvency or liquidation of the private pension provider. The table below sets forth additional information
|
Accumulated value at start of year
|
Compensatory
|
Accumulated value at year end
|
$133,639
|
$12,258
|
$145,897
|
6.4.2
|
Compensation of the Chief Executive Officer
|
6.5
|
Securities Authorized for Issuance under Equity Compensation Plans
|
6.6
|
Performance Graph
|
|
12/31/2013
|
12/31/2014
|
12/31/2015
|
12/31/2016
|
12/31/2017
|
12/31/2018
|
Aeterna Zentaris (NASDAQ)
|
$100.00
|
$43.48
|
$3.25
|
$2.61
|
$1.71
|
$2.13
|
NASDAQ Capital Market Composite Index (^RCMP)
|
$100.00
|
$94.40
|
$78.38
|
$89.85
|
$104.94
|
$88.53
|
NASDAQ Biotechnology Index (^NBI)
|
$100.00
|
$134.10
|
$149.42
|
$117.02
|
$141.66
|
$128.45
|
6.7
|
Summary
|
SECTION 7
|
EMPLOYMENT, CHANGE OF CONTROL AND CONSULTING AGREEMENTS
|
7.1
|
Employment, Change of Control and Consulting Agreements
|
•
|
a "Change of Control" shall be deemed to have occurred in any of the following circumstances: (i) subject to certain exceptions, upon the acquisition by a person (or one or more persons who are affiliates of one another or who are acting jointly or in concert) of a beneficial interest in our securities representing in any circumstance 50% or more of the voting rights attaching to our then outstanding securities; (ii) upon a sale or other disposition of all or substantially all of our assets; (iii) upon a plan of liquidation or dissolution of us; or (iv) if, for any reason, including our amalgamation, merger or consolidation with or into another company, the individuals who, during the term of the change of control agreement, constituted the Board (and any new directors whose appointment by the Board or whose nomination for election by our shareholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors during the term of the change of control agreement or whose appointment or nomination for election was previously so approved) cease to constitute a majority of the members of the Board;
|
•
|
termination of employment for "Cause" includes (but is not limited to) (i) if the Executive commits any fraud, theft, embezzlement or other criminal act of a similar nature, or (ii) if the Executive commits an act of serious misconduct or willful or gross negligence in the performance of his duties.
|
Name
|
Termination Provisions
Value ($) (1) (2) |
Auld, Leslie
|
0
|
Garrison, Brian
|
0
|
Guenther, Eckhard
|
94,800
|
Ward, Michael V.
|
487,500
|
(1)
|
The termination values assume that the triggering event took place on the last business day of our financial year-end (December 31, 2018).
|
(2)
|
Value of earned/unused vacation, if applicable, and amounts owing for expense reimbursement are not included as they are not considered as “incremental” payments made in connection with termination of employment.
|
SECTION 8
|
APPOINTMENT OF AUDITORS AND AUDIT COMMITTEE DISCLOSURE
|
8.1
|
Appointment of Auditors
|
8.2
|
Audit Committee Disclosure
|
8.3
|
Composition of the Audit Committee
|
8.4
|
Education and Relevant Experience
|
8.5
|
Pre-Approval Policies and Procedures
|
8.6
|
External Auditor Service Fees
|
Fees
|
Financial Year Ended
December 31, 2018
|
Financial Year Ended
December 31, 2017
|
Audit Fees
(1)
|
563,558
|
506,309
|
Audit-Related Fees
(2)
|
—
|
113,430
|
Tax Advisory Fees
(3)
|
36,224
|
5,426
|
All other Fees
(4)
|
—
|
—
|
Total Fees:
|
599,782
|
625,165
|
(1)
|
Refers to all fees incurred in respect of audit services, being the professional services rendered by our external auditor for the audit and review of our financial statements as well as services normally provided by the external auditor in connection with statutory and regulatory filings and engagements.
|
(2)
|
Includes audit or attest services not required by statute or regulation, employee benefit plan audits, due diligence services, and accounting consultations on proposed transactions, including the review of prospectuses and prospectus supplements and the delivery of customary consent and comfort letters in connection therewith.
|
(3)
|
Refers to all fees incurred in respect of tax compliance, tax planning and tax advice.
|
(4)
|
Refers to all fees not included in audit fees, audit-related fees and tax fees.
|
SECTION 9
|
APPROVAL OF THE RIGHTS PLAN
|
•
|
the provisions in which future shareholder approval is required to ratify the continued existence of the Rights Plan will be revised to specify that such events will occur at every third annual meeting of the shareholders subsequent to the annual meeting of shareholders whereby the Rights Plan is initially approved, as well as the addition of certain provisions in respect of the effective date of the plan to give effect to the fact that the Rights Plan is in effect a continuation of the Existing Rights Plan;
|
•
|
the definition of “
Acquiring Person
” will exclude Convertible Security Acquisitions (as defined below);
|
•
|
the definition of “
Beneficial Owner
”, “
Beneficial Ownership
” and “
Beneficially Own
” will:
|
◦
|
exclude securities that may be acquired pursuant to any agreement related to an amalgamation, merger, arrangement, business combination or other similar transaction (statutory or otherwise, but for greater certainty not including a Take-over Bid) that is conditional upon shareholder approval prior to such Person acquiring such securities; and
|
◦
|
include securities which are subject to a lock-up or similar agreement to tender or deposit them into any Take-over Bid made by such Person or made by any Affiliate or Associate of such Person or made by any other person acting jointly or in concert with such Person, other than Permitted Lock-up Agreements;
|
•
|
“
Convertible Security Acquisitions
” will be defined to mean an acquisition of Voting Shares by a Person upon the purchase, exercise, conversion or exchange of Convertible Securities, where such Convertible Securities are acquired or received by such Person pursuant to a Permitted Bid Acquisition, an Exempt Acquisition or a Pro Rata Acquisition;
|
•
|
the definition of “
Market Price
” will be the average of the daily closing price per security on the 20 consecutive trading days (i.e. days on which the TSX or another stock exchange or national securities quotation system on which the Common Shares are traded (including for greater certainty, each of the Nasdaq Global Select Market, the Nasdaq Global Market and the Nasdaq Capital Market) is open for the transaction of business, subject to certain exceptions), through and including the trading day immediately preceding such date of determination, subject to certain exceptions;
|
•
|
the definition of “
Permitted Lock-Up Agreement
” will be added (as described below); and
|
•
|
certain other amendments of a non-substantive, “housekeeping” nature have been made to provide for greater clarity and consistency.
|
1.
|
the Rights Plan, as substantially described in the management proxy circular of the Corporation dated March 26, 2019 be, and it is hereby, ratified, confirmed and approved; and
|
2.
|
any one director or officer of the Corporation, be, and each of them is hereby, authorized and directed for and on behalf and in the name of the Corporation, to execute or cause to be executed and to deliver or cause to be delivered all such documents, and to do or cause to be done all such acts and things, as in the opinion of such director or officer may be necessary or desirable in order to give effect to this resolution.’’
|
1.
|
the board of directors of the Corporation be and is hereby authorized, subject to approval of the applicable regulatory authorities, to take such actions as are necessary to amend the Articles of the Corporation to change the Province in Canada where the registered office is situated from Quebec to Ontario and to fix the registered office address in the Province of Ontario to 5300 Commerce Court West, 199 Bay Street, Toronto, Ontario, M5L 1B9.
|
2.
|
any officer or director of the Corporation is hereby authorized to take all action necessary or desirable in his or her opinion to implement the foregoing, including the execution and delivery of all such notices, filings, instruments, deeds and documents, and the taking of any other actions, necessary or desirable in his or her opinion to implement the foregoing.’’
|
SECTION 12
|
INDEBTEDNESS OF DIRECTORS AND OFFICERS
|
SECTION 13
|
INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS
|
SECTION 14
|
SHAREHOLDER PROPOSALS FOR NEXT ANNUAL MEETING OF SHAREHOLDERS
|
•
|
one copy of our audited annual financial statements for our most recently completed financial year together with the report of the auditors thereon and Management’s Discussion and Analysis for such financial year and one copy of any interim financial statements that we published subsequent to the financial statements for our most recent financial year and Management’s Discussion and Analysis thereon; and
|
•
|
one copy of this Circular.
|
Alberta
Suite 600, 530, 8
th
Avenue SW
Calgary, Alberta
T2P 3S8
|
|
Quebec
7
th
Floor
1500 Robert-Bourassa Boulevard
Montréal, Quebec
H3A 3S8
|
Ontario
8
th
Floor
100 University Avenue
Toronto, Ontario
M5J 2Y1
|
|
British Columbia
2
nd
Floor 830
510 Burrard Street
Vancouver, British Columbia
V6C 3B9
|
SECTION 17
|
DIRECTORS APPROVAL
|
1.
|
BOARD OF DIRECTORS
|
A.
|
Disclose the identity of directors who are independent.
|
B.
|
Disclose the identity of directors who are not independent and describe the basis for that determination.
|
C.
|
Disclose whether or not a majority of directors are independent. If a majority of directors are not independent, describe what the Board of Directors (the “Board”) does to facilitate its exercise of independent judgment in carrying out its responsibilities.
|
D.
|
If a director is presently a director of any other issuer that is a reporting issuer (or the equivalent) in a jurisdiction or a foreign jurisdiction, identify both the director and the other issuer.
|
E.
|
Disclose whether or not the independent directors hold regularly scheduled meetings at which non-independent directors and members of management are not in attendance. If the independent directors hold such meetings, disclose the number of meetings held since the beginning of the issuer’s most recently completed financial year. If not, describe what the Board does to facilitate open and candid discussion amongst its independent directors.
|
F.
|
Disclose whether or not the Chair of the Board is an independent director. If the Board has a chair or lead director who is an independent director, disclose the identity of the independent chair or lead director, and describe his or her role and responsibilities. If the Board has neither a chair that is independent nor a lead director that is independent, describe what the Board does to provide leadership for its independent directors.
|
Board Director
|
Board Meeting
|
Audit Committee
|
NGCC
|
Executive Committee
(1)
|
Cardiff, Michael
(2)(3)
|
10/10
|
4/4
|
2/2
|
3/3
|
Dodd, David
|
4/4
|
—
|
—
|
—
|
Egbert, Carolyn
|
10/10
|
—
|
6/6
|
3/3
|
Ernst, Juergen
(4)
|
10/10
|
2/2
|
6/6
|
3/3
|
Smith Hoke, Robin
|
6/6
|
—
|
4/4
|
—
|
Limoges, Gérard
(3)
|
10/10
|
4/4
|
2/2
|
3/3
|
Norton, Brent
|
6/6
|
2/2
|
—
|
—
|
Pollack, Jonathan
|
6/6
|
2/2
|
—
|
—
|
(1)
|
In July 2017, in light of an existing conflicts of interest relating to the business and affairs of the Corporation with Mr. Dodd, former President and Chief Executive Officer and director of the Corporation, the Board created a special committee consisting of Messrs. Cardiff, Ernst, Limoges and Ms. Egbert (the “Executive Committee”). In 2018, the members of the Executive Committee did not receive any compensation for serving on this committee beyond their regular board of director retainers. The attendance record of each member of the executive committee during 2018 is set out above.
|
(2)
|
Mr. Cardiff resigned from the Board for personal reasons in March 2019.
|
(3)
|
Messrs. Cardiff and Limoges served on the NGCC until May 2018.
|
(4)
|
Mr. Ernst served on the Audit Committee until May 2018.
|
2.
|
BOARD MANDATE
|
3.
|
POSITION DESCRIPTIONS
|
A.
|
Disclose whether or not the Board has developed written position descriptions for the chair and the chair of each Board committee. If the Board has not developed written position descriptions for the chair and/or the chair of each Board committee, briefly describe how the Board delineates the role and responsibilities of each such position.
|
B.
|
Disclose whether or not the Board and Chief Executive Officer have developed a written position description for the Chief Executive Officer. If the Board and CEO have not developed such a position description, briefly describe how the Board delineates the role and responsibilities of the Chief Executive Officer.
|
4.
|
ORIENTATION AND CONTINUING EDUCATION
|
A.
|
Briefly describe what measures the Board takes to orient new directors regarding:
|
(i)
|
the role of the Board, its committees and its directors, and
|
(ii)
|
the nature and operation of the issuer’s business.
|
B.
|
Briefly describe what measures, if any, the Board takes to provide continuing education for its directors. If the Board does not provide continuing education, describe how the Board ensures that its directors maintain the skill and knowledge to meet their obligations as directors.
|
5.
|
ETHICAL BUSINESS CONDUCT
|
A.
|
Disclose whether or not the Board has adopted a written code for the directors, officers, and employees. If the Board has adopted a written code:
|
(i)
|
Disclose how a person or company may obtain a copy of the code.
|
(ii)
|
Describe how the Board monitors compliance with its code or, if the Board does not monitor compliance, explain whether and how the Board satisfies itself regarding compliance with its code.
|
(iii)
|
Provide a cross-reference to any material change report filed since the beginning of the most recently completed financial year that pertains to any conduct of a director or executive officer that constitutes a departure from the code.
|
B.
|
Describe any steps the Board takes to ensure directors exercise independent judgment in considering transactions and agreements in respect of which a director or executive officer has a material interest.
|
C.
|
Describe any other steps the Board takes to encourage and promote a culture of ethical business conduct.
|
6.
|
NOMINATION OF DIRECTORS
|
A.
|
Describe the process by which the Board identifies new candidates for Board nomination.
|
B.
|
Disclose whether or not the Board has a nominating committee composed entirely of independent directors. If the Board does not have a nominating committee composed entirely of independent directors, describe what steps the Board takes to encourage an objective nomination process.
|
C.
|
If the Board has a nominating committee, describe the responsibilities, powers and operation of the nominating committee.
|
7.
|
COMPENSATION
|
A.
|
Describe the process by which the Board determines the compensation for the issuer’s directors and officers.
|
B.
|
Disclose whether or not the Board has a compensation committee composed entirely of independent directors. If the Board does not have a compensation committee composed entirely of independent directors, describe what steps the Board takes to ensure an objective process for determining such compensation.
|
C.
|
If the Board has a compensation committee, describe the responsibilities, powers and operation of the compensation committee.
|
8.
|
OTHER BOARD COMMITTEES
|
9.
|
ASSESSMENTS
|
10.
|
DIRECTOR
TERM LIMITS AND OTHER MECHANISMS OF BOARD RENEWAL
|
11.
|
POLICIES REGARDING THE REPRESENTATION OF WOMEN ON THE BOARD
|
A.
|
Disclose whether the issuer has adopted a written policy relating to the identification and nomination of women directors. If the issuer has not adopted such a policy, disclose why it has not done so.
|
B.
|
If the issuer has adopted a policy referred to in A., disclose the following in respect of the policy: (i) a short summary of its objectives and key provisions; (ii) the measures taken to ensure that the policy has been effectively implemented; (iii) annual and cumulative progress by the issuer in achieving the objectives of the policy; and (iv) whether and, if so, how the board or its nominating committee measures the effectiveness of the policy.
|
12.
|
CONSIDERATION OF THE REPRESENTATION OF WOMEN IN THE DIRECTOR IDENTIFICATION AND SELECTION PROCESS.
|
13.
|
CONSIDERATION GIVEN TO THE REPRESENTATION OF WOMEN IN EXECUTIVE OFFICER APPOINTMENTS
|
14.
|
ISSUER’S TARGETS REGARDING THE REPRESENTATION OF WOMEN ON THE BOARD AND IN EXECUTIVE OFFICER POSITIONS
|
15.
|
NUMBER OF WOMEN ON THE BOARD AND IN EXECUTIVE OFFICER POSITIONS
|
A.
|
Disclose the number and proportion (in percentage terms) of directors on the issuer’s board who are women.
|
B.
|
Disclose the number and proportion (in percentage terms) of executive officers of the issuer, including all major subsidiaries of the issuer, who are women.
|
1.
|
STEWARDSHIP RESPONSIBILITY
|
2.
|
ORGANIZATION, POWERS AND ROLE
|
a)
|
General.
The Board delegates to the Corporation’s senior officers the responsibility for the day-to-day management of the Corporation while providing guidance and direction to such senior officers. The Board’s primary roles are overseeing corporate performance and providing quality, depth and continuity of management to meet the Corporation’s strategic objectives.
|
b)
|
Composition.
The Board shall be composed of a minimum of five (5) and a maximum of fifteen (15) directors. The Board is to be constituted of a majority of individuals who qualify as independent directors, as determined by the Board in accordance with applicable securities laws and standards of the stock exchanges on which the Corporation’s securities are listed. The composition of the Board should provide an appropriate mix of skills, knowledge, business expertise and experience in the Corporation’s areas of activities and an understanding of the industry and the geographical areas in which the Corporation operates.
|
c)
|
Appointment.
Directors are elected annually by the shareholders of the Corporation, but the directors may from time to time appoint one or more directors, provided that the total number of directors so appointed does not exceed one third (1/3) of the number of directors elected at the last annual meeting of shareholders. The mandate (or term) of each director terminates at the end of the annual shareholders’ meeting following that at which he or she was elected.
|
d)
|
Chair of the Board.
Members of the Board shall elect a Chair from among the directors of the Corporation and the Chair shall preside at all meetings of the Board. In addition, if and for as long as the Chair is not an independent director, the Board should also nominate a Lead Director, if appropriate, from among the independent directors to take on appropriate duties. Management is encouraged to attend Board meetings, where appropriate, to provide additional insight to matters being considered by the Board. Regularly following meetings of the Board, the directors shall hold meetings at which senior management, including any management director and any non-independent Chair, is not present in order to ensure a free and open discussion between directors. If the Chair is not present at any meeting of the Board, the Lead Director shall preside at the meeting. The Chair of the Board develops the agenda for each meeting of the Board in consultation with the Chief Executive Officer, the Corporate Secretary and the Lead Director (if there is one). The agenda and the appropriate materials are provided to directors of the Corporation on a timely basis prior to any meeting of the Board.
|
e)
|
Quorum and Meetings
. The quorum at any meeting of the Board is a majority of directors in office and meetings of the Board are held at least quarterly and as required. In addition, at one of the quarterly Board meetings or at a special meeting of the Board held for that purpose, at least once a year, the Board must review the Corporation’s strategic plan. Directors may attend all meetings either in person, videoconference or by teleconference; however, directors are expected to attend all board meetings and meetings of committees of which they are members and to review all meeting materials in advance.
|
f)
|
Director Compensation.
Members of the Board shall receive such remuneration for acting as directors as the Board may from time to time determine. The Corporation’s Nominating, Governance and Compensation Committee (“NGCC”) shall periodically review all aspects of such remuneration and make recommendations to the Board respecting the same. The Chief Executive Officer shall receive no compensation for acting as a director.
|
g)
|
Delegation.
The Board may delegate certain responsibilities to Board committees. Such committees shall have a written Board-approved charter, except in the case of special committees of the Board, which may be appointed from time to time. The Board operates by delegating certain of its authorities to management and by reserving certain powers to itself. Subject to applicable law and to the Corporation’s Articles and By-Laws, the Board retains the responsibility for managing its own affairs including:
|
i)
|
planning its composition and size;
|
ii)
|
selecting its Chair;
|
iii)
|
providing orientation and on-going education for its directors;
|
iv)
|
nominating candidates for election to the Board;
|
v)
|
appointing committees;
|
vi)
|
determining director compensation;
|
vii)
|
setting expectations and responsibilities of directors, including attendance at, preparation for and participation in Board and committee meetings;
|
viii)
|
assessing the effectiveness of the Board, committees and directors in fulfilling their responsibilities;
|
ix)
|
determining dividend policies and procedures;
|
x)
|
issuing securities, except as authorized by the Board;
|
xi)
|
purchasing, redeeming or otherwise acquiring shares of the Corporation;
|
xii)
|
making, amending and repealing by-laws of the Corporation;
|
xiii)
|
calling the annual meeting of the shareholders of the Corporation;
|
xiv)
|
filling any vacancy among directors or in the office of auditor of the Corporation or appointing additional directors; or
|
xv)
|
submitting to the shareholders any question or matter requiring the approval of the shareholders.
|
h)
|
Retention of consultants.
The Board has the authority to retain, at the Corporation’s expense, outside advisors and consultants to report directly to the Board of Directors on board-wide issues.
|
i)
|
Fiduciary Duties.
Considering the special relationship between the directors and the Corporation, which places the directors in a position of trust and control, the common law characterizes the nature of the duties owed by the directors of the Corporation as “fiduciary duties.” Generally, a director’s fiduciary duty consists of a duty to act honestly and in good faith and with a particular standard of care. The standard of care required of directors and officers is codified in the CBCA, which provides that every director and officer of a corporation in exercising his/her powers and discharging his or her duties shall:
|
i)
|
act honestly and in good faith with a view to the best interests of the corporation; and,
|
ii)
|
exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances.
|
j)
|
Conflicts of Interest.
If a director faces a potential or actual conflict of interest relating to a matter before the Board, that member should alert the Chair, or depending on when the matter becomes known, the Board as a whole. If the Chair faces a potential or actual conflict of interest, the Board Chair should advise the Chair of the Audit Committee. If the Chair, or the Chair of the Audit Committee, as the case may be, concurs that a potential or actual conflict of interest exists, the member faced with such conflict should disclose to the Board the member’s interest and should not participate in consideration of the matter and should not vote on the matter. The Corporate Secretary should maintain a written record of any disclosure of conflict by a Board member either in the minutes of the Board or otherwise.
|
3.
|
COMMITTEES OF THE BOARD
|
a)
|
elect annually from among its members an Audit Committee, and a Nominating, Governance and Compensation Committee (the “NGCC”), each to be composed of not fewer than three directors. The committees shall each adopt a formal written charter approved by the Board;
|
b)
|
appoint for each committee a Chair from among its members;
|
c)
|
appoint additional committees as circumstances may warrant; and,
|
d)
|
appoint special committees periodically to address certain issues of a more short-term nature.
|
4.
|
RESPONSIBILITIES
|
a)
|
Strategic Planning and Risk Management.
The Board should ensure that a strategic planning process is in place; review and approve the Corporation’s long-and short-term strategies, visions and missions and monitor management’s success in implementing the strategies. The Board should also approve on at least an annual basis, a strategic business plan, taking into account, among other things, business opportunities and risks of the business. As part of the strategic plan review process, the Board should approve and monitor the implementation of the Corporation’s annual business plan and ensure that management puts in place appropriate systems and processes to manage the principal risks with a view to the long-term viability of the Corporation. The Audit Committee should regularly review specific areas of the Corporation’s financial functions, including the integrity of the Corporation’s internal controls and information systems and the NGCC should review risks related to succession planning. Reports on these reviews should be included as part of the regular review by the whole Board of the Corporation’s operating performance.
|
b)
|
Independence and Lead Director.
To facilitate the functioning of the Board independently of Corporate management and the non-independent directors, the Board may appoint one of its independent directors to act as Lead Director. The Lead Director should consult and meet with any or all of the independent directors, at the discretion of either party, and with or without the attendance of the Chair, and should represent such directors in discussions with the Chair on corporate governance issues and other matters. The Lead Director should also promote best practices and high standards of corporate governance and assist in the process of conducting director evaluations.
|
c)
|
Communication and Financial Matters.
The Board believes that accurate, timely and regular communication with its shareholders and the investment community is of ultimate importance. The Corporation has a formal disclosure policy, which has been reviewed and approved by the Board. As part of this policy, the Board should review and approve, upon recommendation by the Audit Committee, the general content and the Audit Committee’s report on the financial aspects of, the Corporation’s Annual Information Form (or the Annual Report on Form 20-F in lieu thereof), Management Proxy Circular, Consolidated Financial Statements, Management’s Discussion and Analysis, the Corporation’s schedule of authority, prospectuses and any other document required to be disclosed or filed by the Corporation before such documents are publicly disclosed or filed with the appropriate regulatory authorities. In addition, as directed and monitored by the Board, senior management is charged with the responsibility of complying with the Corporation’s regulatory disclosure obligations and resounding to inquiries from shareholders, analysts and other interested parties.
|
d)
|
Internal Control and Reporting.
The integrity of the Corporation’s internal control and reporting systems are the primary responsibility of management with oversight review by the Audit Committee, which should meet regularly with both the Corporation’s financial and accounting personnel and the Corporation’s internal and external auditors to review these matters. The Audit Committee should report to the full Board with respect to any issues that arise out of such discussions.
|
e)
|
Corporate Governance.
The NGCC’s role includes making recommendations to the Board on all matters relating to corporate governance, including the appropriateness of the Corporation’s governance structure in view of its position in the targeted marketplace.
|
f)
|
New Board Nominees, Board Size and Board Effectiveness.
The NGCC is responsible for proposing new board nominees. The subject of the board size should be considered periodically by the Board and on an on-going basis by the NGCC. If a Lead Director is in place, the Lead Director and the NGCC should annually assess the effectiveness of the Board as a whole, the committees of the Board, and the contribution of the individual directors and the results of these assessments should be reported to the Board.
|
g)
|
Executive Performance and Compensation.
The Board should:
|
i)
|
Appoint all officers and monitor and assess the performance of the CEO and executives who report to the CEO, following a review of the recommendations of the NGCC in collaboration with the Lead Director, if any;
|
ii)
|
Establish the annual corporate goals and objectives for the CEO; If the Chair is not independent, the Lead Director, in collaboration with the NGCC, should establish the annual corporate goals and objectives for the CEO;
|
iii)
|
Approve the compensation, of the CEO and executives who report to the CEO upon recommendation by the NGCC, taking into consideration Board expectations and fixed goals and objectives;
|
iv)
|
Ensure that the CEO and senior management create a culture of integrity throughout the Corporation that creates and reinforces good conduct and ethical behavior and discourages inappropriate or excessive risk-taking;
|
v)
|
Upon review of the recommendations of the NGCC, approve certain matters relating to all employees, including the Corporation’s broad compensation strategy and philosophy, new long-term and short-term benefit programs or material changes to existing programs and stock option and stock grant awards; and
|
vi)
|
Provide advice and counsel to the CEO in the execution of the CEO’s duties.
|
h)
|
Succession Planning.
The Board should ensure that effective succession planning programs are in place, including programs to appoint, train, develop and monitor management. The NGCC and the Chair, as well as the Lead Director, if any, should periodically review succession planning, including recommendations with respect to appointment of senior officers, as and when required. The full Board should approve the appointment of senior officers and the NGCC should monitor senior management succession.
|
i)
|
Board Compensation.
As part of its mandate, the NGCC should periodically review the adequacy and form of compensation of directors, including minimum share ownership requirements, and should make appropriate recommendations to the Board. In making its recommendations, the NGCC should take into account appropriate, comparative market data and the level and form of compensation necessary to attract directors of the caliber and experience required to effectively oversee an organization of the Corporation’s current size, complexity and market scope.
|
j)
|
Board Orientation and Education.
All new members of the Board should be provided with the Board Mandate, detailed information on the Corporation, its charter, history and policies relevant to the Board and its members. The Board should also sponsor, as appropriate, and encourage continuing education of Board members to ensure current knowledge compatible with the business. Regular visits to business sites and meetings with senior management should also be encouraged and arranged to allow directors the opportunity to familiarize themselves with the Corporation’s operations and business first-hand.
|
k)
|
Position Descriptions
.
The NGCC should formulate for Board approval position descriptions for the Chair, the Lead Director, the CEO and the Chair of each Board committee.
|
l)
|
Confidentiality.
The Board should monitor management’s enforcement of policies respecting confidential treatment of the Corporation’s proprietary information and the confidentiality Board deliberations.
|
m)
|
Code of Conduct.
The Board should ensure a written Code of Conduct (the “Code”) has been adopted by the Corporation, which is applicable to all directors, officers and employees. The Code constitutes written standards that are intended and reasonably designed to promote integrity, ethics and honesty and deter wrongdoing. In particular, the Code should address conflicts of interest, protection and proper use of corporate assets, confidentiality of corporate information, fair dealing with security holders, customers, suppliers, competitors and employees; compliance with laws, rules and regulations, and reporting of any illegal or unethical behavior. The Board should also monitor the Corporation’s compliance with all significant policies and procedures by which the Corporation is operated, including the Code.
|
1.
|
MISSION STATEMENT
|
2.
|
POWERS
|
•
|
Perform activities within the scope of its charter.
|
•
|
Engage independent counsel and other advisers as it deems necessary to carry out its duties.
|
•
|
Set and pay the compensation for any advisors it employs.
|
•
|
Ensure the attendance of officers and/or other key employees having a finance or accounting function at meetings as appropriate.
|
•
|
Have unrestricted access to members of management, employees and relevant information.
|
•
|
Communicate directly with the internal and external auditors.
|
3.
|
COMPOSITION
|
•
|
The Committee shall be formed of at least three members, each of which shall qualify as an independent director, as determined by the Board in accordance with applicable securities laws and standards of the stock exchanges on which the Corporation’s securities are listed.
|
•
|
Each member shall provide a useful contribution to the Committee.
|
•
|
All members must be financially literate as defined in accordance with applicable securities laws and standards of the stock exchanges on which the Corporation’s securities are listed.
|
•
|
In addition, for as long as the Corporation’s securities are listed on the Nasdaq Stock Market, at least one member of the Committee must have past employment experience in finance or accounting, requisite professional certification in accounting, or any other comparable experience or background which results in the individual’s financial sophistication.
|
•
|
The chairperson of the Committee shall be appointed by the Board from time to time.
|
•
|
The term of the mandate of each member shall be one year.
|
•
|
The quorum requirement for any meeting shall be two members.
|
•
|
The secretary of the Committee shall be the secretary of the Corporation or any other individual appointed by the Board.
|
4.
|
MEETINGS
|
•
|
If deemed necessary, the Committee may invite other individuals.
|
•
|
External auditors shall be invited, if needed, to make presentations to the Committee.
|
•
|
The Committee shall meet at least four times a year. Special meetings may be held if needed. If deemed necessary, external auditors may invite members to attend any meeting.
|
•
|
The Committee will meet with the external auditors at least once a year without management presence.
|
•
|
The minutes of each meeting shall be recorded.
|
5.
|
ROLE AND RESPONSIBILITIES
|
A.
|
Financial Information
|
i.
|
Review significant accounting and reporting issues, including recent professional and regulatory pronouncements, and understand their impact on the financial statements.
|
ii.
|
Ask management and external auditors about significant risks and exposures and the plans to minimize such risks.
|
iii.
|
Review the unaudited interim financial statements, the audited annual financial statements in addition to any documents which accompany such financial statements, such as the report of the external auditors, and obtain an explanation from management of all material variances between comparative reporting periods, prior to filing or disclosure. Without restricting the generality of the foregoing, the Committee shall discuss with management and the external auditors to the extent required, any issues and disclosure requirements regarding (a) the use of “pro forma” or “adjusted” non-GAAP/non-IFRS information, (b) any off balance sheet arrangements, and (c) any going concern qualification. Determine whether they are complete and consistent with the information known to Committee members, and assess whether the financial statements reflect appropriate accounting principles and recommend their approval to the Board of Directors.
|
iv.
|
Review and recommend for approval by the Board, all public disclosure documents containing audited or unaudited financial information, including Management’s Discussion and Analysis of financial condition and results of operations, all sections of the Annual Report on Form 20-F, quarterly reports and press releases concerning annual and interim financial results, and consider whether the information is adequate and consistent with members’ knowledge about the Corporation and its operations and financial position.
|
v.
|
Be satisfied that adequate procedures are in place for the review of the Corporation’s public disclosure of financial information extracted or derived from the Corporation’s financial statements, other than the public disclosure referred to in the two preceding paragraphs, and periodically assess the adequacy of those procedures.
|
vi.
|
Review the compliance of the President and Chief Executive Officer and of the Chief Financial Officer certification letter on the Corporation’s controls and procedures disclosure of information and the attestation by management of the financial reports.
|
vii.
|
Pay particular attention to complex and/or unusual transactions such as restructuring charges and derivative disclosures.
|
viii.
|
Focus on judgmental areas such as those involving valuation of assets and liabilities including, for example, the accounting for and disclosure of: obsolete or slow-moving inventory; loan losses; warranty, product, and environmental liability; litigation reserves and other commitments and contingencies.
|
ix.
|
Meet with management and the external auditors to review the financial statements and the results of the audit.
|
x.
|
Consider management’s handling of proposed audit adjustments identified by the external auditors.
|
xi.
|
Ensure that the external auditors communicate certain required matters to the Committee.
|
xii.
|
Be briefed on how management develops and summarizes quarterly financial information, the extent to which the external auditors review quarterly financial information, and whether that review is performed on a pre- or post-issuance basis.
|
xiii.
|
Meet with management and, if a pre-issuance review was completed, with the external auditors, either by telephone or in person, to review the interim financial statements and the results of the review.
|
xiv.
|
To gain insight into the fairness of the interim financial statements and disclosures, obtain explanations from management on whether.
|
•
|
Actual financial results for the quarter or interim period varied significantly from budgeted or projected results;
|
•
|
Changes in financial ratios and relationships in the interim financial statements are consistent with changes in the Corporation’s operations and financing practices;
|
•
|
International Financial Reporting Standards (Generally accepted accounting principles) have been (consistently) applied;
|
•
|
There are any actual or proposed changes in accounting or financial reporting practices;
|
•
|
There are any significant or unusual events or transactions;
|
•
|
The Corporation’s financial and operating controls are functioning effectively;
|
•
|
The Corporation has complied with the terms and conditions of loan agreements or security indentures; and
|
•
|
The interim financial statements contain adequate and appropriate disclosures.
|
xv.
|
Ensure that the external auditors communicate certain required matters to the Committee.
|
B.
|
External Audit
|
i.
|
Review the professional qualification of the auditors (including background and experience of partner and auditing personnel).
|
ii.
|
Consider and make any necessary determinations with respect to the independence of the external auditor and any potential conflicts of interest.
|
iii.
|
Review on an annual basis the performance of the external auditors and make recommendations to the Board for their compensation, their appointment, retention and termination of their appointment.
|
iv.
|
Perform a comprehensive review of the external auditors at least once every five years.
|
v.
|
Oversee the work of the external auditors, including the resolution of disagreements between management and the external auditors regarding financial reporting.
|
vi.
|
Require the external auditors to report directly to the Committee and make sure to receive periodic reports from the external auditors.
|
vii.
|
Review and approve the external auditors’ scope and plan of the annual audit, as well as the approach for the current year in light of the Corporation’s present circumstances and changes in regulatory and other requirements.
|
viii.
|
Annually, or more frequently as may be required, consult with the external auditors, without the presence of management, as to internal controls, the fullness and accuracy of the financial statements, any significant difficulties encountered during the course of the audit or access to required information, the quality of financial personnel, the level of co-operation received from management any unresolved material differences of opinion or disputes.
|
ix.
|
Discuss with the external auditor the appropriateness of the accounting policies applied in the Corporation’s financial reports and whether they are considered as aggressive, balanced or conservative.
|
x.
|
Approve all audit engagement fees and terms as well as reviewing policies for the provision of non-audit services by the external auditors and, when required, the framework for pre-approval of such services.
|
xi.
|
Pre-approve all audit, audit-related and non-audit services to be provided to the Corporation or any of its subsidiaries, by the external auditors (and its affiliates), in accordance with applicable securities laws (or delegate such pre-approval if and to the extent permitted by law), and consider the potential impact of such services on the independence of the external auditors, provided that the external auditors may not be retained by the Corporation to perform specifically listed categories of non-audit services as set forth by the SEC.
|
xii.
|
Review and approve the Corporation’s hiring policies regarding partners, employees and former partners and employees of the present and former external auditor of the Corporation.
|
xiii.
|
Review post-audit or management letters, containing recommendations of the external auditors and management’s response, including the evaluation by the external auditors of the adequacy and effectiveness of management’s internal control systems and procedures for financial reporting, and management’s responses to any identified weaknesses.
|
xiv.
|
Review any other material written communication provided by the external auditors to the Corporation’s management and submitted to the Committee.
|
C.
|
Internal Control
|
i.
|
Evaluate whether management is setting the appropriate tone at the top by communicating the importance of internal controls and ensuring that all individuals possess an understanding of their roles and responsibilities.
|
ii.
|
Understand the controls and processes implemented by management to ensure that the financial statements derive from the underlying financial systems, comply with relevant standards and requirements, and are subject to appropriate management review.
|
iii.
|
Discuss with the external auditors and management, the adequacy and effectiveness in the design and operation of the disclosure controls and internal controls of the Corporation and make recommendations for the improvement of such controls or particular areas where new or more detailed controls or procedures are desirable.
|
iv.
|
Satisfy itself as to the adequacy of the Corporation’s review procedures regarding disclosure of other financial information.
|
v.
|
Gain an understanding of the current areas of financial risk and how these are being handled by the management.
|
vi.
|
Focus on the extent to which management reviews computer systems and applications, the security of such systems and applications, and the contingency plan for processing financial information in the event of a systems breakdown.
|
vii.
|
Gain an understanding of whether internal control recommendations made by external auditors have been implemented by management.
|
viii.
|
Ensure that the external auditors keep the Committee informed about fraud, illegal acts, deficiencies in internal control, and any other matter deemed appropriate.
|
ix.
|
Monitor and supervise procedures for (1) the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal accounting controls or auditing matters, and (2) for the confidential, anonymous submission by employees of concerns regarding questionable accounting or auditing matters.
|
i.
|
Review the effectiveness of the system for monitoring compliance with laws and regulations and the results of management’s investigation and follow-up (including disciplinary action) on any fraudulent acts or accounting irregularities.
|
ii.
|
Periodically obtain updates from management, general counsel, and tax director regarding compliance.
|
iii.
|
Be satisfied that all regulatory compliance matters have been considered in the preparation of the financial statements.
|
iv.
|
Review the findings of any examinations by regulatory agencies.
|
v.
|
Ensure that a Code of Ethical Conduct is formalized in writing and that all employees are aware of it.
|
vi.
|
Review periodically, in consultation with the Nominating, Governance and Compensation Committee and the Board of Directors, the content of the Code of Ethical Conduct and make sure employees are informed of amendments.
|
vii.
|
Evaluate whether management is setting the appropriate tone at the top by communicating the importance of the Code of Ethical Conduct and the guidelines for acceptable business practices.
|
viii.
|
Review the program for monitoring compliance with the Code of Ethical Conduct.
|
ix.
|
Periodically obtain updates from management and general counsel regarding compliance.
|
D.
|
Other Responsibilities
|
i.
|
Meet with the external auditors and management in separate executive sessions to discuss any matters that the Committee or these groups believe should be discussed privately.
|
ii.
|
Ensure that significant findings and recommendations made by the external auditors are received and discussed on a timely basis.
|
iii.
|
Review, with the Corporation’s counsel, any legal matters that could have a significant impact on the Corporation’s financial statements.
|
iv.
|
Review the policies and procedures in effect for considering officers’ expenses and perquisites.
|
v.
|
If necessary, institute special investigations and, if appropriate, hire special counsel or experts to assist.
|
vi.
|
Perform other oversight functions as requested by the full Board.
|
vii.
|
Regularly update the Board of Directors about Committee activities and make appropriate recommendations.
|
viii.
|
Ensure the Board is aware of matters that may significantly impact on the financial condition or affairs of the business.
|
ix.
|
Prepare any reports required by law or standards of the stock exchanges on which the Corporation’s securities are listed or requested by the Board, for example a report on the Committee’s activities and duties to be included in the section on corporate governance in the Annual Report on Form 20-F.
|
x.
|
Prepare and review with the Board, in the manner the Committee deems appropriate, an annual performance evaluation of the Committee and its members, comparing its performance with the requirements of this charter.
|
xi.
|
Review and update the Committee charter annually.
|
xii.
|
Discuss any changes required to be made to this charter with the Board and ensure the charter and any such changes are approved by the Board.
|
a)
|
Retain outside counsel, accountants, outside advisors, consultants, or others to assist in the conduct of an investigation, or as it determines appropriate, to advise or assist in the performance of its functions. The NGCC, or its chair shall pre-approve all services provided to the Corporation at the request of management by any compensation consultant or advisor, or any of its affiliates, retained to assist the NGCC in determining compensation for any of the Corporation’s directors or executive officers. The NGCC shall have sole authority to retain and terminate any search firm to be used to identify director candidates, including sole authority to approve the search firm’s fees and other retention terms;
|
b)
|
Seek any information it requires from employees or external parties. Employees and external parties will be directed to cooperate and comply with the NGCC’s requests; and
|
c)
|
Meet with the senior internal auditor, company officers, external auditors, or outside counsel, as necessary.
|
1.
|
Establish criteria and qualifications for Board membership, including standards for assessing independence. These criteria and qualifications shall include, among other things:
|
a)
|
The highest ethical standards and integrity;
|
b)
|
A willingness to act on and be accountable for Board decisions;
|
c)
|
An ability to provide wise, informed, and thoughtful counsel to top management on a range of issues;
|
d)
|
A history of achievement that reflects superior standards for director candidate and others;
|
e)
|
Loyalty and commitment to driving the success of the Corporation;
|
f)
|
An ability to take tough positions while at the same time working as a team player; and
|
g)
|
A background that provides a portfolio of experience and knowledge commensurate with the Corporation’s needs.
|
2.
|
Identify and consider candidates, including those recommended by shareholders and others, to fill positions on the Board, and assess the contributions and independence of incumbent directors in determining whether to recommend them for re-election to the Board.
|
3.
|
Recommend to the Board candidates for election or re-election at each annual meeting of shareholders and, if the NGCC deems appropriate, for appointment of additional directors between annual meetings of shareholders.
|
4.
|
Recommend to the Board candidates for appointment to the Audit Committee and its committee chair and consider periodic rotation of committee members. The full Board shall select candidates for appointment to the NGCC.
|
5.
|
Annually review the Corporation’s corporate governance processes, and its governance principles, including such issues as the Board’s organization, membership terms, size, composition, and the structure and frequency of Board meetings, and recommend appropriate changes to the Board to ensure effectiveness of decision making.
|
6.
|
Consider questions of possible conflicts of interest of Board members and senior executives, in collaboration with the Audit Committee, and initiate appropriate action to address any such conflicts.
|
7.
|
Make recommendations to the Board regarding resignations of directors in accordance with applicable policies of the Corporation.
|
8.
|
Establish compensation for directors and, as timely required, review the compensation schedule for appropriate competitiveness and make recommendations for revisions to the Board when necessary.
|
9.
|
Review annually with the Chair/CEO the performance of the Corporation’s senior executives and recommend to the Board their appropriate, market competitive, total direct and indirect compensation.
|
10.
|
In collaboration with the Chair, or the Lead Director if the Chair of the Board is not independent, annually review, establish and recommend to the Board the objectives to be achieved by the CEO and recommend to the Board the appropriate compensation for the CEO as measured by achievement of the objectives for the applicable period.
|
11.
|
Oversee risk identification and management in relation to executive compensation policies and practices and review the disclosure in this respect.
|
12.
|
Review periodically with the Chair/CEO and the Board, the succession plan, and its effectiveness, relating to positions held by senior executives, including the CEO, and make recommendations to the Board regarding the recruitment, selection and retention of individuals to fill these positions.
|
13.
|
Oversee the orientation of new directors and continuing education of directors.
|
14.
|
Recommend for Board approval a code of conduct for Board directors, review such code annually and recommend revisions thereto as appropriate.
|
15.
|
Monitor the functions of the Board and its committees, as set forth in their respective mandates, and coordinate and collaborate with the Lead Director, if any, to oversee the annual self-assessments of the performance and procedures of the Board and each of its committees. At a minimum, the self-assessment will solicit feedback from the directors about:
|
a)
|
Overall effectiveness;
|
b)
|
Composition and structure;
|
c)
|
Culture;
|
d)
|
Focus;
|
e)
|
Information and resources; and
|
f)
|
Process.
|
16.
|
Oversee and recommend for Board approval any material change to the organizational structure of the Corporation.
|
17.
|
Review and approve directors’ and officers’ liability insurance coverage.
|
18.
|
Oversee, recommend, advise, ensure and confirm that the Corporation has deployed appropriate human resources policies, procedures and processes are in place with respect to recruitment, retention, workplace conduct, including rules, requirements and guidelines, disclosure (including use of privileged information and “blackout” periods), training, development, disciplinary actions, career pathways, terminations and related policies that create a positive workplace environment and a functional culture focused on achieving business strategy and objectives.
|
19.
|
Oversee, recommend, advise, ensure and confirm that the Corporation deploys an appropriate code of conduct that engenders an ethical culture based on values, principles, integrity and honesty, including a functional system for reporting misconduct, violations of laws, rules or regulations or seeking advice and guidance.
|
20.
|
In collaboration with management, review the structure and governance of the Corporation’s welfare benefits, defined and/or non-qualified retirement or pensions benefit plans, long- and short-term compensation plans, direct and indirect compensation plans, incentive, bonus and awards plans, security-based compensation plans and the like for executive and non-executive employees and make appropriate recommendations to the Board with respect thereto.
|
21.
|
In consultation with the Board, approve stock option and stock grant awards.
|
22.
|
Review the annual statement of corporate governance practices for inclusion within the Corporation’s Management Proxy or Information Circular and/or Annual Information Form/Annual Report on Form 20-F, in accordance with applicable rules and regulations.
|
23.
|
Review corporate governance guidelines applicable to the Corporation, recommend to the Board any revision(s) thereto, monitor and oversee the disclosure of the Corporation’s corporate governance structures, procedures and practices, including relevant decisions requiring Board approval and, where appropriate, measures for receiving shareholder feedback, in accordance with applicable rules, regulations and standard industry practices.
|
24.
|
Assess annually the performance of the Board, its Lead Director, if any, individual directors, the Board committees and their respective chairs, including measurement by any applicable committee mandate, and report its findings to the Board.
|
25.
|
Review periodically the mandates of the Board and its committees and recommend any proposed changes to the Board.
|
26.
|
Nothing contained in this mandate is intended to expand applicable standards of conduct under statutory or regulatory requirements for the directors of the Corporation or the members of the NGCC.
|
A.
|
The Board of Directors of the Corporation, in the exercise of its fiduciary duties to the Corporation, has determined that it is advisable to implement a shareholder rights plan to ensure, to the extent possible, that all shareholders of the Corporation are treated fairly in connection with any take-over offer or other acquisition of control of the Corporation;
|
B.
|
The Board of Directors of the Corporation approved a shareholder rights plan of the Corporation on March 29, 2016, which was approved, ratified and confirmed by the shareholders at the annual and special meeting of shareholders of the Corporation on May 10, 2016 (the “
Original Agreement
”).
|
C.
|
On March 26, 2019, the Board of Directors approved certain amendments to update and restate the Original Agreement in its entirety to be on the terms and conditions and in the form of this agreement to take effect immediately upon receipt of approval of the shareholders at the annual and special meeting of shareholders which was held on [May 8], 2019;
|
D.
|
The Board of Directors had previously:
|
(a)
|
authorized and declared a distribution of one right (a “
Right
”) in respect of each Share outstanding at the Record Time;
|
(b)
|
authorized the issuance of one Right in respect of each Share issued after the Record Time and prior to the earlier of the Separation Time and the Expiration Time; and
|
(c)
|
authorized the issuance of Rights Certificates to holders of Rights pursuant to the terms and subject to the conditions set forth herein.
|
A.
|
Each Right entitles the holder thereof, after the Separation Time, to purchase securities of the Corporation pursuant to the terms and subject to the conditions set forth herein.
|
B.
|
The Corporation desires to confirm the appointment of Computershare Trust Company of Canada as the Rights Agent to act on behalf of the Corporation, and the Rights Agent is willing to so act, in
|
Section 1.1
|
Certain Definitions
|
(a)
|
“
Acquiring Person
” shall mean any Person who is at any time after the Effective Date the Beneficial Owner of 20% or more of the outstanding Voting Shares; provided, however, that the term “Acquiring Person” shall not include:
|
(i)
|
the Corporation or any corporation controlled by the Corporation;
|
(ii)
|
any Person who becomes the Beneficial Owner of 20% or more of the outstanding Voting Shares as a result of one or any combination of:
|
(A)
|
a Voting Share Reduction;
|
(B)
|
a Permitted Bid Acquisition;
|
(C)
|
an Exempt Acquisition;
|
(D)
|
a Pro Rata Acquisition; or
|
(E)
|
a Convertible Security Acquisition;
|
(iii)
|
an underwriter or member of a banking or selling group acting in such capacity that becomes the Beneficial Owner of 20% or more of the Voting Shares in connection with a distribution of securities pursuant to a prospectus or by way of private placement; or
|
(iv)
|
a Person (a “
Grandfathered Person
”) who is the Beneficial Owner of 20% or more of the outstanding Voting Shares determined as of the Record Time, provided, however, that this exemption shall not be, and shall cease to be, applicable to a Grandfathered Person in the event that such Grandfathered Person shall, after the Record Time, (A) cease to own 20 percent or more of the outstanding Voting Shares, or (B) become the Beneficial Owner of additional Voting Shares that increases its
|
(v)
|
for a period of 10 calendar days after the Disqualification Date (as defined below), any Person who becomes the Beneficial Owner of 20% or more of the outstanding Voting Shares as a result of such Person becoming disqualified from relying on Section 1.1(e)(vi) solely because such Person is making or has announced a current intention to make a Take-over Bid, either alone or by acting jointly or in concert with any other Person. For the purposes of this definition, “
Disqualification Date
” means the first date of a public announcement of facts indicating that any Person is making, or has announced a current intention to make a Take-over Bid.
|
(b)
|
“
Affiliate
” shall mean, when used to indicate a relationship with a specified body corporate, a Person that directly or indirectly through one or more intermediaries controls, or is a body corporate controlled by, or under common control with, such specified body corporate.
|
(c)
|
“
Agreement
” means this agreement as may be amended, modified or supplemented from time to time.
|
(d)
|
“
Associate
” shall mean, when used to indicate a relationship with a specified Person, (i) a spouse of that Person, (ii) any Person of the same or opposite sex with whom that Person is living in a conjugal relationship outside marriage, (iii) any relative of that Person if that relative has the same residence as that Person or (iv) any relative of such spouse or other Person referred to in the immediately preceding clauses (i), (ii) or (iii) above, if that relative has the same residence as the specified Person.
|
(e)
|
A Person shall be deemed the “
Beneficial Owner
” of, and to have “
Beneficial Ownership
” of, and to “
Beneficially Own
”:
|
(i)
|
any securities of which such Person or any of such Person’s Affiliates or Associates is owner at law or in equity;
|
(ii)
|
any securities which the Person or any of such Person’s Affiliates or Associates has the right or obligation to acquire within 60 days (where such right is exercisable within a period of 60 days whether or not upon the occurrence of a contingency or the making of a payment) pursuant to any Convertible Security, agreement, arrangement, pledge or understanding, whether or not in writing (other than (A) customary agreements with and between underwriters and/or banking group and/or selling group members with respect to a distribution of securities (B) pledges of securities in the ordinary course of the pledgee’s business) or (C) agreements pursuant to an amalgamation, merger, arrangement, business combination or other similar transaction (statutory or otherwise, but for greater certainty not including a Take-over Bid) that are conditional upon the approval of the shareholders of the Corporation to be obtained prior to such Person acquiring such securities;
|
(iii)
|
any securities which are subject to a lock-up or similar agreement to tender or deposit them into any Take-over Bid made by such Person or made by any Affiliate or
|
(iv)
|
any securities that are Beneficially Owned within the meaning of clause (i), (ii) or (iii) of this Section 1.1(e) by any other Person with whom such Person is acting jointly or in concert;
|
(v)
|
such security has been agreed to be deposited or tendered pursuant to a Permitted Lock-up Agreement or is otherwise deposited or tendered pursuant to any Take-over Bid made by such Person, made by any of such Person’s Affiliates or Associates or made by any other Person acting jointly or in concert with such Person, but only until such time as such deposited or tendered security has been taken up or paid for, whichever shall occur first; or
|
(vi)
|
such
Person, for greater certainty holding such security in the ordinary course of such Person’s business, holds such security, provided that:
|
(A)
|
the ordinary business of that Person (a "
Fund Manager
") includes the management of pension or mutual or investment funds for others (which others, for greater certainty, may include or be limited to one or more employee benefit plans or pension plans) and such security is held by the Fund Manager in the ordinary course of such business in the performance of such Fund Manager’s duties for the account of any other Person (a "
Client
") including non-discretionary accounts held on behalf of a Client by a broker or dealer registered under applicable laws; or
|
(B)
|
such Person (the "
Trust Company
") is licensed to carry on the business of a trust company under applicable law and, as such, acts as trustee or administrator or in a similar capacity in relation to the estates of deceased or incompetent Persons (each, an "
Estate Account
") or in relation to other accounts (each, an "
Other Account
") and holds such security in the ordinary course of such duties for such Estate Accounts or for such Other Accounts; or
|
(C)
|
such Person (the "
Statutory Body
") is an independent Person established by statute for purposes that include, and the ordinary business or activity of such Person includes, the management of investment funds for employee benefit plans, pension plans, insurance plans of various public bodies and the Statutory Body holds such security for the purposes of its activities as such; or
|
(D)
|
such Person (the "
Plan Administrator
") is the administrator or the trustee of one or more pension funds or plans registered under the laws of Canada or any province thereof or the United States or any state thereof (each, a "
Plan
"), or is a Plan;
|
(E)
|
such Person (the “
Crown Agent
”) is acting as an agent of the Crown for purposes that include, and the ordinary business or activity of such Person includes, the management of public assets and such security is held by the Crown Agent in the ordinary course of the management of such public assets; or
|
(F)
|
such Person is a Plan and such security is held by the Plan in the ordinary course of such Plan’s activities;
|
(vii)
|
such Person is a Client of the same Fund Manager as another Person on whose account the Fund Manager holds such security, or because such Person is an Estate Account or an Other Account of the same Trust Company as another Person on whose account the Trust Company holds such security, or because such Person is a Plan with the same Plan Administrator as another Plan on whose account the Plan Administrator holds such security;
|
(viii)
|
such Person is a Client of a Fund Manager and such security is owned at law or in equity by the Fund Manager, or because such Person is an Estate Account or an Other Account of a Trust Company and such security is owned at law or in equity by the Trust Company, or because such Person is a Plan and such security is owned at law or in equity by the Plan Administrator; or
|
(ix)
|
such Person is the registered holder of securities as a result of carrying on the business of, or acting as, a nominee of a securities depository.
|
(f)
|
“
Board of Directors
” shall mean the board of directors of the Corporation or any duly constituted and empowered committee thereof.
|
(g)
|
“
Business Day
” shall mean any day, other than a Saturday or Sunday or a day on which banking institutions in Montreal, Quebec are authorized or obligated by law to close.
|
(h)
|
“
Canada Business Corporations Act
” shall mean the
Canada Business Corporations Act
(Canada), R.S.C. 1985, c. C-44, as amended and the regulations thereunder, as from time to time in effect.
|
(i)
|
“
Canadian Dollar Equivalent
” of any amount which is expressed in United States dollars shall mean on any date the Canadian dollar equivalent of such amount determined by reference to the U.S. - Canadian Exchange Rate in effect on such date.
|
(j)
|
“
Close of Business
” on any date means the time on such date (or, if such date is not a Business Day, the time on the next succeeding Business Day) at which the office of the transfer agent for the Shares in the City of Montreal, Quebec (or, after the Separation Time, the office of the Rights Agent in the City of Montreal, Quebec) is closed to the public; provided, however, that for the purposes of the definition of “Competing Permitted Bid” and the definition of “Permitted Bid”, “Close of Business” on any date means 11:59 p.m. (local time, at the place of deposit) on such date (or, if such date is not a Business Day, 11:59 p.m. (local time, at the place of deposit) on the next succeeding Business Day).
|
(k)
|
“
Competing Permitted Bid
” means a Take-over Bid that
is made by means of a Take-over Bid circular and which also complies with the following additional provisions
:
|
(i)
|
is made after a Permitted Bid or another Competing Permitted Bid (each such Permitted Bid or Competing Permitted Bid being in this definition, the “
Prior Bid
”) has been made and prior to the expiry, termination or withdrawal of that Prior Bid;
|
(ii)
|
satisfies all the components of the definition of a Permitted Bid provided that it is not required to satisfy the requirement set forth in Clause (ff)(ii)(A) thereof; and
|
(iii)
|
contains, and the take-up and payment for securities deposited or tendered thereunder are subject to, an irrevocable and unqualified condition that no Voting Shares and/or Convertible Securities shall be taken up or paid for pursuant to the Take-over Bid prior to the Close of Business on the last day of the minimum initial deposit period that such Take-over Bid must remain open for deposits of securities thereunder pursuant to NI 62-104 after the date of the Take-over Bid constituting the Competing Permitted Bid,
|
(l)
|
“
controlled
”: a Person is “controlled” by another Person or two or more Persons acting jointly or in concert if and only if:
|
(i)
|
in the case of a body corporate, securities entitled to vote in the election of directors of such body corporate carrying more than 50% of the votes for the election of the directors are held, directly or indirectly, by or for the benefit of the other Person or Persons and the votes carried by such securities are entitled, if exercised, to elect a majority of the board of directors of such body corporate; or
|
(ii)
|
in the case of a Person which is not a body corporate, more than 50% of the voting interests of such entity are held, directly or indirectly, by or for the benefit of the other Person or Persons;
|
(m)
|
“
Convertible Security
” means, at any time, any securities issued by the Corporation from time to time (other than the Rights) carrying any exercise, conversion or exchange right to which the holder thereof may acquire Voting Shares or other securities which are convertible into or exercisable or exchangeable for Voting Shares
(
whether such right is exercisable immediately or exercisable after a specified period and whether or not on condition or the happening of any contingency).
|
(n)
|
“
Convertible Security Acquisition
” means the acquisition of Voting Shares by a Person upon the purchase, exercise, conversion or exchange of Convertible Securities acquired or received by such Person pursuant to a Permitted Bid Acquisition, an Exempt Acquisition or a Pro Rata Acquisition.
|
(o)
|
“
Co-Rights Agents
” shall have the meaning ascribed thereto in Subsection 4.1a).
|
(p)
|
“
Disposition Date
” shall have the meaning ascribed thereto in Subsection 5.1b).
|
(q)
|
“
Effective Date
” shall mean 5:01 p.m. on March 29, 2016.
|
(r)
|
“
Election to Exercise
” shall have the meaning ascribed thereto in Subsection 2.2d).
|
(s)
|
“
Exempt Acquisition
” means a share acquisition (i) in respect of which the Board of Directors has waived the application of Section 3.1 pursuant to Subsection 5.1b), 5.1d) or 5.1e) or (ii) pursuant to an amalgamation, merger or other statutory procedure requiring shareholder approval.
|
(t)
|
“
Exercise Price
” shall mean, as of any date from and after the Separation Time, the price at which a holder of a Right may purchase the securities issuable upon exercise of one whole Right which, subject to adjustment in accordance with the terms hereof, shall be an aggregate dollar amount equal to the Market Price per Share (determined as at the Separation Time) multiplied by five (5).
|
(u)
|
“
Expiration Time
” shall mean the earlier of: (i) the Termination Time; and (ii) the Close of Business on the date on which a Reconfirmation Meeting occurs and at which this Agreement is not reconfirmed or presented for reconfirmation as contemplated in Section 5.20.
|
(v)
|
“
Fiduciary
” shall mean, when acting in that capacity, a trust company registered under the trust company legislation of Canada or any province thereof, a trust company organized under the laws of any state of the United States of America, a portfolio manager registered under the securities legislation of one or more provinces of Canada or an investment adviser registered under the United States Investment Advisers Act of 1940 or any other securities legislation of the United States of America or any state of the United States of America.
|
(w)
|
“
Flip-in Event
” shall mean a transaction or event in or pursuant to which any Person becomes an Acquiring Person.
|
(x)
|
“
holder
” shall have the meaning ascribed thereto in Section 2.8.
|
(y)
|
“
Independent Shareholders
” shall mean holders of outstanding Voting Shares, other than (i) any Acquiring Person or Offeror other than a Person who is deemed not to Beneficially Own such Voting Shares by reason of Section 1.1(e)(vi)
hereof; (ii) any Person acting jointly or in concert with any Acquiring Person or Offeror; (iii) any Associate or Affiliate of any Acquiring Person or Offeror; and (iv) any employee benefit plan, stock purchase plan, deferred profit sharing plan and any similar plan or trust for the benefit of employees of the Corporation or a corporation controlled by the Corporation, unless the beneficiaries of the plan or trust direct the manner in which the Voting Shares are to be voted or withheld from voting or direct whether the Voting Shares are to be deposited or tendered to a Take-over Bid.
|
(z)
|
"
Market Price
" per security of any securities on any date of determination shall mean the VWAP of such securities for the twenty (20) consecutive Trading Days through and including the Trading Day immediately preceding such date of determination, provided, however, that (i) if on any such date the securities are not traded on any exchange or in the over-the-counter market, the Market Price per share of such securities on such date shall mean the fair market value per security of the securities on such date as determined by a nationally or internationally recognized investment dealer or investment banker selected by the Board of Directors, and (ii) if the Market Price so determined is expressed in United States dollars, such amount shall be converted to the Canadian Dollar Equivalent.
|
(aa)
|
"
NI 62-104
" means National Instrument 62-104 –
Take-Over Bids and Issuer Bids
.
|
(bb)
|
“
Nominee
” shall have the meaning ascribed thereto in Subsection 2.2c).
|
(cc)
|
“
Offer to Acquire
” shall include:
|
(i)
|
an offer to purchase or a solicitation of an offer to sell Voting Shares, or a public announcement of an intention to make such an offer or solicitation; and
|
(ii)
|
an acceptance of an offer to sell Voting Shares, whether or not such offer to sell has been solicited;
|
(dd)
|
“
Offeror
” shall mean a Person who has announced a current intention to make, or who is making, a Take-over Bid.
|
(ee)
|
“
Offeror’s Securities
” shall mean the Voting Shares Beneficially Owned on the date of a Take-over Bid by an Offeror.
|
(ff)
|
“
Permitted Bid
” means a Take-over Bid that is made by means of a take-over bid circular and that also complies with the following additional provisions:
|
(i)
|
the Take-over Bid shall be made to all holders of Voting Shares of record (other than the Offeror); and
|
(ii)
|
the Take-over Bid contains, and the take-up and payment for securities tendered or deposited thereunder are subject to, an irrevocable and unqualified condition that no securities shall be taken up or paid for pursuant to the Take-over Bid:
|
(A)
|
prior to the close of business on the date which is not less than one hundred and five (105) days following the date of the Take-over Bid or such shorter minimum period as determined in accordance with section 2.28.2 or section 2.28.3 of NI 62-104 for which a Take-over Bid (that is not exempt from any of the requirements of division 5 (Bid Mechanics) of NI 62-104) must remain open for deposit of securities thereunder; and
|
(B)
|
unless, at the close of business on such date in (A), more than 50% of the then outstanding Voting Shares held by Independent Shareholders have been deposited or tendered pursuant to the Take-over Bid and have not been withdrawn;
|
(iii)
|
the Take-over Bid contains an irrevocable and unqualified provision that securities may be deposited pursuant to such Take-over Bid at any time during the period of time described in Section 1.1(ff)(ii)(A) above and during any extension of such Take-over Bid and any securities deposited pursuant to the Take-over Bid may be withdrawn until taken up and paid for; and
|
(iv)
|
the Take-over Bid contains an irrevocable and unqualified provision that if the requirement set forth in Section 1.1(ff)(ii)(B) is satisfied and such securities are taken up by the Offeror, the Offeror will make a public announcement of that fact and the Take-over Bid will remain open for deposits and tenders of Voting Shares for not less than 10 days from the date of such public announcement;
|
(gg)
|
“
Permitted Bid Acquisition
” means an acquisition of Voting Shares made pursuant to a Permitted Bid or a Competing Permitted Bid.
|
(hh)
|
“
Permitted
Lock-up Agreement
” means an agreement (the "
Lock-up Agreement
") between an Offeror or any Affiliate or Associate of an Offeror and one or more holders of Voting Shares (each such holder herein referred to as a “
Locked-up Person
”) who are not Affiliates or Associates of the Offeror and who are not, other than by virtue of entering into such agreement, acting jointly or in concert with the Offeror, the terms of which are publicly disclosed and a copy of which is made available to the public (including the Corporation) not later than the date of the Lock-up Bid (as hereinafter defined) or, if the Lock-up Bid has
|
(i)
|
the Lock-up Agreement permits the Locked-up Person to withdraw its Voting Shares and/or Convertible Securities from the Lock-up Agreement and the Lock-up Bid in order to deposit or tender the Voting Shares and/or Convertible Securities to another Take-over Bid or to support another transaction prior to the Voting Shares and/or Convertible Securities being taken up and paid for under the Lock-up Bid:
|
(A)
|
at a price or value per Voting Share or Convertible Security that exceeds the price or value per Voting Share or Convertible Security offered under the Lock-up Bid; or
|
(B)
|
for a number of Voting Shares or Convertible Securities that exceeds by as much as or more than a number specified in the Lock-up Agreement (the “
Specified Number
”) the number of Voting Shares or Convertible Securities that the Offeror has offered to purchase under the Lock-up Bid at a price or value per Voting Share or Convertible Security that is not less than the price or value per Voting Share or Convertible Security offered under the Lock-up Bid, provided that the Specified Number is not greater than 7% of the number of Voting Shares or Convertible Securities offered to be purchased under the Lock-up Bid; or
|
(C)
|
at such price or value that exceeds by as much as or more than an amount specified in the Lock-up Agreement (the “
Specified Amount
”) the offering price for each Voting Share or Convertible Security contained in or proposed to be contained in the Lock-up Bid, provided that the Specified Amount is not greater than 7% of the offering price contained in or proposed to be contained in the Lock-up Bid;
|
(ii)
|
no “break-up” fees, “topping” fees, penalties, expenses or other amounts that exceed in aggregate the greater of:
|
(A)
|
2½% of the price or value of the aggregate consideration payable under the Lock-up Bid to a Locked-up Person; and
|
(B)
|
50% of the amount by which the price or value of the consideration received by a Locked-up Person under another Take-over Bid or transaction exceeds
|
(ii)
|
“
Person
”
shall include any individual, firm, limited partnership, limited liability company or partnership, association, trust, trustee, executor, administrator, legal or personal representative, government, governmental body, entity or authority, group, body corporate, or other incorporated or unincorporated organization or association, syndicate, joint venture or any other entity, whether or not having legal personality, and any of the foregoing in any derivative, representative or fiduciary capacity and pronouns have a similar extended meaning.
|
(jj)
|
“
Privacy Laws
” shall have the meaning ascribed thereto in Section 4.6.
|
(kk)
|
“
Pro Rata Acquisition
” means an acquisition by a Person of Voting Shares pursuant to (i) any dividend reinvestment plan, share purchase plan or other plan of the Corporation made available to all holders of Voting Shares (other than holders resident in any jurisdiction where participation in such plan is restricted or impractical as a result of applicable law); (ii) a stock dividend, a stock split or other event pursuant to which such Person becomes the Beneficial Owner of Voting Shares on the same pro rata basis as all other holders of Voting Shares of the same class or series; (iii) the acquisition or exercise of rights to purchase Voting Shares distributed to all holders of Voting Shares (other than holders resident in any jurisdiction where such distribution or exercise is restricted or impractical as a result of applicable law) by the Corporation pursuant to a rights offering (but only if such rights are acquired directly from the Corporation); or (iv) a distribution of Voting Shares or Convertible Securities in respect thereof offered pursuant to a prospectus or by way of a private placement by the Corporation or a conversion or exchange of any such Convertible Security, provided that, in the cases of (iii) and (iv) above, such Person does not thereby acquire a greater percentage of Voting Shares or Convertible Securities so offered than the Person’s percentage of Voting Shares Beneficially Owned immediately prior to such acquisition.
|
(ll)
|
“
Reconfirmation Meeting
” shall have the meaning ascribed thereto in Section 5.20.
|
(mm)
|
“
Record Time
” means 5:01 p.m. on March 29, 2016, being the Effective Date.
|
(nn)
|
“
Redemption Price
” shall have the meaning attributed thereto in Subsection 5.1a).
|
(oo)
|
“
Regular Cash Dividend
” means cash dividends paid on the Shares in any fiscal year of the Corporation to the extent that such cash dividends do not exceed in the aggregate in any fiscal year the greatest of:
|
(i)
|
100% of the aggregate consolidated net income of the Corporation, before extraordinary items, for its immediately preceding fiscal year; and
|
(ii)
|
200% of the aggregate amount of cash dividends declared payable by the Corporation on its Shares in its immediately preceding fiscal year; and
|
(iii)
|
300% of the arithmetic mean of the aggregate amounts of cash dividends declared payable by the Corporation on its Shares in its three immediately preceding fiscal years
.
|
(pp)
|
“
Right
” shall mean the rights described herein to purchase securities pursuant to the terms and subject to the conditions set forth herein.
|
(qq)
|
“
Rights Certificate
” shall mean the certificates representing the Rights after the Separation Time which shall be substantially in the form attached hereto as Exhibit A.
|
(rr)
|
“
Rights Register
” and “
Rights Registrar
” shall have the respective meanings ascribed thereto in Subsection 2.6a).
|
(ss)
|
“
Securities Act
” shall mean the
Securities Act
, R.S.Q., c. V-1.1, as amended and the regulations, rules and policy statements made thereunder, as from time to time in effect.
|
(tt)
|
“
Separation Time
” means the Close of Business on the eighth Trading Day after the earlier of:
|
(i)
|
the Stock Acquisition Date; and
|
(ii)
|
the date of the commencement of, or first public announcement or disclosure of the intent of any Person (other than the Corporation or any corporation controlled by the Corporation) to commence, a Take-over Bid (other than a Permitted Bid, so long as such Take-over Bid continues to satisfy the requirements of a Permitted Bid);
|
(uu)
|
“
Shares
” means the common shares in the share capital of the Corporation, as such shares may be subdivided, consolidated, reclassified or otherwise changed from time to time.
|
(vv)
|
“
Stock Acquisition Date
” shall mean the first date of public announcement or disclosure by the Corporation or an Acquiring Person of facts indicating that a Person has become an Acquiring Person (which, for the purposes of this definition, shall include, without limitation, an early warning report filed pursuant to National Instrument 62-103 – The Early Warning System and Related Take-over Bid and Insider Reporting Issues (adopted in Québec as Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues) or Section 13(d) of the
U.S. Exchange Act
disclosing such information).
|
(ww)
|
“
Take-over Bid
” means an Offer to Acquire Voting Shares of any class, or Convertible Securities with respect thereto, where the Voting Shares subject to the Offer to Acquire, together with the Voting Shares into or for which the securities subject to the Offer to Acquire are convertible or exchangeable and the Offeror’s Securities constitute in the aggregate 20% or more of the outstanding Voting Shares at the date of the Offer to Acquire.
|
(xx)
|
“
Termination Time
” means the time at which the right to exercise Rights shall terminate pursuant to Section 5.1 hereof.
|
(yy)
|
“
Trading Day
” when used with respect to any securities, means the day on which the principal Canadian or United States securities exchange (as determined by the Board of Directors acting in good faith) on which such securities are listed or admitted to trading is open for the transaction of business or, if the securities are not listed or admitted to trading on any Canadian or United States securities exchange, a Business Day.
|
(zz)
|
“
TSX
” means the Toronto Stock Exchange.
|
([[)
|
“
U.S. - Canadian Exchange Rate
” on any date shall mean:
|
(i)
|
if on such date the Bank of Canada sets an average noon spot rate of exchange for the conversion of one United States dollar into Canadian dollars, such rate; and
|
(ii)
|
in any other case, the rate for such date for the conversion of one United States dollar into Canadian dollars which is calculated in the manner which shall be determined by the Board of Directors from time to time acting in good faith.
|
(aaa)
|
“
U.S. Exchange Act
” means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder as from time to time in effect.
|
(bbb)
|
“
Voting Share Reduction
” means an acquisition or redemption by the Corporation or any corporation controlled by the Corporation of Voting Shares which, by reducing the number of Voting Shares outstanding, increases the percentage of Voting Shares Beneficially Owned by any Person to 20% or more of the Voting Shares then outstanding.
|
(ccc)
|
“
Voting Shares
” means the Shares and any other securities the holders of which are entitled to vote generally on the election of directors of the Corporation, and “voting shares”, when used with reference to any Person other than the Corporation, means common shares of such other Person and any other securities the holders of which are entitled to vote generally on the election of the directors of such other Person.
|
(ddd)
|
“
VWAP
” means, with respect to any class of securities, the volume weighted average trading price of the securities, calculated by dividing the aggregate sale price by the total volume of the securities traded on the TSX for the relevant period, as adjusted, as the case may be, by the TSX (provided that, if at the date of determination such securities are listed or admitted to trading on more than one stock exchange or national securities quotation system (including, for greater certainty, each of the Nasdaq Global Select Market, the Nasdaq Global Market and the Nasdaq Capital Market), such volume shall be determined based on the stock exchange or quotation system on which such securities are then listed or admitted to trading on which the largest number of such securities were traded during the most recently completed calendar year or, if a calendar year has not been completed prior to the date of
|
Section 1.2
|
Currency
|
Section 1.3
|
Number and Gender
|
Section 1.4
|
Sections and Headings
|
Section 1.5
|
Statutory References
|
Section 1.6
|
Determination of Percentage Ownership
|
Section 1.7
|
Acting Jointly or in Concert
|
Section 2.1
|
Legend on Share Certificates
|
(a)
|
Certificates representing the Shares, including without limitation Shares issued upon the conversion of Convertible Securities, issued after the Record Time but prior to the Close of Business on the earlier of the Separation Time and the Expiration Time shall also evidence one Right for each Share represented thereby and shall have impressed on, printed on, written on or otherwise affixed to them the following legend:
|
(b)
|
Certificates representing Shares that have been issued prior to, and remain outstanding at, the Record Time, shall evidence one Right for each Share evidenced thereby until the earlier of the Separation Time and the Expiration Time notwithstanding the absence of the legend required by Subsection 2.1a).
|
Section 2.2
|
Initial Exercise Price; Exercise of Rights; Detachment of Rights
|
(a)
|
Right to entitle holder to purchase one Share prior to adjustment.
Subject to adjustment as herein set forth, including without limitation as set forth in Article 3, each Right will entitle the holder thereof, from and after the Separation Time and prior to the Expiration Time, to purchase one Share for the Exercise Price (which Exercise Price and number of Shares are subject to adjustment as set forth below). Notwithstanding any other provision of this Agreement, any Rights held by the Corporation or any of its subsidiaries shall be void.
|
(b)
|
Rights not exercisable until Separation Time.
Until the Separation Time, (i) the Rights shall not be exercisable and no Right may be exercised and (ii) for administrative purposes, each Right will be evidenced by the certificate for the associated Shares registered in the name of the holder thereof (which certificate shall be deemed to represent a Rights Certificate) and will be transferable only together with, and will be transferred by a transfer of, such associated Shares.
|
(c)
|
Delivery of Rights Certificate and disclosure statement
.
From and after the Separation Time and prior to the Expiration Time, the Rights may be exercised, and the registration and transfer of the Rights shall be separate from and independent of Shares. Promptly following the Separation Time, the Corporation will prepare or cause to be prepared and the Rights Agent will mail to each holder of record of Shares as of the Separation Time and, in respect of each Convertible Security converted into Shares after the Separation Time and prior to the Expiration Time, promptly after such conversion, the Corporation will prepare or cause to be prepared and the Rights Agent will mail to the holder so converting (other than in each case an Acquiring Person or any other Person whose Rights are or become void pursuant to the provisions of Section 3.1(b) hereof and, in respect of any Rights Beneficially Owned by such Acquiring Person or other Person whose Rights are or become void pursuant to the provisions of Section 3.1(b) hereof, which are not held of record by such Acquiring Person or other Person, the holder of record of such rights (a “
Nominee
”)) at such holder’s address as shown by the records of the Corporation (the Corporation hereby agreeing to furnish copies of such record to the Rights Agent for this purpose):
|
(i)
|
a Rights Certificate in substantially the form of Exhibit A hereto appropriately completed, representing the number of Rights held by such holder at the Separation Time and having such marks of identification or designation and such legends, summaries or endorsements printed thereon as the Corporation may deem appropriate and as are not inconsistent with the provisions of this Agreement, or as may be required to comply with any law, rule or regulation or judicial or administrative order, or with any article, requirement or regulation of any stock exchange or quotation system on which the Rights may from time to time be listed or traded, or to conform to usage; and
|
(ii)
|
a disclosure statement prepared by the Corporation describing the Rights;
|
(d)
|
Exercise of Rights.
Rights may be exercised in whole or in part on any Business Day after the Separation Time and prior to the Expiration Time by submitting to the Rights Agent at its principal office in Montreal, Quebec, or any other office of the Rights Agent designated for that purpose from time to time by the Corporation:
|
(i)
|
the Rights Certificate evidencing such Rights;
|
(ii)
|
an election to exercise (an “
Election to Exercise
”) substantially in the form attached to the Rights Certificate duly completed and executed in a manner acceptable to the Rights Agent; and
|
(iii)
|
payment by certified cheque, banker’s draft or money order payable to the order of the Rights Agent, or by wire transfer to an account designated by the Rights Agent, of a sum equal to the Exercise Price multiplied by the number of Rights being exercised and a sum sufficient to cover any transfer tax or charge which may be payable in respect of any transfer involved in the transfer or delivery of Rights Certificates or the issuance or delivery of certificates for Shares in a name other than that of the holder of the Rights being exercised.
|
(e)
|
Duties of Rights Agent upon receipt of Election to Exercise.
Upon receipt of a Rights Certificate, which is accompanied by an appropriately completed and duly executed Election to Exercise (which does not or is not deemed to indicate that such Right is null and void as provided by Subsection 3.1b)) and payment as set forth in Subsection 2.2d), the Rights Agent (unless otherwise instructed by the Corporation) will thereupon promptly:
|
(i)
|
requisition from the transfer agent of the Shares certificates representing the number of Shares to be purchased (the Corporation hereby irrevocably authorizing its transfer agent to comply with all such requisitions);
|
(ii)
|
after receipt of such share certificates, deliver such certificates to, or to the order of, the registered holder of such Rights Certificate, registered in such name or names as may be designated by such holder;
|
(iii)
|
when appropriate, requisition from the Corporation the amount of cash, if any, to be paid in lieu of issuing fractional Shares;
|
(iv)
|
when appropriate, after receipt of such cash, deliver such cash to, or to the order of, the registered holder of the Rights Certificate; and
|
(v)
|
tender to the Corporation all payments received on exercise of the Rights.
|
(f)
|
Partial Exercise of Rights.
If the holder of any Rights shall exercise less than all of the Rights evidenced by such holder’s Rights Certificate, a new Rights Certificate evidencing the Rights remaining unexercised will be issued by the Rights Agent to such holder or to such holder’s duly authorized assigns.
|
(g)
|
Duties of the Corporation.
The Corporation covenants and agrees that it will:
|
(i)
|
take all such action as may be necessary and within its power to ensure that all Shares delivered upon the exercise of Rights shall, at the time of delivery of the certificates for such Shares (subject to payment of the Exercise Price), be duly and validly authorized, executed, issued and delivered as fully paid and non-assessable;
|
(ii)
|
take all such action as may reasonably be considered to be necessary and within its power to comply with any applicable requirements of the
Canada Business Corporations Act
, the
Securities Act
, the
U.S. Exchange Act
, the
United States Securities Act of 1933
, as amended, and applicable comparable legislation of each of the provinces and territories of Canada and states of the United States of America, or the rules and regulations thereunder or any other applicable law, rule or regulation, in connection with the issuance and delivery of the Rights, the Rights Certificates and the issuance of any Shares upon exercise of the Rights;
|
(iii)
|
use reasonable efforts to cause all Shares issued upon exercise of the Rights to be listed on the stock exchanges on which the Shares are listed at that time;
|
(iv)
|
cause to be reserved and kept available out of its authorized and unissued Shares, the number of Shares that, as provided in this Agreement, will from time to time be sufficient to permit the exercise in full of all outstanding Rights;
|
(v)
|
pay when due and payable, if applicable, any and all federal, provincial, state and municipal taxes (not in the nature of income, capital gains or withholding taxes) and charges which may be payable in respect of the original issuance or delivery of the Rights Certificates or certificates for Shares issued upon the exercise of Rights, provided that the Corporation shall not be required to pay any transfer tax or charge which may be payable in respect of any transfer of Rights or the issuance or delivery of certificates for Shares issued upon the exercise of Rights, in a name other than that of the holder of the Rights being transferred or exercised; and
|
(vi)
|
after the Separation Time, except as permitted by Section 5.1 or Section 5.4, not take (or permit any corporation it controls to take) any action if at the time such action is taken it is reasonably foreseeable that such action will diminish substantially or otherwise eliminate the benefits intended to be afforded by the Rights.
|
Section 2.3
|
Adjustments to Exercise Price; Number of Rights
|
(a)
|
The Exercise Price, the number and kind of securities subject to purchase upon exercise of each Right and the number of Rights outstanding are subject to adjustment from time to time as provided in this Section 2.3 and in Article 3.
|
(b)
|
Adjustment to Exercise Price upon changes to share capital.
In the event that the Corporation shall at any time after the Record Time and prior to the Expiration Time:
|
(i)
|
declare or pay a dividend on the Shares payable in Voting Shares or Convertible Securities in respect thereof other than in the ordinary course of business or pursuant to any dividend reinvestment plan or program;
|
(ii)
|
subdivide or change the then outstanding Shares into a greater number of Shares;
|
(iii)
|
consolidate, combine or change the then outstanding Shares into a smaller number of Shares; or
|
(iv)
|
issue any Voting Shares (or Convertible Securities in respect thereof) in respect of, in lieu of, or in exchange for existing Shares, whether in a reclassification, amalgamation, statutory arrangement, consolidation or otherwise;
|
(A)
|
If the Exercise Price and number of Rights outstanding are to be adjusted:
|
i.
|
the Exercise Price in effect after such adjustment will be equal to the Exercise Price in effect immediately prior to such adjustment divided by the number of Shares (or other securities of the Corporation) that a holder of one Share immediately prior to such dividend, subdivision, change, consolidation or issuance would hold thereafter as a result thereof; and
|
ii.
|
each Right held prior to such adjustment will become that number of Rights equal to that number that is equal to the number of Shares (or other securities of the Corporation) that a holder of one Share immediately prior to such dividend, subdivision, change, consolidation or issuance would hold immediately thereafter as a result thereof, and the adjusted number of Rights will be deemed to be allocated among the Shares with respect to which the original Rights were associated (if they remain outstanding) and the securities of the Corporation issued in respect of such dividend, subdivision, change, consolidation or issuance, so that each such Share (or other security of the Corporation) will have exactly one Right associated with it.
|
(B)
|
If the securities purchasable upon exercise of Rights are to be adjusted, the securities purchasable upon exercise of each Right after such adjustment will be the securities that a holder of the securities purchasable upon exercise of one Right immediately prior to such dividend, subdivision, change, consolidation or issuance would hold thereafter as a result thereof.
|
(c)
|
Adjustments pursuant to Subsection 2.3b) shall be made successively, whenever an event referred to in Subsection 2.3b) occurs.
|
(d)
|
If an event occurs which would require an adjustment under both this Section 2.3 and Section 3.1 hereof, the adjustment provided for in this Section 2.3 shall be in addition to, and shall be made prior to, any adjustment required pursuant to Section 3.1 hereof.
|
(e)
|
If, after the Record Time and prior to the Expiration Time, the Corporation shall issue any shares of its capital other than Shares in a transaction of a type described in Section 2.3(b)
|
(f)
|
Adjustment to Exercise Price upon issue of rights, options and warrants.
In the event the Corporation shall, at any time after the Record Time and prior to the Expiration Time, fix a record date for the making of a distribution to all holders of Shares of Convertible Securities entitling them (for a period expiring within 45 calendar days after such record date) to subscribe for or purchase Shares (or other Convertible Securities in respect of Shares) at a price per Share (or, in the case of such other Convertible Security, having a conversion, exchange or exercise price per share (including the price required to be paid to purchase such other Convertible Security)) less than 90% of the Market Price per Share on such record date, the Exercise Price in effect after such record date will equal the Exercise Price in effect immediately prior to such record date multiplied by a fraction;
|
(i)
|
of which the numerator shall be the number of Shares outstanding on such record date plus the number of Shares which the aggregate offering price of the total number of Shares so to be offered (and/or the aggregate initial conversion, exchange or exercise price of the Convertible Securities so to be offered (including the price required to be paid to purchase such Convertible Securities)) would purchase at such Market Price per Share; and
|
(ii)
|
of which the denominator shall be the number of Shares outstanding on such record date plus the number of additional Shares to be offered for subscription or purchase (or into which the Convertible Securities so to be offered are initially convertible, exchangeable or exercisable).
|
(g)
|
Adjustment to Exercise Price upon Corporate Distributions.
In the event the Corporation shall, at any time after the Record Time and prior to the Expiration Time, fix a record date for the making of a distribution to all holders of Shares of (i) evidences of indebtedness or assets (other than a Regular Cash Dividend or a dividend paid in Shares, but including any dividend payable in securities other than Shares), (ii) Convertible Securities entitling them to subscribe for or purchase Voting Shares (or Convertible Securities in respect of Voting Shares), at a price per Voting Share (or, in the case of a Convertible Security in respect of Voting Shares, having a conversion, exchange or exercise price per share (including the price required to be paid to purchase such Convertible Security)) less than 90% of the Market Price per Share on such record date (excluding Convertible Securities referred to in Subsection 2.3f)) or (iii) other securities of the Corporation, the Exercise Price in effect after such record date shall be equal to the Exercise Price in effect immediately prior to such record date less the fair market value (as determined in good faith by the Board of Directors) of the portion of the assets, evidences of indebtedness, Convertible Securities or other securities so to be distributed applicable to each of the securities purchasable upon exercise of one Right. Such adjustment shall be made successively whenever such a record date is fixed.
|
(h)
|
Each adjustment made pursuant to Section 2.3 shall be made as of
|
(i)
|
the payment or effective date for the applicable dividend, subdivision, change, consolidation or issuance, in the case of an adjustment made pursuant to Subsection 2.3b) above; and
|
(ii)
|
the record date for the applicable dividend or distribution, in the case of an adjustment made pursuant to Subsections 2.3f) or 2.3g) above, subject to readjustment to reverse the same if such distribution shall not be made.
|
(i)
|
Corporation may provide for alternate means of adjustment.
In the event the Corporation shall, at any time after the Record Time and prior to the Expiration Time, issue any shares (other than Shares), or Convertible Securities to subscribe for or purchase any such shares, or Convertible Securities in respect of any such shares, in a transaction referred to in any of clauses 2.3b)i) to (iv), Subsection 2.3f) or Subsection 2.3g) above, if the Board of Directors acting in good faith determines that the adjustments contemplated by Subsections 2.3b), 2.3f) and 2.3g) above in connection with such transaction would not appropriately protect the interests of the holders of Rights, the Board of Directors may from time to time acting in good faith determine what other adjustments, if any, to the Exercise Price, number of Rights or securities purchasable upon exercise of Rights would be appropriate in the circumstances, if any, and such other adjustments (if any) shall be made upon the Board of Directors providing written certification thereof to the Rights Agent pursuant to Subsection 2.3q) and no adjustments contemplated by Subsections 2.3b), 2.3f) or 2.3g) shall be made notwithstanding the terms thereof. The Corporation and the Rights Agent shall amend this Agreement to provide for any such other adjustments contemplated by this Subsection 2.3i), subject to the prior approval of the TSX (if the Shares are then listed on the TSX), and of the shareholders of the Corporation or the holders of Rights obtained in accordance with Section 5.4.
|
(j)
|
De minimis threshold for adjustment to Exercise Price
.
Notwithstanding anything herein to the contrary, no adjustment of the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least 1% in such Exercise Price; provided, however, that any adjustments which by reason of this Subsection 2.3j) are not required to be made shall be carried forward and taken into account in any subsequent adjustment. All adjustments to the Exercise Price made pursuant to this Section 2.3 shall be calculated to the nearest cent.
|
(k)
|
Rights to evidence right to purchase Shares at adjusted Exercise Price.
Each Right originally issued by the Corporation subsequent to any adjustment made to the Exercise Price hereunder shall evidence the right to purchase, at the adjusted Exercise Price, the number of Shares purchasable from time to time hereunder upon exercise of the Rights, all subject to further adjustment as provided herein.
|
(l)
|
Adjustment to number of Shares purchasable upon adjustment to Exercise Price.
Unless the Corporation shall have exercised its election as provided in Subsection 2.3m) to adjust the number of Rights in lieu of any adjustment in the number of Shares purchasable upon the exercise of a Right, upon each adjustment of the Exercise Price as a result of the calculations made in Subsections 2.3f) and 2.3g), each Right outstanding immediately prior to the making of such adjustment shall thereafter evidence the right to purchase, at the adjusted Exercise Price, that number of Shares obtained by:
|
(i)
|
multiplying (A) the number of Shares covered by a Right immediately prior to such adjustment, by (B) the Exercise Price in effect immediately prior to such adjustment; and
|
(ii)
|
dividing the product so obtained by the Exercise Price in effect immediately after such adjustment.
|
(m)
|
Election to adjust number of Rights upon adjustment to Exercise Price.
The Corporation may elect on or after the date of any adjustment of the Exercise Price to adjust the number of Rights, in lieu of any adjustment in the number of Shares purchasable upon the exercise of a Right. Each of the Rights outstanding after the adjustment in the number of Rights shall be exercisable for the number of Shares for which a Right was exercisable immediately prior to such adjustment. Each Right held of record prior to such adjustment of the number of Rights shall become the number of Rights obtained by dividing the relevant Exercise Price in effect immediately prior to adjustment of the relevant Exercise Price by the relevant Exercise Price in effect immediately after adjustment of the relevant Exercise Price. The Corporation shall make a public announcement of its election to adjust the number of Rights pursuant to this Subsection 2.3m), indicating the record date for the adjustment; and, if known at the time, the amount of the adjustment to be made. This record date may be the date on which the relevant Exercise Price is adjusted or any day thereafter, but, if the Rights Certificates have been issued, shall be at least 10 calendar days later than the date of the public announcement. If Rights Certificates have been issued, upon each adjustment of the number of Rights pursuant to this Subsection 2.3m), the Corporation shall, as promptly as practicable, cause to be distributed to holders of record of Rights Certificates on such record date, Rights Certificates evidencing, subject to Section 5.5, the additional Rights to which such holders shall be entitled as a result of such adjustment, or, at the option of the Corporation, shall cause to be distributed to such holders of record in substitution and
|
(n)
|
Corporation may in certain cases defer issues of securities.
In any case in which this Section 2.3 shall require that an adjustment in an Exercise Price be made effective as of a record date for a specified event, the Corporation may elect to defer until the occurrence of such event the issuance to the holder of any Right exercised after such record date of the number of Shares and other securities of the Corporation, if any, issuable upon such exercise over and above the number of Shares and other securities of the Corporation, if any, issuable upon such exercise on the basis of the relevant Exercise Price in effect prior to such adjustment; provided, however, that the Corporation shall deliver to such holder an appropriate instrument evidencing such holder’s right to receive such additional Shares (fractional or otherwise) or other securities upon the occurrence of the event requiring such adjustment.
|
(o)
|
Corporation has discretion to reduce Exercise Price for tax reasons.
Notwithstanding anything in this Section 2.3 to the contrary, the Corporation shall be entitled to make such adjustments in the Exercise Price, in addition to those adjustments expressly required by this Section 2.3, as and to the extent that in its good faith judgment the Board of Directors shall determine to be advisable in order that any (i) subdivision or consolidation of the Shares, (ii) issuance wholly for cash of any Shares at less than the applicable Market Price, (iii) issuance wholly for cash of any Shares or securities that by their terms are exchangeable for or convertible into or give a right to acquire Shares, (iv) stock dividends, or (v) issuance of Convertible Securities referred to in this Section 2.3, hereafter made by the Corporation to holders of its Shares, shall not be taxable to such shareholders, subject to the prior approval of the TSX (if the Shares are then listed on the TSX).
|
(p)
|
Rights Certificates may contain Exercise Price before adjustment.
Irrespective of any adjustment or change in the securities purchasable upon exercise of the Rights, the Rights Certificates theretofore and thereafter issued may continue to represent the securities so purchasable which were represented in the initial Rights Certificates issued hereunder.
|
(q)
|
Adjustment to Rights exercisable into shares other than Shares.
If, as a result of an adjustment made pursuant to Section 3.1, the holder of any Right thereafter exercised shall become entitled to receive any securities other than Shares, thereafter the number of such other securities so receivable upon exercise of any Right and the applicable Exercise Price thereof shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as may be practicable to the provisions with respect to the Shares contained in the foregoing Sections of this Section 2.3 and the provisions of this Agreement with respect to the Shares shall apply on like terms to any such other securities.
|
(r)
|
Notice in Respect of Adjustments.
Whenever an adjustment to the Exercise Price or a change in the securities purchasable upon the exercise of Rights is made pursuant to this Section 2.3, the Corporation shall:
|
(i)
|
promptly prepare a certificate setting forth such adjustment and a brief statement of the facts accounting for such adjustment; and
|
(ii)
|
promptly file with the Rights Agent and with each transfer agent for the Shares a copy of such certificate and mail a brief summary thereof to each holder of Rights who requests a copy.
|
Section 2.4
|
Date on Which Exercise is Effective
|
Section 2.5
|
Execution, Authentication, Delivery and Dating of Rights Certificates
|
(a)
|
The Rights Certificates shall be executed on behalf of the Corporation by any two officers of the Corporation. The signature of any of these officers on the Rights Certificates may be manual or facsimile. Rights Certificates bearing the manual or facsimile signatures of individuals who were at any time the proper officers of the Corporation shall bind the Corporation, notwithstanding that such individuals or any of them have ceased to hold such offices prior to the countersignature and delivery of such Rights Certificates.
|
(b)
|
Promptly after the Corporation learns of the Separation Time, the Corporation will notify the Rights Agent of such Separation Time and will deliver Rights Certificates executed by the Corporation to the Rights Agent for countersignature and a statement describing the Rights, and the Rights Agent shall countersign manually (or by facsimile signature in a manner satisfactory to the Corporation) and deliver such Rights Certificates and statement to the holders of the Rights pursuant to Section 2.2 hereof. No Rights Certificate shall be valid for any purpose until countersigned by the Rights Agent as aforesaid.
|
(c)
|
Each Rights Certificate shall be dated the date of countersignature thereof.
|
Section 2.6
|
Registration, Transfer and Exchange
|
(a)
|
Following the Separation Time, the Corporation shall cause to be kept a register (the “
Rights Register
”) in which, subject to such reasonable regulations as it may prescribe, the Corporation will provide for the registration and transfer of Rights. The Rights Agent is hereby appointed “Rights Registrar” for the purpose of maintaining the Rights Register for the Corporation and registering Rights and transfers of Rights as herein provided and the Rights Agent hereby accepts such appointment. In the event that the Rights Agent shall cease
|
(b)
|
After the Separation Time and prior to the Expiration Time, upon surrender for registration of transfer or exchange of any Rights Certificate, and subject to the provisions of Subsections 2.6d) and 3.1b) below, the Corporation will execute, and the Rights Agent will countersign, register and deliver, in the name of the holder or the designated transferee or transferees, as required pursuant to the holder’s instructions, one or more new Rights Certificates evidencing the same aggregate number of Rights as did the Rights Certificates so surrendered.
|
(c)
|
All Rights issued upon any registration of transfer or exchange of Rights Certificates shall be valid obligations of the Corporation, and such Rights shall be entitled to the same benefits under this Agreement as the Rights surrendered upon such registration of transfer or exchange.
|
(d)
|
Every Rights Certificate surrendered for registration of transfer or exchange shall be duly endorsed, or be accompanied by a written instrument of transfer in form satisfactory to the Corporation or the Rights Agent, as the case may be, duly executed by the registered holder thereof or such holder’s attorney duly authorized in writing. As a condition to the issuance of any new Rights Certificate under this Section 2.6, the Corporation may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Rights Agent) in connection therewith.
|
(e)
|
The Corporation shall not be required to register the transfer or exchange of any Rights after the Rights have been terminated pursuant to the provisions of this Agreement.
|
Section 2.7
|
Mutilated, Lost, Stolen and Destroyed Rights Certificates
|
(a)
|
If any mutilated Rights Certificate is surrendered to the Rights Agent prior to the Expiration Time, the Corporation shall execute and the Rights Agent shall countersign and deliver in exchange therefor a new Rights Certificate evidencing the same number of Rights as did the Rights Certificate so surrendered.
|
(b)
|
If there shall be delivered to the Corporation and the Rights Agent prior to the Expiration Time: (i) evidence to their reasonable satisfaction of the ownership, destruction, loss or theft of any Rights Certificate; and (ii) such security or indemnity as may be reasonably required by them to save each of them and any of their agents harmless, then, in the absence of notice to the Corporation or the Rights Agent that such Rights Certificate has been acquired by a bona fide purchaser, the Corporation shall execute and, upon the Corporation’s request the Rights Agent shall countersign and deliver, in lieu of any such destroyed, lost or stolen Rights Certificate, a new Rights Certificate evidencing the same number of Rights as did the Rights Certificate so destroyed, lost or stolen.
|
(c)
|
As a condition to the issuance of any new Rights Certificate under this Section 2.7, the Corporation may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Rights Agent) connected therewith.
|
(d)
|
Every new Rights Certificate issued pursuant to this Section 2.7 in lieu of any destroyed, lost or stolen Rights Certificate shall evidence a contractual obligation of the Corporation, whether or not the destroyed, lost or stolen Rights Certificate shall be at any time enforceable by anyone, and shall be entitled to all the benefits of this Agreement equally and proportionately with any and all other Rights duly issued hereunder.
|
Section 2.8
|
Persons Deemed Owners
|
Section 2.9
|
Delivery and Cancellation of Certificates
|
Section 2.10
|
Agreement of Rights Holders
|
(a)
|
to be bound by and subject to the provisions of this Agreement, as amended or supplemented from time to time in accordance with the terms hereof, in respect of all Rights held;
|
(b)
|
that, prior to the Separation Time, each Right will be transferable only together with, and will be transferred by a transfer of, the associated share certificate representing such Right;
|
(c)
|
that, after the Separation Time, the Rights Certificate will be transferable only on the Rights Register as provided herein;
|
(d)
|
that prior to due presentment of a Rights Certificate (or, prior to the Separation Time, the associated share certificate representing the Shares) for registration of transfer, the Corporation, the Rights Agent and any agent of the Corporation or the Rights Agent may deem and treat the Person in whose name the Rights Certificate (or, prior to the Separation Time, the associated Shares certificate) is registered as the absolute owner thereof and of the Rights evidenced thereby (notwithstanding any notations of ownership or writing on such Rights Certificate or the associated share certificate made by anyone other than the Corporation or the Rights Agent) for all purposes whatsoever, and neither the Corporation nor the Rights Agent shall be affected by any notice to the contrary;
|
(e)
|
that such holder of Rights has waived its right to receive any fractional Rights or any fractional Shares or other securities upon exercise of a Right;
|
(f)
|
that, subject to the provisions of Section 5.4, without the approval of any holder of Rights or Voting Shares and upon the sole authority of the Board of Directors acting in good faith, this Agreement may be supplemented or amended from time to time as provided herein; and
|
(g)
|
that notwithstanding anything in this Agreement to the contrary, neither the Corporation nor the Rights Agent shall have any liability to any holder of a Right or any other Person as a result of its inability to perform any of its obligations under this Agreement by reason of any preliminary or permanent injunction or other order, decree or ruling issued by a court of competent jurisdiction or by a governmental, regulatory or administrative agency or commission, or any statute, rule, regulation or executive order promulgated or enacted by any governmental authority, prohibiting or otherwise restraining performance of such obligation.
|
Section 3.1
|
Flip-in Event
|
(a)
|
Subject to Sections 3.1b) and 5.1, in the event that prior to the Expiration Time a Flip-in Event occurs, each Right shall thereafter constitute, effective at the close of business on the eighth Trading Day after the Stock Acquisition Date, the right to purchase from the Corporation, upon exercise thereof in accordance with the terms hereof, that number of Shares as have an aggregate Market Price on the date of consummation or occurrence of such Flip-in Event equal to twice the Exercise Price for an amount in cash equal to the Exercise Price (such Right to be appropriately adjusted in a manner analogous to the applicable adjustment provided for in Section 2.3 in the event that, after such date of consummation or occurrence, an event of a type analogous to any of the events described in Section 2.3 shall have occurred with respect to such Shares).
|
(b)
|
Notwithstanding anything in this Agreement to the contrary, upon the occurrence of any Flip-in Event, any Rights that are or were Beneficially Owned on or after the earlier of the Separation Time and the Stock Acquisition Date, or which may thereafter be Beneficially Owned, by:
|
(i)
|
an Acquiring Person (or any Affiliate or Associate of an Acquiring Person or any other Person acting jointly or in concert with an Acquiring Person or any Associate or Affiliate of such other Person); or
|
(ii)
|
a transferee of Rights, direct or indirect, from an Acquiring Person (or from any Affiliate or Associate of an Acquiring Person or any Person acting jointly or in concert with an Acquiring Person or any Associate or Affiliate thereof) where such a transferee becomes a transferee concurrently with or subsequent to the Acquiring Person becoming such in a transfer that the Board of Directors, acting in good faith, has determined is part of a plan, arrangement or scheme of an Acquiring Person (or of any Person acting jointly or in concert with an Acquiring Person or any Associate or Affiliate of an Acquiring Person), that has the purpose or effect of avoiding clause 3.1b)i);
|
(c)
|
Any Rights Certificate that represents Rights Beneficially Owned by a Person described in either of clauses 3.1b)i) or 3.1b)ii) or transferred to any Nominee of any such Person, and any Rights Certificate issued upon transfer, exchange, replacement or adjustment of any other Rights Certificate referred to in this sentence, shall contain or will be deemed to contain the following legend:
|
(d)
|
After the Separation Time, the Corporation shall do all such acts and things necessary and within its power to ensure compliance with the provisions of this Section 3.1 including, without limitation, all such acts and things as may be required to satisfy the requirements of the Canada Business Corporations Act, the Securities Act and the securities laws or comparable legislation in each of the provinces of Canada and in any other jurisdiction where the Corporation is subject to such laws and the rules of the stock exchanges or quotation systems where the Shares are listed or quoted at such time in respect of the issue of Shares upon the exercise of Rights in accordance with this Agreement.
|
(e)
|
In the event that there shall not be sufficient Shares authorized for issuance to permit the exercise in full of the Rights in accordance with this Section 3.1, the Corporation shall take such actions as may be reasonably necessary to authorize additional Shares for issuance upon the exercise of the Rights.
|
Section 3.2
|
Fiduciary Duties of the Board of Directors of the Corporation
|
Section 4.1
|
General
|
(a)
|
The Corporation hereby appoints the Rights Agent to act as agent for the Corporation and the holders of the Rights in accordance with the terms and conditions hereof, and the Rights Agent hereby accepts such appointment. The Corporation may from time to time appoint such co-rights agents (“
Co-Rights Agents
”) as it may deem necessary or desirable subject to the prior written approval of the Rights Agent. In the event the Corporation appoints one or more Co-Rights Agents, the respective duties of the Rights Agent and Co-Rights Agents shall be as the Corporation may determine with the written approval of the Rights Agent. The Corporation agrees to pay to the Rights Agent reasonable compensation for all services rendered by it hereunder and, from time to time, on demand of the Rights Agent, its reasonable expenses and other disbursements reasonably incurred in the administration and execution of this Agreement and the exercise and performance of its duties hereunder, including the reasonable fees and disbursements of counsel and other experts consulted by the Rights Agent pursuant to Subsection 4.3a). The Corporation also agrees to indemnify the Rights Agent, its officers, directors, employees and agents for, and to hold it harmless against any loss, liability, cost, claim, action, damage, suit or expense, incurred without negligence, bad faith or willful misconduct on the part of the Rights Agent for anything done or omitted by the Rights Agent in connection with the acceptance and administration of this Agreement including its reasonable legal costs and expenses, which right to indemnification will survive the termination of this Agreement or the removal or resignation of the Rights Agent.
|
(b)
|
The Rights Agent shall be protected and shall incur no liability for or in respect of any action taken, suffered or omitted by it in connection with its administration of this Agreement in reliance upon any certificate for Shares, Rights Certificate, certificate for other securities of the Corporation, instrument of assignment or transfer, power of attorney, endorsement, affidavit, letter, notice, direction, consent, certificate, statement, or other paper or document believed by it to be genuine and to be signed, executed and, where necessary, verified or acknowledged, by the proper Person or Persons.
|
(c)
|
The Corporation shall inform the Rights Agent in a reasonably timely manner of events which may materially affect the administration of this Agreement by the Rights Agent and, at any time upon request, shall provide to the Rights Agent an incumbency certificate certifying the then current officers of the Corporation.
|
Section 4.2
|
Merger, Amalgamation, Consolidation or Change of Name of Rights Agent
|
(a)
|
Any corporation into which the Rights Agent or any successor Rights Agent may be merged or amalgamated or with which it may be consolidated, or any corporation resulting from any merger, amalgamation or consolidation to which the Rights Agent or any successor Rights Agent is a party, or any corporation succeeding to the shareholder services business
|
(b)
|
In case at any time the name of the Rights Agent is changed and at such time any of the Rights Certificates shall have been countersigned but not delivered, the Rights Agent may adopt the countersignature under its prior name and deliver Rights Certificates so countersigned; and in case at that time any of the Rights Certificates shall not have been countersigned, the Rights Agent may countersign such Rights Certificates either in its prior name or in its changed name; and in all such cases such Rights Certificates shall have the full force provided in the Rights Certificates and in this Agreement.
|
Section 4.3
|
Duties of Rights Agent
|
(a)
|
The Rights Agent may retain and consult with legal counsel (who may be legal counsel for the Corporation) or such other experts that the Rights Agent considers necessary to carry out its duties under this Agreement and the opinion of such counsel or other expert will be full and complete authorization and protection to the Rights Agent as to any action taken or omitted by it in good faith and in accordance with such opinion; the Rights Agent may also, with the approval of the Corporation (such approval not to be unreasonably withheld), consult with such other experts (at the expense of the Corporation) as the Rights Agent shall consider necessary or appropriate to properly carry out the duties and obligations imposed under this Agreement and the Rights Agent shall be entitled to act and rely in good faith on the advice of any such expert.
|
(b)
|
Whenever in the performance of its duties under this Agreement the Rights Agent deems it necessary or desirable that any fact or matter be proved or established by the Corporation prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a certificate signed by a person believed by the Rights Agent to be a senior officer of the Corporation and delivered to the Rights Agent; and such certificate will be full authorization to the Rights Agent for any action taken or suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate.
|
(c)
|
The Rights agent will be liable hereunder only for its own fault, negligence, gross negligence, bad faith or wilful misconduct.
|
(d)
|
The Rights Agent will not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement or in the certificates for Shares, or the Rights Certificates (except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and will be deemed to have been made by the Corporation only.
|
(e)
|
The Rights Agent will not be under any responsibility in respect of the validity of this Agreement or the execution and delivery hereof (except the due authorization, execution and delivery hereof by the Rights Agent) or in respect of the validity or execution of any share certificate, or Rights Certificate (except its countersignature thereon) nor will it be responsible for any breach by the Corporation of any covenant or condition contained in this Agreement or in any Rights Certificate; nor will it be responsible for any change in the exercisability of the Rights (including the Rights becoming void pursuant to Subsection 3.1b) hereof or any adjustment required under the provisions of Section 2.3) hereof or responsible for the manner, method or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment (except with respect to the exercise of Rights after receipt of the certificate contemplated by Section 2.3 describing any such adjustment or any written notice from the Corporation or any holder that a Person has become an Acquiring Person); nor will it by any act hereunder be deemed to make any representation or warranty as to the authorization of any Shares to be issued pursuant to this Agreement or any Rights or as to any Shares, when issued, being duly and validly authorized, issued and delivered as fully paid and non-assessable.
|
(f)
|
The Corporation agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement.
|
(g)
|
The Rights Agent is hereby authorized and directed to accept instructions with respect to the performance of its duties hereunder from any person designated in writing by the Corporation, and to apply to such individuals for advice or instructions in connection with its duties, and it shall not be liable for any action taken or suffered by it in good faith in accordance with instructions of any such individual. It is understood that instructions to the Rights Agent shall, except where circumstances make it impractical or the Rights Agent otherwise agrees, be given in writing and, where not in writing, such instructions shall be confirmed in writing as soon as reasonably practicable after the giving of such instructions.
|
(h)
|
Subject to applicable law, the Rights Agent and any shareholder or director, officer or employee of the Rights Agent may buy, sell or deal in Shares, Rights or other securities of the Corporation or become pecuniarily interested in any transaction in which the Corporation may be interested, or contract with or lend money to the Corporation or otherwise act as fully and freely as though it were not the Rights Agent under this Agreement. Nothing herein shall preclude the Rights Agent from acting in any other capacity for the Corporation or for any other legal entity.
|
(i)
|
The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorneys or agents, and the Rights Agent will not be answerable or accountable for any act, default, neglect or misconduct of any such attorneys or agents or for any loss to the Corporation resulting from
|
Section 4.4
|
Change of Rights Agent
|
Section 4.5
|
Compliance with Anti-Money Laundering Legislation
|
Section 4.6
|
Privacy Legislation
|
Section 4.7
|
Liability
|
Section 5.1
|
Redemption, Waiver and Termination
|
(a)
|
Subject to the prior consent of the holders of the Voting Shares or the Rights obtained as set forth herein, the Board of Directors acting in good faith may, at any time prior to a Flip-in Event as to which the application of Section 3.1 has not been waived pursuant to this Section 5.1, elect to redeem all but not less than all of the then outstanding Rights at a redemption price of $0.00001 per Right (appropriately adjusted in a manner analogous to the applicable adjustments provided for in Section 2.3 in the event that an event of the type analogous to any of the events described in Section 2.3 shall have occurred) (such redemption price being herein referred to as the “
Redemption Price
”).
|
(b)
|
The Board of Directors shall waive the application of Section 3.1 in respect of the occurrence of any Flip-in Event if the Board of Directors has determined, following the Stock Acquisition Date and prior to the Separation Time, that a Person became an Acquiring Person by inadvertence and without any intention to become, or knowledge that it would become, an Acquiring Person under this Agreement and, in the event that such a waiver is granted by the Board of Directors, such Stock Acquisition Date shall be deemed not to have occurred. Any such waiver pursuant to this Subsection 5.1b) may only be given on the condition that such Person, within 10 days after the foregoing determination by the Board of Directors or such later date as the Board of Directors may determine (the “
Disposition Date
”), has reduced its Beneficial Ownership of Voting Shares such that the Person is no longer an Acquiring Person. If the Person remains an Acquiring Person at the Close of Business on the Disposition Date, the Disposition Date shall be deemed to be the date of occurrence of a further Stock Acquisition Date and Section 3.1 shall apply thereto.
|
(c)
|
In the event that a Person acquires Voting Shares pursuant to a Permitted Bid or an Exempt Acquisition referred to in Subsection 5.1d), then the Board of Directors of the Corporation shall, immediately upon the consummation of such acquisition and without further formality, be deemed to have elected to redeem the Rights at the Redemption Price.
|
(d)
|
The Board of Directors acting in good faith may, prior to the occurrence of the relevant Flip-in Event, upon prior written notice delivered to the Rights Agent, determine to waive the application of Section 3.1 to a Flip-in Event that may occur by reason of a Take-over Bid
|
(e)
|
The Board of Directors acting in good faith may, with the prior consent of the holders of Voting Shares obtained as set forth herein, prior to the occurrence of the relevant Flip-in Event, upon prior written notice delivered to the Rights Agent, determine to waive the application of Section 3.1 to a Flip-in Event that may occur by reason of an acquisition of Voting Shares other than pursuant to a Take-over Bid made by means of a take-over bid circular to all holders of record of Voting Shares and other than in the circumstances set out in Subsection 5.1b). In the event that the Board of Directors proposes such a waiver, the Board of Directors shall extend the Separation Time to a time and date subsequent to and not more than 10 Business Days following the meeting of shareholders held to approve such waiver.
|
(f)
|
Where a Take-over Bid that is not a Permitted Bid is withdrawn or otherwise terminated after the Separation Time has occurred and prior to the occurrence of a Flip-in Event, the Board of Directors may elect to redeem all the outstanding Rights at the Redemption Price without the consent of the holders of the Voting Shares or the Rights and reissue Rights under this Agreement to holders of record of Voting Shares immediately following such redemption. Upon the Rights being redeemed and reissued pursuant to this Subsection 5.1f), all the provisions of this Agreement shall continue to apply as if the Separation Time had not occurred and Rights Certificates representing the number of Rights held by each holder of record of Shares at the Separation Time had not been mailed to each such holder, and for all purposes of this Agreement the Separation Time shall be deemed not to have occurred and the Corporation shall be deemed to have issued replacement Rights to the holders of its then outstanding Shares.
|
(g)
|
If the Board of Directors is deemed under Subsection 5.1c) to have elected or elects under Subsection 5.1a) to redeem the Rights, the right to exercise the Rights will thereupon, without further action and without notice, terminate and the only right thereafter of the holders of Rights shall be to receive the Redemption Price.
|
(h)
|
Within 10 days after the Board of Directors is deemed under Subsection 5.1c) to have elected or elects under Subsection 5.1a) or (f) to redeem the Rights, the Corporation shall give notice of redemption to the holders of the then outstanding Rights by mailing such notice to each such holder at his last address as it appears upon the registry books of the Rights Agent or, prior to the Separation Time, on the registry books of the transfer agent for the Voting Shares. Any notice which is mailed in the manner herein provided shall be deemed given, whether or not the holder receives the notice. Each such notice of redemption will state the method by which the payment of the Redemption Price will be made.
|
(i)
|
If a redemption of Rights pursuant to Subsection 5.1a) or a waiver of a Flip-in Event pursuant to Subsection 5.1e) is proposed at any time prior to the Separation Time, such redemption or waiver shall be submitted for approval to the holders of Voting Shares. Such approval
|
(j)
|
If a redemption of Rights pursuant to Subsection 5.1a) or a waiver of a Flip-in Event pursuant to Subsection 5.1e) is proposed at any time after the Separation Time, such redemption or waiver shall be submitted for approval to the holders of Rights. Such approval shall be deemed to have been given if the redemption or waiver is approved by holders of Rights as set forth in Subsection 5.4d).
|
Section 5.2
|
Expiration
|
Section 5.3
|
Issuance of New Rights Certificates
|
Section 5.4
|
Supplements and Amendments
|
(a)
|
Subject to Subsections 5.4b) and (c) and this Subsection 5.4a), the Corporation may from time to time amend, vary or delete any of the provisions of this Agreement and the Rights; provided, however, that no amendment, variation or deletion made on or after the date of the 2022 meeting of shareholders at which the resolution referred to in Section 5.20 is to be considered shall be made without the prior consent of the holders of the Rights, given as provided in Subsection 5.4b) below, except that amendments, variations or deletions made for any of the following purposes shall not require such prior approval but shall be subject to subsequent ratification in accordance with Subsection 5.4b):
|
(i)
|
in order to make such changes as are necessary in order to maintain the validity of this Agreement and the Rights as a result of any change in any applicable legislation, regulations or rules; or
|
(ii)
|
in order to make such changes as are necessary in order to cure any clerical or typographical error.
|
(b)
|
Any amendment, variation or deletion to or from this Agreement made by the Board of Directors pursuant to Subsection 5.4a) shall:
|
(i)
|
if made prior to the Separation Time, be submitted to the shareholders of the Corporation at the next meeting of shareholders and the shareholders may, by resolution passed by a majority of the votes cast by Independent Shareholders who vote in respect of such amendment, variation or deletion, confirm or reject such amendment or supplement; or
|
(ii)
|
if made after the Separation Time, be submitted to the holders of Rights at a meeting to be held on a date not later than the date of the next meeting of shareholders of the Corporation and the holders of Rights may, by resolution passed by a majority of the votes cast by the holders of Rights which have not or are not deemed to have become void pursuant to Subsection 3.1b) who vote in respect of such amendment, variation or deletion, confirm or reject such amendment or supplement.
|
(c)
|
For greater certainty and notwithstanding anything herein contained, (i) no amendment, variation or deletion to the provisions of Article 4 shall be made except with the concurrence of the Rights Agent thereto, and (ii) neither the exercise by the Board of Directors of any power or discretion conferred on it hereunder nor the making by the Board of Directors of any determination or the granting of any waiver it is permitted to make or give hereunder shall constitute an amendment, variation or deletion of the provisions of this Agreement or the Rights, for purposes of this Section 5.4 or otherwise.
|
(d)
|
The approval, confirmation or consent of the holders of Rights with respect to any matter arising hereunder shall be deemed to have been given if the action requiring such approval, confirmation or consent is authorized by the affirmative votes of the holders of Rights present or represented at and entitled to be voted at a meeting of the holders of Rights and representing a majority of the votes cast in respect thereof. For the purposes hereof, each outstanding Right (other than Rights which are void pursuant to the provisions hereof or which, prior to the Separation Time, are held otherwise than by Independent Shareholders) shall be entitled to one vote, and the procedures for the calling, holding and conduct of the meeting shall be those, as nearly as may be, which are provided in the Corporation’s by- laws and the Canada Business Corporations Act with respect to meetings of shareholders of the Corporation.
|
(e)
|
The Corporation shall be required to provide the Rights Agent with notice in writing of any such amendment, variation or deletion to this Agreement as referred to in this Section 5.4 within 5 days of effecting such amendment, variation or deletion.
|
(f)
|
Any supplement or amendment to this Agreement pursuant to Subsections 5.4b) through (e) shall be subject to the receipt of any requisite approval or consent from any governmental
|
Section 5.5
|
Fractional Rights and Fractional Shares
|
(a)
|
The Corporation will not be required to issue fractions of Rights or to distribute Rights Certificates which evidence fractional Rights.
Any such fractional Right shall be null and void and the Corporation will not have any obligation or liability in respect thereof.
|
(b)
|
The Corporation shall not be required to issue fractional Shares upon exercise of the Rights or to distribute certificates that evidence fractional Shares. In lieu of issuing fractional Shares, the Corporation shall pay to the registered holder of Rights Certificates at the time such Rights are exercised as herein provided, an amount in cash equal to the same fraction of the Market Price of one Share at the date of such exercise. The Rights Agent shall have no obligation to make any payments in lieu of fractional Shares unless the Corporation shall have provided the Rights Agent with the necessary funds to pay in full all amounts payable in accordance with Subsection 2.2e)iii).
|
Section 5.6
|
Rights of Action
|
Section 5.7
|
Holder of Rights Not Deemed a Shareholder
|
Section 5.8
|
Notice of Proposed Actions
|
Section 5.9
|
Notices
|
(a)
|
if to the Corporation:
|
(b)
|
if to the Rights Agent:
|
(c)
|
if to the holder of any Rights, to the address of such holder as it appears on the registry books of the Rights Agent or, prior to the Separation Time, on the registry books of the Corporation for the Shares.
|
Section 5.10
|
Costs of Enforcement
|
Section 5.11
|
Regulatory Approvals
|
Section 5.12
|
Declaration as to Non-Canadian and Non-U.S. Holders
|
Section 5.13
|
Successors
|
Section 5.14
|
Benefits of this Agreement
|
Section 5.15
|
Determination and Actions by the Board of Directors
|
Section 5.16
|
Governing Law
|
Section 5.17
|
Language
|
Section 5.18
|
Counterparts
|
Section 5.19
|
Severability
|
Section 5.20
|
Reconfirmation
|
Section 5.21
|
Time of the Essence
|
|
|
AETERNA ZENTARIS INC.
|
|
By:
|
|
||
|
Name: Michael V. Ward
|
||
|
Title: President and Chief Executive Officer
|
|
|
COMPUTERSHARE TRUST COMPANY OF CANADA
|
|
By:
|
|
||
|
Name: Martine Gauthier
|
||
|
Title: Professional, Client Services
|
||
By:
|
|
||
|
Name: Steve Gilbert
|
||
|
Title: Professional, Client Services
|
|
|
AETERNA ZENTARIS INC.
|
|
By:
|
|
||
|
Authorized Signing Officer
|
||
By:
|
|
||
|
Authorized Signing Officer
|
|
|
COMPUTERSHARE TRUST COMPANY OF CANADA,
in the City of Montreal
|
|
By:
|
|
||
|
Authorized Signing Officer
|
Date:
|
|
|
|
|
|
|
Signature
|
|
|
|
(Signature must correspond to name as written upon the face of this Rights Certificate in every particular, without alteration or enlargement or any change whatsoever)
|
|
Signature Guaranteed
|
|
|
|
|
|
|
Signature
|
||
|
|
||
|
(Please print name below signature)
|
Date:
|
|
|
|
|
|
|
Signature
|
|
|
|
(Signature must correspond to name as written upon the face of this Rights Certificate in every particular, without alteration or enlargement or any change whatsoever)
|
|
Signature Guaranteed
|
|
|
|
|
|
|
Signature
|
||
|
|
||
|
(Please print name below signature
|
|
|
|
Signature
|
||
|
||
(Veuillez écrire le nom en lettres moulées sous la signature)
|
Date:
|
|
|
|
|
|
|
Signature
|
|
|
|
(La signature doit correspondre en tous points au nom apparaissant au recto du présent certificat de Droits, sans modification, ajout ni changement d’aucune sorte.)
|
|
(Signature avalisée)
|
|
|
|
|
Signature
|
||
|
||
(Veuillez écrire le nom en lettres moulées sous la signature)
|